{
    "asthma": {
        "description": "This document outlines the Asthma Pathway in India, covering its high burden, diagnosis challenges (spirometry access, underdiagnosis), stepwise pharmacological management for adults and children, exacerbation protocols, and key interventions to avoid.",
        "lines": {
            "L1": {
                "type": "Tile",
                "content": "Asthma Pathway"
            },
            "L2": {
                "type": "Heading",
                "content": "Background"
            },
            "L3": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> GBD study estimates <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pmc.ncbi.nlm.nih.gov/articles/PMC9149387/pdf/00528-2021.pdf' target='_blank'> 34.3 million </a> patients with asthma in India, accounting for 13.09%"
            },
            "L4": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span>  of the total asthma burden "
            },
            "L5": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> India <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pmc.ncbi.nlm.nih.gov/articles/PMC9149387/pdf/00528-2021.pdf' target='_blank'>has 3x higher</a> asthma mortality and 2x higher asthma morbidity compared to global "
            },
            "L6": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> burdens "
            },
            "L7": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Asthma is <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pmc.ncbi.nlm.nih.gov/articles/PMC9149387/pdf/00528-2021.pdf' target='_blank' >underdiagnosed and undertreated</a> in India <br><br>"
            },
            "L8": {
                "type": "Heading",
                "content": "Main Source Documents"
            },
            "L9": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>   <a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf' target='_blank'>GINA</a>"
            },
            "L10": {
                "type": "sub_child",
                "content": "Global Initiative for Asthma. Global Strategy for Asthma Management and"
            },
            "L11": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> Prevention, 2023. Updated May 2023. Available from: www.ginasthma.org"
            },
            "L12": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> UpToDate"
            },
            "L13": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <a style='color: #2463eb; text-decoration: underline; margin-left: 0px; margin-right:5px' href='https://www.indiachest.org/wp-content/uploads/2016/07/asthma_guidelines_ics_nccp_2015.pdf' target='_blank'> Indian Guidelines</a> (2015)"
            },
            "L14": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> UK guidelines (BTS, NICE)"
            },
            "L15": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> US   <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='' target='_blank'>NIH guidelines</a>"
            },
            "L16": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> WHO <a style='color: #2463eb; text-decoration: underline; margin-right:5px; margin-left:5px' href='https://www.who.int/publications/i/item/who-package-of-essential-noncommunicable-(pen)-disease-interventions-for-primary-health-care' target='_blank'>https://www.who.int/publications/i/item/who-package-of-essential-</a> "
            },
            "L17": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> <a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='https://www.who.int/publications/i/item/who-package-of-essential-noncommunicable-(pen)-disease-interventions-for-primary-health-care' target='_blank'>  noncommunicable-(pen)-disease-interventions-for-primary-health-care</a> "
            },
            "L18": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> International Union Against Tuberculosis and Lung Disease (The Union)"
            },
            "L19": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Review article NIH discussing management of asthma in LMIC- shortcomings/ available"
            },
            "L20": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> resources <a style='color: #2463eb; text-decoration: underline; margin-right:5px; margin-left:5px' href='https://pmc.ncbi.nlm.nih.gov/articles/PMC9474897/' target='_blank'>https://pmc.ncbi.nlm.nih.gov/articles/PMC9474897/</a> <br><br>"
            },
            "L21": {
                "type": "Heading",
                "content": "Key points for contextualisation"
            },
            "L22": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>  Diagnosis"
            },
            "L23": {
                "type": "sub_child",
                "content": "Diagnosis of asthma requires evidence of variable expiratory airflow obstruction"
            },
            "L24": {
                "type": "sub_child",
                "content": "The gold standard approach requires access to spirometry."
            },
            "L25": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>  Treatment – ensuring appropriate, evidence-based stepwise treatment"
            },
            "L26": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Education – including appropriate use of inhalers, literacy?"
            },
            "L27": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Non-pharmacological management"
            },
            "L28": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Key barriers"
            },
            "L29": {
                "type": "sub_child",
                "content": "Environmental (how to address?)"
            },
            "L30": {
                "type": "sub_child",
                "content": "<a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='https://www.thelancet.com/action/showPdf?pii=S2214-109X%2822%2900330-8' target='_blank'>Financial</a> – inhalers remain expensive/unaffordable in LMICs"
            },
            "L31": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>  Currently do not address:"
            },
            "L32": {
                "type": "sub_child",
                "content": "Children 0-5 <br><br>"
            },
            "L33": {
                "type": "Heading",
                "content": "Diagnosis"
            },
            "L34": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Intermittent dyspnoea, cough, wheeze, chest tightness"
            },
            "L35": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Diagnosis requires symptoms + variable expiratory airflow obstruction"
            },
            "L36": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Spirometry criteria:"
            },
            "L37": {
                "type": "sub_child",
                "content": "FEV1/FVC < 0.7"
            },
            "L38": {
                "type": "sub_child",
                "content": "AND reversibility (improvement in FEV1/FVC after 2-4 puffs of SABA)"
            },
            "L39": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span>  daily/ Cefotaxime1 g IV every six hours*"
            },
            "L40": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Increase of ≥12 percent <b style='margin-left:5px; margin-right:5px;'>and</b> 200 mL in FEV1"
            },
            "L41": {
                "type": "sub_child",
                "content": "Alternatively: 20% improvement in peak expiratory flow 15 minutes after"
            },
            "L42": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> bronchodilation (for LMICs)"
            },
            "L43": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> In high-income settings, asthma is often overdiagnosed, or diagnosed without diagnostic"
            },
            "L44": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> testing <br><br>"
            },
            "L45": {
                "type": "Heading",
                "content": "Differential Diagnosis (based on “cough” per <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.uptodate.com/contents/asthma-in-adolescents-and-adults-evaluation-and-diagnosis?search=asthma%20differential%20diagnosis&sectionRank=1&usage_type=default&anchor=H20489068&source=machineLearning&selectedTitle=1%7E150&display_rank=1#H20489068' target='_blank'>UpToDate </a> )"
            },
            "L46": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> chronic obstructive pulmonary disease"
            },
            "L47": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> gastroesophageal reflux disease"
            },
            "L48": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> pneumonia"
            },
            "L49": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> rhinitis or rhinosinus"
            },
            "L50": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> post-viral tussive syndrome"
            },
            "L51": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> eosinophilic bronchitis"
            },
            "L52": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> cough induced by angiotensin converting enzyme inhibitors"
            },
            "L53": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> infection with Bordetella pertussis <br><br>"
            },
            "L54": {
                "type": "Heading",
                "content": "Non-pharmacological management (most important)"
            },
            "L55": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Smoking cessation"
            },
            "L56": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Avoid triggers <br><br>"
            },
            "L57": {
                "type": "None",
                "content": "<b>Step 1</b>: Infrequent symptoms (<2 times/week)"
            },
            "L58": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Low dose ICS/rapid onset LABA (Track 1) OR"
            },
            "L59": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> SABA + ICS whenever SABA used (Track 2) <br><br>"
            },
            "L60": {
                "type": "None",
                "content": "<b>Step 2</b>: Symptoms or need for inhaler ≥ 2 times/week"
            },
            "L61": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Low dose ICS-formoterol as needed (Track 1) OR"
            },
            "L62": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Low dose ICS daily AND SABA (Track 2)<br><br>"
            },
            "L63": {
                "type": "None",
                "content": "<b>Step 3</b>: symptoms on most days, nocturnal awakening due to asthma ≥ once/month, risk factors"
            },
            "L64": {
                "type": "None",
                "content": "for exacerbations"
            },
            "L65": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Low dose ICS-formoterol for maintenance and reliever (MART; Track 1) OR"
            },
            "L66": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Low dose ICS-LABA AND SABA (Track 2) <br><br>"
            },
            "L67": {
                "type": "None",
                "content": "<b>Step 4</b>: severe uncontrolled asthma with ≥ of: daytime symptoms ≥ 2 times/week, nocturnal"
            },
            "L68": {
                "type": "None",
                "content": "awakening due to asthma, reliever needed > 2 times/week, activity limitation"
            },
            "L69": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Low dose ICS-formoterol for maintenance and reliever (MART; Track 1) OR"
            },
            "L70": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Low dose ICS-LABA AND SABA (Track 2)<br><br>"
            },
            "L71": {
                "type": "None",
                "content": "<b>Step 5</b>: Consider high dose ICS-LABA and Add-on LAMA<br><br>"
            },
            "L72": {
                "type": "Heading",
                "content": "Stepwise treatment of children ages 6-11"
            },
            "L73": {
                "type": "None",
                "content": "<b>Step 1:</b> Symptoms less than twice a month and no risk factors for exacerbation"
            },
            "L74": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> As needed SABA<br><br>"
            },
            "L75": {
                "type": "None",
                "content": "<b>Step 2:</b> Symptoms or need for reliever more than twice a month but less than daily"
            },
            "L76": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Low dose ICS with as-needed SABA<br><br>"
            },
            "L77": {
                "type": "None",
                "content": "<b>Step 3:</b> Symptoms most days, nocturnal awakenings due to asthma, especially in the context of"
            },
            "L78": {
                "type": "None",
                "content": "risk factors for exacerbation"
            },
            "L79": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Low dose ICS-LABA with as needed SABA OR"
            },
            "L80": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Medium dose ICS with as needed SABA<br><br>"
            },
            "L81": {
                "type": "None",
                "content": "<b>Step 4:</b> As for Step 3, but with poor lung function"
            },
            "L82": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Medium dose ICS-LABA AND referral to specialist<br><br>"
            },
            "L83": {
                "type": "None",
                "content": "<b>Step 5:</b> consider high dose ICS-LABA<br><br>"
            },
            "L84": {
                "type": "Heading",
                "content": "Dosage adjustments"
            },
            "L85": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Day to day adjustments"
            },
            "L86": {
                "type": "sub_child",
                "content": "Reliever inhaler can be adjusted as needed (i.e. used more)"
            },
            "L87": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Short term adjustments: increase in ICS dose for 1-2 weeks may be necessary (e.g. if"
            },
            "L88": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> viral illness, or allergen/pollution exposure)<br><br>"
            },
            "L89": {
                "type": "Heading",
                "content": "Stepping down therapy"
            },
            "L90": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Continue with same treatment and once good asthma control has been achieved and"
            },
            "L91": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> maintained for 2–3 months, consider stepping down gradually to find the patient’s lowest"
            },
            "L92": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> treatment that controls both symptoms and exacerbations.<br><br>"
            },
            "L93": {
                "type": "Heading",
                "content": "If poor response to therapy"
            },
            "L94": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Inhaler technique!!"
            },
            "L95": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Confirm/reconsider diagnosis"
            },
            "L96": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Assess risk factors and comorbidities"
            },
            "L97": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Consider stepping up treatment<br><br>"
            },
            "L98": {
                "type": "Heading",
                "content": "Management of exacerbations- location of management based on extent of exacerbation.<br><br>"
            },
            "L99": {
                "type": "Heading",
                "content": "Home therapy"
            },
            "L100": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> All patients should be provided an asthma action plan"
            },
            "L101": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Home therapy of exacerbations depends on whether we are doing Step 1 or Step 2"
            },
            "L102": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Increase reliever for acute exacerbation"
            },
            "L103": {
                "type": "sub_child",
                "content": "If usual reliever is ICS-LABA, increase frequency not exceeding maximum daily"
            },
            "L104": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> dosage of inhaler"
            },
            "L105": {
                "type": "sub_child",
                "content": "If usual reliever is SABA, then increase frequency"
            },
            "L106": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Increase preventer to prevent future exacerbations"
            },
            "L107": {
                "type": "sub_child",
                "content": "If usual preventer is ICS-formoterol, continue maintenance ICS-formoterol AND"
            },
            "L108": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> increase reliever ICS-formoterol as required"
            },
            "L109": {
                "type": "sub_child",
                "content": "If usual preventer is ICS with SABA as reliever, quadruple ICS dose"
            },
            "L110": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Above changes should be continued for 1-2 weeks"
            },
            "L111": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If peak flow is < 60% of previous best peak flow, OR if not improving after 48 hours"
            },
            "L112": {
                "type": "sub_child",
                "content": "Continue reliever and preventer"
            },
            "L113": {
                "type": "sub_child",
                "content": "Add prednisone 40-50mg"
            },
            "L114": {
                "type": "sub_child",
                "content": "<b>Contact doctor</b><br><br>"
            },
            "L115": {
                "type": "Heading",
                "content": "Clinic management"
            },
            "L116": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Assess clinical stability"
            },
            "L117": {
                "type": "sub_child",
                "content": "If severe: If unable to talk in full sentences, respiratory rate > 30, accessory"
            },
            "L118": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> muscle use, HR > 120, SpO2 on air < 90%, peak flow < 50%"
            },
            "L119": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Transfer to higher center of care"
            },
            "L120": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> In the interim, give SABA, ipratropium bromide, O2, systemic"
            },
            "L121": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\"></span> corticosteroid"
            },
            "L122": {
                "type": "sub_child",
                "content": "If mild or moderate: talks in phrases, prefers sitting to lying down, not agitated,"
            },
            "L123": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> respiratory rate increased from baseline, accessory muscles not used, pulse 100-"
            },
            "L124": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> 120 beats per minute, O2 saturation on air 90-95%, peak flow >50% predicted or"
            },
            "L125": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> best"
            },
            "L126": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Treat at clinic"
            },
            "L127": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Salbutamol 4-10 puffs via spacer, every 20 minutes for 1 hour"
            },
            "L128": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Prednisolone 40-50mg (adults), children 1-2mg/kg max 40mg"
            },
            "L129": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> O2 therapy if available: target SpO2 93-95% (children 94-98%)"
            },
            "L130": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Reassess at 1 hour"
            },
            "L131": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> If worsening, requires transfer to higher center of care"
            },
            "L132": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> If improving, discharge, signs of improvement below"
            },
            "L133": {
                "type": "None",
                "content": " - <span style=\"font-size: 0.7rem; margin-left: 90px; width: 1.35rem;\">o</span> Improving symptoms, no SABA requirement"
            },
            "L134": {
                "type": "None",
                "content": " - <span style=\"font-size: 0.7rem; margin-left: 90px; width: 1.35rem;\">o</span> Peak flow 60-80% of predicted or personal best"
            },
            "L135": {
                "type": "None",
                "content": " - <span style=\"font-size: 0.7rem; margin-left: 90px; width: 1.35rem;\">o</span> SpO2 > 94% on room air"
            },
            "L136": {
                "type": "None",
                "content": " - <span style=\"font-size: 0.7rem; margin-left: 90px; width: 1.35rem;\">o</span> Safe discharge destination"
            },
            "L137": {
                "type": "None",
                "content": " - <span style=\"font-size: 0.7rem; margin-left: 90px; width: 1.35rem;\">o</span> Ensure has home action plan"
            },
            "L138": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 120px; width: 1.35rem;\">▪︎</span> Prednisolone – to be continued for 5-7 days"
            },
            "L139": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 120px; width: 1.35rem;\"></span> (adults), 3-5 days (children)"
            },
            "L140": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 120px; width: 1.35rem;\">▪︎</span> Follow up within 2-7 days (adults), 1-2 days"
            },
            "L141": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 120px; width: 1.35rem;\"></span> (children)"
            },
            "L142": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 120px; width: 1.35rem;\">▪︎</span> continue the rescue inhaler as needed. rescue inhaler"
            },
            "L143": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 120px; width: 1.35rem;\"></span> may be SABA, low dose ICS-LABA, or ICS-SABA"
            },
            "L144": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 120px; width: 1.35rem;\">▪︎</span> up titrate maintenance inhaler- ICS-LABA – to be"
            },
            "L145": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 120px; width: 1.35rem;\"></span> continued or uptitrated<br><br>"
            },
            "L146": {
                "type": "Heading",
                "content": "Asthma-COPD overlap"
            },
            "L147": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Both are obstructive conditions with overlapping diagnostic criteria"
            },
            "L148": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Some patients may have features of both conditions"
            },
            "L149": {
                "type": "sub_child",
                "content": "Particularly if long standing asthma and risk factors for COPD (e.g. smoking)"
            },
            "L150": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> For patients with features of both asthma and COPD, treat as asthma with ICS"
            },
            "L151": {
                "type": "sub_child",
                "content": "First line therapy for COPD (i.e. LAMA or LABA without ICS) is not appropriate"
            },
            "L152": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> for patients with features of asthma (see CSA COPD pathway)<br><br>"
            },
            "L153": {
                "type": "Heading",
                "content": "Other topics to address"
            },
            "L154": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Risk factor modification/non-pharmacological measures?"
            },
            "L155": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Other than avoiding smoke/pollution, this is tricky"
            },
            "L156": {
                "type": "Heading",
                "content": "Interventions to avoid"
            },
            "L157": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Do not use oral steroids as a first line therapy for asthma"
            },
            "L158": {
                "type": "sub_child",
                "content": "“It is not acceptable in 2022 to manage asthma with SABAs and oral"
            },
            "L159": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> corticosteroids instead of preventive ICS-containing treatments” – GINA"
            },
            "L160": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Avoid SABA monotherapy, even in cases of mild asthma"
            },
            "L161": {
                "type": "sub_child",
                "content": "Associated with <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://erj.ersjournals.com/content/55/4/1901872' target='_blank'>increased rates</a> of asthma-related death, and urgent asthma-"
            },
            "L162": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> related healthcare"
            },
            "L163": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Do not treat asthma exacerbations with corticosteroid therapy"
            },
            "L164": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Do not treat asthma with methylxanthines (e.g. theophylline)<br><br>"
            },
            "L165": {
                "type": "Heading",
                "content": "Vaccinations"
            },
            "L166": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Influenza"
            },
            "L167": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Pneumococcal"
            },
            "L168": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> COVID-19"
            }
        },
        "Tables": {
            "T1": {
                "title": "List of available drugs along with cost information",
                "type": "Table",
                "after": "L168",
                "content": [
                    [
                        "Drug Class",
                        "Drug name",
                        "Type",
                        "Brand",
                        "Pricing"
                    ],
                    [
                        "<b>SABA<b>",
                        "Salbutamol",
                        "Rotacaps",
                        "Cipla - Asthalin",
                        "200 mcg - 60 capsules in 1 bottle - Rs 98/pack "
                    ],
                    [
                        "",
                        "",
                        "Metered dose inhaler",
                        "Cipla - Asthalin",
                        "Rs 110/ box "
                    ],
                    [
                        "",
                        "",
                        "Respules",
                        "Cipla - Asthalin",
                        "2.5mg/2.5 ml pack of 5 - Rs 28 "
                    ],
                    [
                        "",
                        "Levisalbutamol",
                        "Rotacaps",
                        "Cipla-Levolin",
                        "100 mcg - 30 capsules in 1 bottle - Rs 30/pack "
                    ],
                    [
                        "",
                        "",
                        "Metered dose inhaler",
                        "Cipla-Levolin",
                        "50 mcg inhaler / Rs 200 per pack "
                    ],
                    [
                        "",
                        "",
                        "Respules",
                        "Cipla - Levolin ,\nLupin-Salbair",
                        "0.63~Mg/1 respule - Rs 5 per respule,\n0.63mg/2.5 mL respule - Rs 7 per respule "
                    ],
                    [
                        "<b>Combination - SABA and SAMA<b>",
                        "Ipravent and Levosalbutamol",
                        "Rotacaps",
                        "Cipla - Duolin",
                        "60 capsules 100 +40 mcg/ Rs 144 per bottle "
                    ],
                    [
                        "",
                        "",
                        "Metered dose inhaler",
                        "Cipla - Duolin Forte",
                        "200 mdi inhaler - Rs 393 "
                    ],
                    [
                        "",
                        "",
                        "Respules",
                        "Cipla - Duolin",
                        "3 ml respules - pack of 5 - Rs 104 "
                    ],
                    [
                        "<b>ICS</b>",
                        "Fluticasone",
                        "Rotacaps",
                        "",
                        ""
                    ],
                    [
                        "",
                        "",
                        "Metered dose inhaler",
                        "Cipla - Flohale",
                        "125 mcg/dose, Rs 267/ inhaler "
                    ],
                    [
                        "",
                        "",
                        "Respules",
                        "Cipla-Flohale",
                        "0.5 mg respules - Rs 240 "
                    ],
                    [
                        "",
                        "Budesonide",
                        "Rotacaps",
                        "Cipla - Budecort",
                        "200 mcg, 30 capsules in 1 bottle - Rs 92 "
                    ],
                    [
                        "",
                        "",
                        "Metered dose inhaler",
                        "Cipla-Budesonide inhaler",
                        "100, 200 mg - Rs 400 "
                    ],
                    [
                        "",
                        "",
                        "Respules",
                        "Cipla - Budecort respules",
                        "0.5 mg respules, Rs 115 - pack of 5 "
                    ],
                    [
                        "",
                        "Ciclesonide",
                        "Rotacaps",
                        "Cipla - Ciclohale",
                        "400 mcg - 30 capsules, Rs 195 "
                    ],
                    [
                        "",
                        "",
                        "Metered dose inhaler",
                        "Cipla-Ciclohale,\nRanbaxy - Osonide",
                        "Ciclohale- 160 mcg - Rs 350,\nOsonide- 160 mcg - Rs 300 "
                    ],
                    [
                        "",
                        "",
                        "Respules",
                        "NA",
                        ""
                    ],
                    [
                        "<b>Triple therapy, combination drug ICS+LABA+LAMA</b>",
                        "beclometasone dipropionate/<br>formoterol fumarate/<br>glycopyrronium bromide (BDP/FF/G)",
                        "pressurized metered-dose inhaler",
                        "TRIMBOW®, Chiesi Farmaceutici SpA",
                        "Single dosage - 87/5/9 µg (two inhalations twice daily) "
                    ],
                    [
                        "",
                        "Fluticasone <br>Furoate/Umeclidinium/<br>Vilanterol FF/UMEC/VI",
                        "Multidose dry-powder inhaler (MDDPI) formulation to be delivered through the ELLIPTA inhaler device (Single-Inhaler Triple Therapy (SITT))",
                        "TRELEGY ELLIPTA®, GlaxoSmithKline",
                        "Single dosage - 92/22/55 µg (one inhalation per day) - Maintenance treatment of both asthma and COPD "
                    ],
                    [
                        "",
                        "GlaxoSmithKline FF/UMEC/VI",
                        "Dry powder inhaler",
                        "Trelegy Ellipta",
                        "Once daily - Maintenance treatment of COPD; ₹2822/box "
                    ],
                    [
                        "",
                        "AstraZeneca BDP/FOR/GP Beclomethasone/Formoterol/<br>Glycopyrronium",
                        "pressurized metered-dose inhaler",
                        "BREZTRI",
                        "Twice daily (CJ: can't find this drug online; probably not sold in India yet) "
                    ],
                    [
                        "",
                        "Novartis IND/GLY/MF Indacaterol/Glycopyrronium/ Mometasone furoate",
                        "Dry powder inhaler",
                        "Enerzair Breezhaler",
                        "Once daily (CJ: can't find this drug online; probably not sold in India yet) "
                    ],
                    [
                        "",
                        "Glenmark GLY/FOR/FP Glycopyrronium/Formoterol/<br>Fluticasone propionate",
                        "Dry powder inhaler",
                        "Airz-FF",
                        "Twice daily ; ₹535/box of 30 capsules "
                    ],
                    [
                        "",
                        "Cipla GLY/FOR/BUD Glycopyrronium/<br>Formoterol/Budesonide",
                        "Dry powder inhaler",
                        "Glycohale-FB",
                        "Twice daily; ₹184.7/box of 10 rotacaps "
                    ],
                    [
                        "",
                        "Tiotropium/Formoterol/<br>Ciclesonide (TFC)",
                        "Dry powder inhaler (DPI)/\nPressured metered dose inhaler (pMDI)",
                        "Triohale®, Cipla",
                        "18 mcg/12 mcg/400 mcg - once-daily; ₹1132/ inhaler with 200 metered doses "
                    ],
                    [
                        "<b>ICS and LABA-combination</b>",
                        "Fluticasone and Salmeterol",
                        "Rotacaps",
                        "Macleods Pharma-Flutrol,\nZydus Cadila-Forair R cap,\nSeroflo- 500 rotacaps",
                        "Flutrol rota capsule- 50/100 mcg- Rs 155,\nForair R cap- 100/50 mcg- Rs 361- for 30 capsules,\nSeroflo500 rotacaps -500/50 mcg- Rs 472 "
                    ],
                    [
                        "",
                        "",
                        "Respules",
                        "Lupin Labs-Esiflo,",
                        "Esiflo- 100/50 mcg- 30 capsules Rs 108 "
                    ],
                    [
                        "",
                        "",
                        "Metered dose inhaler",
                        "Glenmark - Airtec SF,\nSun pharma-Combitide",
                        "Airtec SF- 50 mcg/100 mcg- Rs 330, Combitide - 25/125 mcg - Rs 292 "
                    ],
                    [
                        "<span style=\"font-style: italic;\">(rapid onset)</span>",
                        "Budesonide and Formoterol",
                        "Rotacaps, Respules",
                        "Zydus cadila - Formonide Resicaps,",
                        "Formonide resicaps- 200/6 mcg- Rs 147- for a bottle of 30 "
                    ],
                    [
                        "",
                        "",
                        "Metered dose inhaler",
                        "Kopran Pharma-VentFB inhaler",
                        "Vent FB inhaler - 100/6 mcg- Rs 134 "
                    ],
                    [
                        "",
                        "Fluticasone and Vilanterol",
                        "Rotacaps",
                        "",
                        ""
                    ],
                    [
                        "<b>ICS and SABA combo</b>",
                        "Budesonide(0.5 Mg) + Salbutamol/Albuterol(1.25 Mg)",
                        "",
                        "",
                        "Budesal 0.5mg 2ml Packet Of 5 Respules for ~ Rs 240\nDerisal 0.5mg 2ml Packet Of 7 Respules for ~ RS 340 "
                    ],
                    [
                        "",
                        "Levosalbutamol (50mcg) + Beclometasone (50mcg)",
                        null,
                        "Cipla",
                        "Aerocort Inhaler for ~Rs 270 / 1 Packet 200 MDI Inhaler "
                    ],
                    [
                        "",
                        "",
                        "Respules",
                        "",
                        ""
                    ],
                    [
                        "",
                        "",
                        "Metered dose inhaler",
                        "",
                        ""
                    ],
                    [
                        "<b>LABA+LAMA</b>",
                        "Formoterol Fum.",
                        "single inhaler device disposable",
                        "Tioform",
                        "Dosage- 6 or 12 µg (18/12 mcg; 9/6 mcg); ₹677 "
                    ],
                    [
                        "<b>Prednisolone</b>",
                        "",
                        "(40-50mg)",
                        "various brands\nDepomax S 40mg Injection,\nMpss 40mg Injection",
                        "40mg oral - avg Rs 25/ strip of 10 tablets\nRs 100-150 "
                    ]
                ]
            }
        }
    },
    "fever": {
        "description": "This pathway addresses adult acute fever in India's resource-limited settings. It covers diagnosis challenges, common causes, severity assessment, and empiric antimicrobial treatments for various infections like malaria, typhoid, and dengue.",
        "lines": {
            "L1": {
                "type": "Tile",
                "content": "Adult Undifferentiated Acute Fever Pathway"
            },
            "L2": {
                "type": "Heading",
                "content": "Definition"
            },
            "L3": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>  Symptoms of fever (2 consecutive temperature elevations > 38.3°C (100.9 °F) or a single"
            },
            "L4": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> oral temperature > 38.3°C (100.9°F) in neutropenic persons without evidence of an"
            },
            "L5": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> environmental cause OR a temperature elevation > 38°C for > 1 hour) for a period of 3-"
            },
            "L6": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> 14 days\n"
            },
            "L7": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> No clear localizable symptoms to suggest immediate diagnosis<br><br>"
            },
            "L8": {
                "type": "Heading",
                "content": "Background"
            },
            "L9": {
                "type": "None",
                "content": " - Infectious Diseases are the leading cause of morbidity and mortality in India."
            },
            "L10": {
                "type": "None",
                "content": " - Undifferentiated acute febrile syndromes vary by season, location and may present a challenge to"
            },
            "L11": {
                "type": "None",
                "content": " - the general practitioner. They are overwhelmingly caused by infectious<br><br>"
            },
            "L12": {
                "type": "None",
                "content": " - Fever episodes in rural tropical areas may be 4 per person per year in rural and 0.5 per person per"
            },
            "L13": {
                "type": "None",
                "content": " - year in urban areas.<br><br>"
            },
            "L14": {
                "type": "None",
                "content": " - Early presentation may be nonspecific and overlapping for many infections and may make"
            },
            "L15": {
                "type": "None",
                "content": " - distinguishing self-limited illness from more severe illness difficult.<br><br>"
            },
            "L16": {
                "type": "None",
                "content": " - Early recognition and appropriate specific antimicrobial therapy may lead to decreased morbidity"
            },
            "L17": {
                "type": "None",
                "content": " - and mortality for some infections. However indiscriminate empiric antibiotic therapy should be"
            },
            "L18": {
                "type": "None",
                "content": " - avoided in conditions where there may be limited role to avoid emergence of antimicrobial"
            },
            "L19": {
                "type": "None",
                "content": " - resistance. PMID: [28356302](about:blank), 27139474, [29581252](about:blank)<br><br>"
            },
            "L20": {
                "type": "Heading",
                "content": "Local context"
            },
            "L21": {
                "type": "Heading",
                "content": "What causes AUFI?"
            },
            "L22": {
                "type": "Heading",
                "content": "Other challenges"
            },
            "L23": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Patients in many parts of India do not need to see a doctor to obtain antibiotics for fever"
            },
            "L24": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Access to reliable clinical bacteriology laboratory for identification and antimicrobial"
            },
            "L25": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> susceptibility testing on specimens (blood cultures, urine cultures) is an important part of"
            },
            "L26": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> the clinical evaluation and treatment in the AUFI pathway but may be limited in low"
            },
            "L27": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> resource location or have an unacceptable turnaround time within the clinical context of"
            },
            "L28": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> such patient encounters. A follow up encounter may be necessary to make therapy"
            },
            "L29": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> changes based on antimicrobial susceptibility results and may not be feasible. (PMID:"
            },
            "L30": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> 29519767)"
            },
            "L31": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Burden of multidrug resistant organisms as a cause of community onset acute febrile"
            },
            "L32": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> illness is high and may lead to higher mortality unless antibiotic therapy is guided by"
            },
            "L33": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> antimicrobial susceptibility testing. (PMID 28329303; 35065702)"
            },
            "L34": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Patients and clinicians may be reluctant to undergo invasive procedures including blood"
            },
            "L35": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> sampling due to perceptions that tests may be timely or expensive or irrelevant. The post analytical"
            },
            "L36": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> laboratory clinician interaction may not be timely or in person"
            },
            "L37": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Prior antibiotic therapy may render a blood culture sample sterile and decrease yield."
            },
            "L38": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Cross reactivity as well as background positivity from prior infections in endemic areas"
            },
            "L39": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> are limitations of serologic tests used to diagnose some infections (Dengue, Leptospirosis"
            },
            "L40": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> and Chikungunya) and convalescent testing to confirm diagnosis may not be feasible."
            },
            "L41": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> Hence clinical diagnosis should guide therapy in cases where test results are discordant to"
            },
            "L42": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> presentation"
            },
            "L43": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> In endemic areas, background seroprevalence may be high for antibody-based tests"
            },
            "L44": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> (example >50% Leptospira Ab in Andamans, slum dwellers or sewer workers)"
            },
            "L45": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Sensitivity of serologic tests for Dengue, Leptospirosis and Scrub typhus are limiting, but"
            },
            "L46": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> remember the clinical suspicion may increase predictive value of a positive test."
            },
            "L47": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> The Widal test for typhoid is widely used but is not recommended due to low sensitivity"
            },
            "L48": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> and specificity. However, if it is performed elsewhere, or is the only test available, it"
            },
            "L49": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> should be used in clinical decision making only for its negative predictive value which is"
            },
            "L50": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span>  around 95% even in high prevalence settings. (PMID 24995178)"
            },
            "L51": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>  Patients may not present to CSA partner sites with mild-moderate symptoms (can present"
            },
            "L52": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span>  directly to pharmacy for antibiotics) <br><br>"
            },
            "L53": {
                "type": "Heading",
                "content": "Key questions to answer"
            },
            "L54": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>  What to test/when to test"
            },
            "L55": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>  How to treat/what to treat with<br><br>"
            },
            "L56": {
                "type": "Heading",
                "content": "Resources"
            },
            "L57": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>  UpToDate"
            },
            "L58": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>  National Centre for Disease Control in India (NCDC): National Treatment Guidelines for"
            },
            "L59": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span>  Antimicrobial Use in Infectious Diseases"
            },
            "L60": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>  WHO report on fever management in peripheral healthcare settings (2013)"
            },
            "L61": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>  WHO: Good clinical diagnostic practice: a guide for clinicians in developing countries to"
            },
            "L62": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span>  the clinical diagnosis of disease and to making proper use of clinical diagnostic services."
            },
            "L63": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> http://apps.who.int/iris/bitstream/10665/119735/1/dsa236.pdf (2005)"
            },
            "L64": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> National Vector Borne Disease Control Program guidelines (2013)"
            },
            "L65": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>  MSF<br><br>"
            },
            "L66": {
                "type": "Heading",
                "content": "Proposed Pathway"
            },
            "L67": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>  Early assessment of severity and SIRS response"
            },
            "L68": {
                "type": "sub_child",
                "content": "If unstable, resuscitate"
            },
            "L69": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>  Define clinical syndrome and identify clinical cues. This is guided by history and"
            },
            "L70": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span>  physical exam. A good practice is to conduct a system-based review of symptoms"
            },
            "L71": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span>  (negative history). Clinical history would include assessment for"
            },
            "L72": {
                "type": "sub_child",
                "content": "Sore throat runny nose"
            },
            "L73": {
                "type": "sub_child",
                "content": "ear pain, sinus pain, dental pain,"
            },
            "L74": {
                "type": "sub_child",
                "content": " headache, photophobia, vomiting, altered consciousness,"
            },
            "L75": {
                "type": "sub_child",
                "content": "cough, sputum, shortness of breath, wheezing"
            },
            "L76": {
                "type": "sub_child",
                "content": "diarrhea (blood, mucus) and abdominal pain"
            },
            "L77": {
                "type": "sub_child",
                "content": "painful urination, hematuria, flank pain"
            },
            "L78": {
                "type": "sub_child",
                "content": "skin rash, ulcer"
            },
            "L79": {
                "type": "sub_child",
                "content": "joint pain, swelling or bone pain"
            },
            "L80": {
                "type": "sub_child",
                "content": "bleeding from mucus membranes, rash"
            },
            "L81": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> Physical examination would assess for"
            },
            "L82": {
                "type": "sub_child",
                "content": "rapid pulse, rapid respiratory rate (exception: slow pulse in typhoid fever)"
            },
            "L83": {
                "type": "sub_child",
                "content": "pallor, jaundice"
            },
            "L84": {
                "type": "sub_child",
                "content": "stiff neck, photophobia"
            },
            "L85": {
                "type": "sub_child",
                "content": "red throat, pus on tonsils, red bulging eardrums,"
            },
            "L86": {
                "type": "sub_child",
                "content": "sinus tenderness decayed teeth"
            },
            "L87": {
                "type": "sub_child",
                "content": "respiratory distress (use of accessory muscles, chest indrawing, grunting, nasal"
            },
            "L88": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span>  flaring), rhonchi, bronchial breathing, pleural rub"
            },
            "L89": {
                "type": "sub_child",
                "content": "abdominal tenderness, liver or spleen enlargement, masses, ascites loin/pelvic"
            },
            "L90": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span>  tenderness"
            },
            "L91": {
                "type": "sub_child",
                "content": "skin rash, ulcer,"
            },
            "L92": {
                "type": "sub_child",
                "content": "lymphangitis swollen tender joints bone tenderness, swelling bleeding, petechiae"
            },
            "L93": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> lymphadenopathy."
            },
            "L94": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>  Underlying risk factors or comorbidity which may either increase severity of condition or"
            },
            "L95": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> impact management- diabetes mellitus, sickle cell disease, malignancy, pregnancy, HIV,"
            },
            "L96": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> alcoholic liver disease, prior antibiotic therapy ( may increase risk of MDR organisms)"
            },
            "L97": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Appropriate initial investigations"
            },
            "L98": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Appropriate empiric therapy awaiting results of clinical investigations"
            },
            "L99": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Consider overlapping diagnoses <br><br>"
            },
            "L100": {
                "type": "Heading",
                "content": "Initial clinical evaluation"
            },
            "L101": {
                "type": "None",
                "content": " - Defining the initial syndrome can be useful to narrow down the possible infectious agent."
            },
            "L102": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Fever – Malaria, leptospirosis, dengue, typhoid, scrub typhus, other rickettsial illness,"
            },
            "L103": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> chikungunya, pyelonephritis"
            },
            "L104": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Fever with thrombocytopenia/rash: dengue, malaria,leptospirosis,"
            },
            "L105": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Fever with rash -dengue, measles, typhoid, rubella, HIV, viral illness, scrub typhus,"
            },
            "L106": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> meningococcal infection"
            },
            "L107": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Fever with respiratory symptoms- influenza, community acquired pneumonia,"
            },
            "L108": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> COVID-19"
            },
            "L109": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Fever with hepatorenal syndrome: falciparum malaria, leptospirosis, scrub typhus and"
            },
            "L110": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> hepatitis E or A with fulminant hepatic failure. Modest elevation in leptospirosis and"
            },
            "L111": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> malarial hepatitis. Higher in viral hepatitis."
            },
            "L112": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Fever with mental status change- meningitis, encephalitis ( HSV, Japanese B,"
            },
            "L113": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> enterovirus) cerebral malaria, typhoid encephalopathy, scrub typhus <br><br>"
            },
            "L114": {
                "type": "Heading",
                "content": "General supportive care"
            },
            "L115": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Antipyretics to control fever- paracetamol in most cases. 500-1000mg PO q8h. Max"
            },
            "L116": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> 4g/day."
            },
            "L117": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Tepid sponging"
            },
            "L118": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Assess hydration status. If able to take PO, allow for water, lime juice, kanji or ORS"
            },
            "L119": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> solution, especially if diarrheal symptoms or vomiting."
            },
            "L120": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> IV fluids if unable to take orally, ongoing dehydration due to vomiting or diarrhea"
            },
            "L121": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> with severe dehydration, ileus or shock or confusion. Normal saline for most patients."
            },
            "L122": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Oxygen if respiratory symptoms and low oxygen saturation. Assess for need for"
            },
            "L123": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> higher level of care"
            },
            "L124": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Mask for contacts if respiratory viral syndrome suspected <br><br>"
            },
            "L125": {
                "type": "Heading",
                "content": "Initial investigations"
            },
            "L126": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Fever with URI symptoms of duration <3 days should be managed with supportive"
            },
            "L127": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> care unless convincing signs of pneumonia exist or conditions like purulent tonsillitis"
            },
            "L128": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> or otitis media are present."
            },
            "L129": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> leptospirosis. Leucopenia in Dengue, Thrombocytopenia in malaria and Dengue."
            },
            "L130": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Creatinine, liver function tests (SGPT, SGOT, bilirubin and alkaline phosphatase)"
            },
            "L131": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> POC glucose"
            },
            "L132": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Urinalysis if urinary symptoms present. A reflex sample for urine culture should be"
            },
            "L133": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> drawn by clean catch midstream sample."
            },
            "L134": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Malaria rapid antigen card test [ HRP- P falciparum (high Sn and Sp)/LD antigen"
            },
            "L135": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> (lower Sn and high Sp)]. If available malarial smear. Negative RDT should be"
            },
            "L136": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> followed by smear (or repeat RDT) if suspicion high. Malaria less likely if 2 neg"
            },
            "L137": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span>  RDTs. Malarial RDTs may stay positive for >3-4 weeks in highly endemic areas."
            },
            "L138": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Dengue card test for NS1 Ag, IgM and IgG"
            },
            "L139": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Influenza or COVID antigen test. <br><br>"
            },
            "L140": {
                "type": "Heading",
                "content": "Focused work up"
            },
            "L141": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If initial RDTs are negative, and fever >3 days, enteric fever, leptospirosis and scrub"
            },
            "L142": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> typhus or other etiologies may need to be investigated."
            },
            "L143": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Elevated transaminases may suggest enteric fever or rickettsiosis vs other cause of AUFI"
            },
            "L144": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> (PMID 35491421)"
            },
            "L145": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Blood cultures should be a high priority to rule out typhoid/enteric fever or other"
            },
            "L146": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> infections where severe presentation could be due to bacteremia. At least 20-30 ml of"
            },
            "L147": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> blood should be collected and inoculated in aerobic bottles. Anaerobic cultures may be"
            },
            "L148": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> drawn where resources exist."
            },
            "L149": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> A chest X ray may reveal occult pneumonia and could be an ordered test if respiratory"
            },
            "L150": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> symptoms are prominent"
            },
            "L151": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> IgM antibodies for leptospirosis and scrub typhus could be ordered. Sensitivity of such"
            },
            "L152": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> tests is poor, especially earlier in illness. Microscopic agglutination test (MAT), the"
            },
            "L153": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> reference standard for diagnosing leptospirosis but may not be available."
            },
            "L154": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> IgM ELISA for scrub typhus may be available. The indirect fluorescent Ab (IFA) is a"
            },
            "L155": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> mainstay but may not be available. Most common cutoff titer is 1:50 <br><br>"
            },
            "L156": {
                "type": "Heading",
                "content": "Anti-microbial treatment of AUFI"
            },
            "L157": {
                "type": "None",
                "content": " - In non-malarial AUFI, when patient has moderate to serious severity of illness, empirical"
            },
            "L158": {
                "type": "None",
                "content": " - treatment may be indicated while awaiting results of tests including blood cultures. Doxycycline"
            },
            "L159": {
                "type": "None",
                "content": " - or azithromycin may be appropriate initial therapy for those who are not seriously ill and do not"
            },
            "L160": {
                "type": "None",
                "content": " - need parenteral antimicrobial therapy. (PMID 24748368). Both the drugs have a comparable"
            },
            "L161": {
                "type": "None",
                "content": " - efficacy against rickettsia organisms and Leptospira. Azithromycin may be a better option if"
            },
            "L162": {
                "type": "None",
                "content": " - enteric fever suspected and may have lower incidence of adverse effects (PMID 17638600,"
            },
            "L163": {
                "type": "None",
                "content": " - 22975540, 22718054). For those needing parenteral antimicrobial therapy a combination of"
            },
            "L164": {
                "type": "None",
                "content": " - ceftriaxone and doxycycline may be appropriate. <br><br>"
            },
            "L165": {
                "type": "Heading",
                "content": "Treatment for malaria"
            },
            "L166": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> P vivax: Chloroquine X3 days [10mg/kg on day 1 (4 tabs) , 10mg/kg on day 2 (4 tabs)"
            },
            "L167": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> and 5 mg /kg on day 3 (2 tabs)] + primaquine 0.25 mg/kg/d (6 tabs/d) X14 days*"
            },
            "L168": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> P falciparum:"
            },
            "L169": {
                "type": "sub_child",
                "content": "NE: Artemether-Lumefantrine [80mg/480mg (4 tabs) BID] X3 days and"
            },
            "L170": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> primaquine 0.75 mg/kg on day 2"
            },
            "L171": {
                "type": "sub_child",
                "content": "Other states: Artesunate 200 mg X3 days + sulfadoxine-pyrimethamine (750"
            },
            "L172": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span>  mg/37.5 mg X1 dose) plus primaquine 0.75 mg/kg on day 2"
            },
            "L173": {
                "type": "None",
                "content": " - (* Primaquine is contraindicated in infants, pregnant women and individuals with G6PD"
            },
            "L174": {
                "type": "None",
                "content": " - deficiency)<br><br>"
            },
            "L175": {
                "type": "Heading",
                "content": "Suggested Treatment Regimens for Enteric fever <br><br>"
            },
            "L176": {
                "type": "None",
                "content": " - Severe illness or inpatient care (confusion, prolonged fever, organ dysfunction)"
            },
            "L177": {
                "type": "sub_child",
                "content": "Ceftriaxone 2g IV daily (50-100 mg/kg/d) for 10-14 days*"
            },
            "L178": {
                "type": "sub_child",
                "content": "Cefotaxime 1-2g IV q 8h (150-200mg/kg/d) for 10-14 days* <br><br>"
            },
            "L179": {
                "type": "None",
                "content": " - Ambulatory care"
            },
            "L180": {
                "type": "sub_child",
                "content": "Azithromycin: 1g PO daily (10-20 mg/kg/d) for 7 days"
            },
            "L181": {
                "type": "sub_child",
                "content": "Cefixime 400 mg PO twice daily (20mg/kg in 2 divided doses) for 10-14 days# <br><br>"
            },
            "L182": {
                "type": "None",
                "content": " - Fluoroquinolones should not be used. TMP/SMX 960 mg BID may be considered if"
            },
            "L183": {
                "type": "None",
                "content": " - susceptibility testing confirms no drug resistance."
            },
            "L184": {
                "type": "None",
                "content": " - (*antimicrobial susceptibility testing to rule out XDR S typhi)"
            },
            "L185": {
                "type": "None",
                "content": " - (# may be used for de-escalation from initial IV therapy. May be associated with slower"
            },
            "L186": {
                "type": "None",
                "content": " - defervescence and higher rate of on treatment failure)<br><br>"
            },
            "L187": {
                "type": "Heading",
                "content": "Treatment for leptospirosis"
            },
            "L188": {
                "type": "None",
                "content": " - Mild disease:"
            },
            "L189": {
                "type": "sub_child",
                "content": "Doxycycline 100 mg BID (2 mg/kg/d in 2 doses) X 7 days"
            },
            "L190": {
                "type": "sub_child",
                "content": "Azithromycin 500 mg PO daily for 3 days or 10 mg/kg on day 1 f/b 5 mg/kg/d for"
            },
            "L191": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> 2 days"
            },
            "L192": {
                "type": "None",
                "content": " - Severe disease"
            },
            "L193": {
                "type": "sub_child",
                "content": "Penicillin G (1.5 -3 million U IV q 6h), OR Ceftriaxone 1-2 g IV"
            },
            "L194": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span>  daily/ Cefotaxime1 g IV every six hours*"
            },
            "L195": {
                "type": "None",
                "content": " - (*Penicillin and cephalosporins lack activity against rickettsiae and so should be avoided when"
            },
            "L196": {
                "type": "None",
                "content": " - rickettsial infection cannot be ruled out) <br><br>"
            },
            "L197": {
                "type": "Heading",
                "content": "Treatment for scrub typhus"
            },
            "L198": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>  Doxycycline 100 mg PO/IV BID (2 mg/kg/d in 2 doses) X 7 days"
            },
            "L199": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Azithromycin 500 mg PO/IV daily for 3#L200<br><br>"
            },
            "L200": {
                "type": "Heading",
                "content": "Follow up activities"
            },
            "L201": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Reassess for"
            },
            "L202": {
                "type": "sub_child",
                "content": "Not improving in the expected time frame"
            },
            "L203": {
                "type": "sub_child",
                "content": "Getting worse in spite of appropriate treatment"
            },
            "L204": {
                "type": "sub_child",
                "content": "New symptoms appear- e.g., rash, seizures, altered sensorium, jaundice, reduced"
            },
            "L205": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> urine output, etc."
            },
            "L206": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Isolation of patient from other household contacts if possible"
            }
        },
        "Tables": {
            "T1": {
                "title": "Can broadly be malarial or non-malarial.",
                "type": "Table",
                "after": "L21",
                "content": [
                    [
                        "Infection",
                        "Areas (Epidemiology)",
                        "Seasonality (Epidemiology)",
                        "Clinical features",
                        "Diagnostic test"
                    ],
                    [
                        "Malaria",
                        "All over but higher Eastern, NE (falciparum predominant), central and South India (vivax predominant)",
                        "Higher 2 months after start of monsoon season",
                        " Paroxysmal fevers, chills, sweats. Hyperparasitemia with P falciparum can cause shock, renal failure, hemolysis",
                        "RDT<br>Malarial smear (sensitivity may be low and user dependent)<br>2nd line- malaria PCR"
                    ],
                    [
                        "Dengue fever",
                        " All over and more cases in south, west",
                        "Also, in monsoon period",
                        "Fever + headache, retroorbital pain, myalgia, arthralgia",
                        "NS1 Ag and IgM/IgG"
                    ],
                    [
                        "",
                        "NE, east. Urban->rural",
                        "",
                        "rash. Platelets <150k. Symptoms last 2-7 days. 3-7 days after initial symptoms pt can develop dengue shock or hemorrhagic fever with purpura, bleeding and hypotension.",
                        "(Sn 75-93% and Sp 88-100%).<br>Detectable 1-9 days post fever, higher in primary infection.<br>IgM band cross reacts with Chikungunya.<br>2nd line Dengue PCR or IgM capture ELISA (MAC-ELISA)"
                    ],
                    [
                        "Typhoid/enteric fever",
                        "All over; Urban predominance",
                        "Endemic but higher Jul-Oct, occasional food borne epidemic",
                        "Fever malaise. Diarrhea <50%. Splenomegaly. Secondary worsening in week 2. Could lead to encephalopathy and intestinal perforation",
                        "Blood cultures (pos 40-80%). Need higher volume of cultured blood"
                    ],
                    [
                        "Leptospirosis",
                        "South, west and eastern India",
                        "Urban slums after flooding. a/w rodent exposure. In rural areas work in paddy fields or having pets at home",
                        "Fever, malaise, headache. Conjunctival suffusion and myalgias prominent. Jaundice, hepatitis and renal failure, pulmonary hemorrhage (5-15%)",
                        "IgM ELISA<br>2nd line microscopic agglutination test >200<br>Sn of both tests low (<50%) in first week and may be improved when tested in week 2 (PMID10586903)"
                    ],
                    [
                        "Scrub Typhus",
                        "Northeast, east and south India. Majority rural, agricultural laborers",
                        "Higher in Aug to January",
                        "Fever, headache, myalgias, rash, lymph node swelling, confusion. May have eschar (22%) at site of mite bite which predates symptoms by around 7-10 days.",
                        "IgM ELISA<br>2nd line PCR or IFA"
                    ],
                    [
                        "Chikungunya",
                        "All over but max KA, MH, TL, UK",
                        "Rainy season through winter.",
                        "Fever, polyarthralgia, rash, headache, conjunctivitis, back pain, nausea, rash. 30-",
                        "IgM ELISA"
                    ],
                    [
                        "",
                        "",
                        "",
                        "40% can have chronic peripheral arthritis",
                        ""
                    ],
                    [
                        "Influenza or other viral URI",
                        "All over",
                        "Post monsoon season and second peak in Jan-Mar",
                        "Close contact history. Fever, cough, myalgia, sore throat, headache",
                        "Flu Ag, COVID Ag on nasal or nasopharyngeal swab"
                    ],
                    [
                        "Other causes include focal infection with bacteremia e.g pyelonephritis or abdominal abscess or acute meningoencephalitis: Japanese B encephalitis, HSV encephalitis, Nipah virus disease",
                        "",
                        "",
                        "",
                        ""
                    ]
                ]
            },
            "T2": {
                "title": "Severity Assessment",
                "type": "Table",
                "after": "L99",
                "content": [
                    [
                        "Parameter",
                        "Potential Cause / Association",
                        "Action / Assessment"
                    ],
                    [
                        "Temperature – high grade fever, associated rigors",
                        "May be associated with bacteremia, abscesses, malaria, pyelonephritis or cholangitis.",
                        "Assess for dehydration esp in summer months.<br>Blood cultures have higher yield with rigors"
                    ],
                    [
                        "HR -tachycardia out of proportion to fever (expect 10 beats increase per deg F rise, or 18 bts/deg C)",
                        "May be a sign of myocarditis.(COVID or viral illness)",
                        "Reassess after fluid administration/rehydration"
                    ],
                    [
                        "RR- tachypnoea out of proportion to fever (Normal RR 16-24/min. Any RR above 30 /min- view with caution)",
                        "May be a sign of pneumonia or sepsis",
                        "Assess with pulse oximetry if available Chest X ray if available."
                    ],
                    [
                        "BP",
                        "Low BP may be a sign of sepsis or shock/dehydration",
                        "Administration of intravenous fluids or rehydration. 30ml/kg over 30 minutes Repeat bolus if severe dehydration persists/pulses remain weak Then 70ml/kg over 2.5 hours Reassess after fluid administration"
                    ],
                    [
                        "Hydration- assess tongue/oral mucosa, skin turgor, urine output by history",
                        "Can occur due to diarrheal illness, or from nausea/vomiting, low PO intake",
                        "Administration of intravenous fluids or rehydration with ORS if due to fluid losses. 2.2 – 4 litres of ORS over 4 hours"
                    ],
                    [
                        "Mental status",
                        "May be from sepsis, cerebral malaria, typhoid encephalopathy, scrub typhus, meningitis",
                        "Assess neck stiffness, need for lumbar puncture. Assess for ability to protect airway Assess for focal weakness, periodic breathing, directional gaze"
                    ]
                ]
            }
        }
    },
    "pneumonia": {
        "description": "This pathway outlines Adult Community Acquired Pneumonia management, covering assessment, diagnostics, risk stratification, empiric antibiotic therapy, and discharge planning, with adaptations for resource-limited settings and specific infections.",
        "lines": {
            "L1": {
                "type": "Tile",
                "content": "Adult Community Acquired Pneumonia Pathway"
            },
            "L2": {
                "type": "Heading",
                "content": "Methods"
            },
            "L3": {
                "type": "None",
                "content": " - Existing guidelines from professional bodies, clinical resources, and intergovernmental"
            },
            "L4": {
                "type": "None",
                "content": " - resources for the management of pneumonia in resource-limited settings"
            },
            "L5": {
                "type": "Link",
                "content": " - ATS/IDSA 2019 guidelines",
                "link": "https://www.atsjournals.org/doi/pdf/10.1164/rccm.201908-1581ST"
            },
            "L6": {
                "type": "None",
                "content": " - UpToDate"
            },
            "L7": {
                "type": "Link",
                "content": " - Indian guidelines",
                "link": "https://journals.lww.com/lungindia/Fulltext/2012/29052/Guidelines_for_diagnosis_and_management_of.1.aspx"
            },
            "L8": {
                "type": "sub_child",
                "content": "Joint ICS/NCCP(I) recommendations 2012"
            },
            "L9": {
                "type": "Link",
                "content": " - MSF",
                "link": "https://medicalguidelines.msf.org/en"
            },
            "L10": {
                "type": "Link",
                "content": " - Indian Council of Medical Research antimicrobial guidelines",
                "link": "https://main.icmr.nic.in/sites/default/files/guidelines/Treatment_Guidelines_2019_Final.pdf"
            },
            "L11": {
                "type": "Link",
                "content": " - British Thoracic Society",
                "link": "https://thorax.bmj.com/content/64/Suppl_3/iii1"
            },
            "L12": {
                "type": "Heading",
                "content": "<br><br>This pathway is suitable for"
            },
            "L13": {
                "type": "None",
                "content": " - Adults presenting to CSA clinics<br><br>"
            },
            "L14": {
                "type": "Heading",
                "content": "Initial assessment"
            },
            "L15": {
                "type": "None",
                "content": " - Assess stability"
            },
            "L16": {
                "type": "sub_child",
                "content": "If unstable, resuscitate +/- transfer to higher level of care"
            },
            "L17": {
                "type": "None",
                "content": " - Consider differential diagnoses"
            },
            "L18": {
                "type": "None",
                "content": " - Obtain pulse oximetry<br><br>"
            },
            "L19": {
                "type": "Heading",
                "content": "Radiography for CAP"
            },
            "L20": {
                "type": "None",
                "content": " - Routine chest radiography is not required for patients who have:"
            },
            "L21": {
                "type": "sub_child",
                "content": "A clinical presentation consistent with CAP <b>AND</b>"
            },
            "L22": {
                "type": "sub_child",
                "content": "Are candidates for outpatient management <b>AND</b>"
            },
            "L23": {
                "type": "sub_child",
                "content": "No compelling differential diagnoses <b>AND</b>"
            },
            "L24": {
                "type": "sub_child",
                "content": "No relevant co-morbidities <b>AND</b>"
            },
            "L25": {
                "type": "sub_child",
                "content": "No hypoxia/evidence of severe disease <b>AND</b>"
            },
            "L26": {
                "type": "sub_child",
                "content": "NB: our preference is for all patients to have CXR if possible. However,"
            },
            "L127": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> infrastructure limitations can prohibit this. In the case CXR is not available,"
            },
            "L128": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> careful clinical diagnosis can be considered. In outpatient settings globally, <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/29167296/' target='_blank'>CAP</a> "
            },
            "L129": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/29167296/' target='_blank'>is often diagnosed without CXR.</a>"
            },
            "L30": {
                "type": "None",
                "content": " - Chest XR should be obtained for patients who are:"
            },
            "L31": {
                "type": "sub_child",
                "content": "Unwell, clinically unstable, have evidence of severe disease, or hypoxic <b>OR</b>"
            },
            "L32": {
                "type": "sub_child",
                "content": "If there are relevant co-morbidities <b>OR</b>"
            },
            "L33": {
                "type": "sub_child",
                "content": "If there is diagnostic uncertainty<br><br>"
            },
            "L34": {
                "type": "Heading",
                "content": "Lab tests for CAP"
            },
            "L35": {
                "type": "None",
                "content": " - All patients with suspected CAP should be screened for COVID-19"
            },
            "L36": {
                "type": "None",
                "content": " - During flu season, consider screening patients with suspected CAP for influenza A/B"
            },
            "L37": {
                "type": "None",
                "content": " - Patients suspected of tuberculosis should be investigated according to local"
            },
            "L38": {
                "type": "None",
                "content": " - protocols/CSA pathway (to be written)<br><br>"
            },
            "L39": {
                "type": "Heading",
                "content": "Location of treatment"
            },
            "L40": {
                "type": "None",
                "content": " - Decision to manage patient as an outpatient or inpatient to be determined through risk stratification and clinical judgment"
            },
            "L41": {
                "type": "None",
                "content": " - CRB65, CURB65 and PSI can be used to stratify risk (Appendix 3)"
            },
            "L42": {
                "type": "sub_child",
                "content": "CRB65 is the simplest tool and does not require blood tests"
            },
            "L43": {
                "type": "None",
                "content": " - Investigations such as arterial blood gas, full blood count, and biochemistry may aid in risk stratification (and are required by the PSI)<br><br>"
            },
            "L44": {
                "type": "Heading",
                "content": "IF patient suitable for outpatient management of CAP"
            },
            "L45": {
                "type": "None",
                "content": " - i.e. clinically stable, low CRB65"
            },
            "L46": {
                "type": "None",
                "content": " - Initiate empiric therapy for CAP with first line oral agent (Appendix 1)"
            },
            "L47": {
                "type": "None",
                "content": " - Re-assess patient in 48–72 hours"
            },
            "L48": {
                "type": "None",
                "content": " - Outpatient CAP should be treated for 5 days"
            },
            "L49": {
                "type": "sub_child",
                "content": "Ensure afebrile > 48 hours and clinically stable prior to stopping antibiotics<br><br>"
            },
            "L50": {
                "type": "Heading",
                "content": "IF patient requires inpatient management of CAP"
            },
            "L51": {
                "type": "None",
                "content": " - Assess capacity to manage at CSA partner site"
            },
            "L52": {
                "type": "sub_child",
                "content": "Arrange transfer if required"
            },
            "L53": {
                "type": "None",
                "content": " - Use the ATS/IDSA Major and Minor criteria to determine regular ward vs ICU level care (Appendix 4)"
            },
            "L54": {
                "type": "None",
                "content": " - Take sputum and blood cultures if possible (only in severe CAP, as defined in the appendix)"
            },
            "L55": {
                "type": "None",
                "content": " - Start IV empiric antibiotic therapy as soon as possible (Appendix 1)"
            },
            "L56": {
                "type": "sub_child",
                "content": "If patient requires transfer, give first dose of antibiotics prior to transfer"
            },
            "L57": {
                "type": "sub_child",
                "content": "If intravenous access not possible at CSA site, then IM ceftriaxone can be considered as a temporising measure"
            },
            "L58": {
                "type": "None",
                "content": " - Give antibiotics for at least 5 days"
            },
            "L59": {
                "type": "None",
                "content": " - Initial empiric therapy can be de-escalated as patient clinically improves"
            },
            "L60": {
                "type": "None",
                "content": " - If patient does not improve clinically on empiric therapy, re-assess patient and consider:"
            },
            "L61": {
                "type": "sub_child",
                "content": "Resistant organisms (MRSA, Pseudomonas)"
            },
            "L62": {
                "type": "sub_child",
                "content": "Complications of CAP (Parapneumonic effusion, Empyema)"
            },
            "L63": {
                "type": "sub_child",
                "content": "Alternative diagnosis<br><br>"
            },
            "L64": {
                "type": "Heading",
                "content": "In influenza positive"
            },
            "L65": {
                "type": "None",
                "content": " - If within 3 days of symptom onset, start oseltamivir 75mg BD for 5 days"
            },
            "L66": {
                "type": "None",
                "content": " - Cover with empirical antibiotics given the risk for bacterial superinfection/co-infection<br><br>"
            },
            "L67": {
                "type": "Heading",
                "content": "If Covid positive"
            },
            "L68": {
                "type": "None",
                "content": " - As per CSA Covid pathway<br><br>"
            },
            "L69": {
                "type": "Heading",
                "content": "Plan for discharge"
            },
            "L70": {
                "type": "None",
                "content": " - Follow-up should be arranged with patient prior to discharge"
            },
            "L71": {
                "type": "sub_child",
                "content": "Arrange follow up in 48–72 hours to assess response and stability"
            },
            "L72": {
                "type": "sub_child",
                "content": "Arrange an additional follow up in 4–6 weeks to if patient requires"
            },
            "L73": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> Covid/Influenza/Pneumococcal vaccine catch-up"
            },
            "L74": {
                "type": "None",
                "content": " - Checklist for discharge (Appendix 5)<br><br>"
            },
            "L75": {
                "type": "Heading",
                "content": "Interventions to avoid"
            },
            "L76": {
                "type": "None",
                "content": " - The following tests do not need to be done routinely for suspected CAP suitable for outpatient management"
            },
            "L77": {
                "type": "sub_child",
                "content": "Sputum culture"
            },
            "L78": {
                "type": "sub_child",
                "content": "Blood culture"
            },
            "L79": {
                "type": "sub_child",
                "content": "Urinary antigens"
            },
            "L80": {
                "type": "sub_child",
                "content": "Inflammatory markers (CRP, procalcitonin)"
            },
            "L81": {
                "type": "sub_child",
                "content": "These tests can be considered if severe CAP requiring inpatient management, or if patient has co-morbidities"
            },
            "L82": {
                "type": "None",
                "content": " - Do not treat CAP empirically with carbapenems (e.g. meropenem, imipenem)"
            },
            "L83": {
                "type": "sub_child",
                "content": "Carbapenems have an unnecessarily broad spectrum of coverage for CAP"
            },
            "L84": {
                "type": "None",
                "content": " - Do not treat CAP empirically with anti-MRSA or anti-pseudomonal agents"
            },
            "L85": {
                "type": "sub_child",
                "content": "Most CAP is not caused by MRSA or pseudomonas – these organisms do not need to be routinely covered"
            },
            "L86": {
                "type": "None",
                "content": " - Do not prescribe steroids for CAP"
            },
            "L87": {
                "type": "sub_child",
                "content": "Multiple trials have failed to show a clinical benefit from corticosteroid administration in CAP"
            },
            "L88": {
                "type": "sub_child",
                "content": "Exception – Severe CAP (CAPECOD trial)"
            },
            "L89": {
                "type": "None",
                "content": " *Avoid respiratory fluroquinolones unless TB ruled out "
            },
            "L90": {
                "type": "None",
                "content": " - If prior history of respiratory MRSA"
            },
            "L91": {
                "type": "sub_child",
                "content": "Add vancomycin (15mg/kg every 12 hours)"
            },
            "L92": {
                "type": "sub_child",
                "content": "Obtain cultures/PCR to guide ongoing therapy"
            },
            "L93": {
                "type": "sub_child",
                "content": "Vancomycin/MRSA cover should be stopped if MRSA is not identified on laboratory testing<br><br>"
            },
            "L94": {
                "type": "None",
                "content": " - If prior history of respiratory pseudomonas aeruginosa"
            },
            "L95": {
                "type": "sub_child",
                "content": "Initiate treatment with antipseudomonal cover (piperacillin/tazobactam 4.5g every 6 hours or cefepime 2g three times daily)"
            },
            "L96": {
                "type": "sub_child",
                "content": "Obtain cultures/PCR to guide ongoing therapy"
            },
            "L97": {
                "type": "sub_child",
                "content": "Pseudomonal cover should be stopped if pseudomonas is not identified on laboratory testing<br><br>"
            },
            "L98": {
                "type": "None",
                "content": " - If MRSA or pseudomonas is suspected based on patient (e.g. underlying structural lung disease) or epidemiological factors"
            },
            "L99": {
                "type": "sub_child",
                "content": "In non-severe disease, obtain cultures/PCR but withhold MRSA/pseudomonas cover unless confirmed on laboratory testing"
            },
            "L100": {
                "type": "sub_child",
                "content": "In severe disease, add MRSA or pseudomonas coverage, obtain cultures/PCR to guide ongoing need for MRSA/pseudomonas coverage<br><br>"
            },
            "L101": {
                "type": "None",
                "content": " - If influenza positive"
            },
            "L102": {
                "type": "sub_child",
                "content": "Add Oseltamivir 75mg twice daily"
            },
            "L103": {
                "type": "None",
                "content": "*Sputum sample should be sent for TB testing in patients commencing on respiratory fluroquinolones"
            },
            "L104": {
                "type": "None",
                "content": " - NOTES: "
            },
            "L105": {
                "type": "sub_child",
                "content": "Characteristics of penicillin allergy should be clarified prior to initiation of treatment "
            },
            "L106": {
                "type": "sub_child",
                "content": "While up to 10% of patients report penicillin allergies, greater than 90% of these patients"
            },
            "L107": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> do not have evidence of penicillin allergy on subsequent testing<br><br>"
            },
            "L108": {
                "type": "Heading",
                "content": "Appendix 3 – Validated Severity Scales"
            },
            "L109": {
                "type": "Heading",
                "content": "Appendix 4 – ATS/IDSA Major and Minor criteria for determining regular ward vs ICU disposition<br><br>"
            },
            "L110": {
                "type": "Heading",
                "content": "Validated definition includes either one major criterion or three or more minor criteria"
            },
            "L111": {
                "type": "None",
                "content": "- If meeting this definition, patient should be managed in an intensive care setting<br><br>"
            },
            "L112": {
                "type": "Heading",
                "content": "Major criteria"
            },
            "L113": {
                "type": "None",
                "content": " - Septic shock with need for vasopressors"
            },
            "L114": {
                "type": "None",
                "content": " - Respiratory failure requiring mechanical ventilation<br><br>"
            },
            "L115": {
                "type": "Heading",
                "content": "Minor criteria"
            },
            "L116": {
                "type": "None",
                "content": " - Respiratory rate ≥ 30 breaths/min"
            },
            "L117": {
                "type": "None",
                "content": " - PaO2/FIO2 ratio ≤ 250"
            },
            "L118": {
                "type": "None",
                "content": " - Multilobar infiltrates Confusion/disorientation"
            },
            "L119": {
                "type": "None",
                "content": " - Uremia (blood urea nitrogen level ≥ 20 mg/dl)"
            },
            "L120": {
                "type": "None",
                "content": " - Leukopenia* (white blood cell count < 4,000 cells/µl)"
            },
            "L121": {
                "type": "None",
                "content": " - Thrombocytopenia (platelet count < 100,000 cells/µl)"
            },
            "L122": {
                "type": "None",
                "content": " - Hypothermia (core temperature < 36 C)"
            },
            "L123": {
                "type": "None",
                "content": " - Hypotension requiring aggressive fluid"
            },
            "L124": {
                "type": "None",
                "content": " - Resuscitation<br><br>"
            },
            "L125": {
                "type": "None",
                "content": "*Due to infection alone (i.e. not chemotherapy related)"
            }
        },
        "Tables": {
            "T1": {
                "title": "Appendix 1: Empiric Treatment of Pneumonia",
                "type": "Table",
                "after": "L88",
                "content": [
                    [
                        "",
                        "Outpatient first line (no risk factors)",
                        "Outpatient with comorbidities/recent antibiotic use",
                        "Inpatient, NOT severe",
                        "Inpatient, severe"
                    ],
                    [
                        "CSA",
                        "Amoxicillin 1g three times daily <b>OR</b><br>Doxycycline 100mg twice daily <b>OR</b><br>Azithromycin 500mg first day then 250mg daily thereafter <b>OR</b><br>Clarithromycin 500mg twice daily",
                        "Amoxicillin/Clavulanate 875/125 twice daily <b>OR</b> cefuroxime 500mg twice daily<br><br><b>AND</b><br><br>Doxycycline 100mg twice daily <b>OR</b><br>Azithromycin 500mg first day then 250mg daily thereafter <b>OR</b><br>Clarithromycin 500mg twice daily",
                        "Ceftriaxone 1-2g daily<br><br><b>AND</b><br><br>Azithromycin 500mg daily <b>OR</b><br>Clarithromycin 500mg twice daily",
                        "Ceftriaxone 1-2g daily<br><br><b>AND</b><br><br>Azithromycin 500mg daily <b>OR</b><br>Clarithromycin 500mg twice daily"
                    ]
                ]
            },
            "T2": {
                "title": "Appendix 2: Empiric treatment of CAP at CSA partner sites in patients with confirmed anaphylactic reaction to penicillins",
                "type": "Table",
                "after": "L102",
                "content": [
                    [
                        "",
                        "Outpatient first line (no risk factors)",
                        "Outpatient with comorbidities/recent antibiotic use",
                        "Inpatient, NOT severe",
                        "Inpatient, severe"
                    ],
                    [
                        "CSA",
                        "Doxycycline 100mg twice daily <b>OR</b><br>Azithromycin 500mg first day then 250mg daily thereafter <b>OR</b><br>Clarithromycin 500mg twice daily",
                        "Doxycycline 100mg twice daily <b>OR</b><br>Azithromycin 500mg first day then 250mg daily thereafter <b>OR</b><br>Clarithromycin 500mg twice daily<br><br><b>OR</b><br><br>Levofloxacin 750mg daily <b>OR</b><br>Moxifloxacin 400mg daily*",
                        "Levofloxacin 750mg daily <b>OR</b><br>Moxifloxacin 400mg daily*",
                        "Aztreonam 2g every 8 hours<br><br><b>AND</b><br><br>Levofloxacin 750mg daily<br><b>OR</b><br>Moxifloxacin 400mg daily"
                    ]
                ]
            },
            "T3": {
                "title": "CURB-65",
                "type": "Table",
                "after": "L108",
                "content": [
                    [
                        "Criteria",
                        "Points"
                    ],
                    [
                        "Confusion",
                        "+1"
                    ],
                    [
                        "Urea > 7 mmol/L",
                        "+1"
                    ],
                    [
                        "Respiratory Rate ≥ 30",
                        "+1"
                    ],
                    [
                        "Systolic BP < 90 mmHg or Diastolic BP ≤ 60 mmHg",
                        "+1"
                    ],
                    [
                        "Age ≥ 65",
                        "+1"
                    ],
                    [
                        "Total score",
                        ""
                    ]
                ]
            },
            "T4": {
                "title": "",
                "type": "Table",
                "after": "L108",
                "content": [
                    [
                        "CURB-65 Score",
                        "Mortality Risk",
                        "Recommendation"
                    ],
                    [
                        "0",
                        "0.6%",
                        "Low risk, consider outpatient treatment"
                    ],
                    [
                        "1",
                        "2.7%",
                        "Low risk, consider outpatient treatment"
                    ],
                    [
                        "2",
                        "6.8%",
                        "Short inpatient hospitalization or closely supervised outpatient treatment"
                    ],
                    [
                        "3",
                        "14.0%",
                        "Severe pneumonia, inpatient management, consider ICU"
                    ],
                    [
                        "4 or 5",
                        "27.8%",
                        "Severe pneumonia, inpatient management, consider ICU"
                    ]
                ]
            },
            "T5": {
                "title": "CRB-65",
                "type": "Table",
                "after": "L108",
                "content": [
                    [
                        "Criteria",
                        "Points"
                    ],
                    [
                        "Confusion",
                        "+1"
                    ],
                    [
                        "Respiratory Rate ≥ 30",
                        "+1"
                    ],
                    [
                        "Systolic BP < 90 mmHg or Diastolic BP ≤ 60 mmHg",
                        "+1"
                    ],
                    [
                        "Age ≥ 65",
                        "+1"
                    ],
                    [
                        "Total score",
                        ""
                    ]
                ]
            },
            "T6": {
                "title": "CRB-65 Interpretation",
                "type": "Table",
                "after": "L108",
                "content": [
                    [
                        "Score",
                        "Recommendation"
                    ],
                    [
                        "0",
                        "Low risk, consider outpatient treatment"
                    ],
                    [
                        "1",
                        "Increased risk, consider inpatient management"
                    ],
                    [
                        "2",
                        "Increased risk, consider inpatient management"
                    ],
                    [
                        "3-4",
                        "High risk, inpatient management"
                    ]
                ]
            },
            "T7": {
                "title": "Appendix 5 – Checklist for discharge",
                "type": "Table",
                "after": "L125",
                "content": [
                    [
                        "Intervention",
                        "Outcome"
                    ],
                    [
                        "Diagnosis",
                        "CAP vs DDx"
                    ],
                    [
                        "COVID test",
                        "Pos/Neg"
                    ],
                    [
                        "TB screen",
                        "Pos/Neg"
                    ],
                    [
                        "CXR",
                        "Findings"
                    ],
                    [
                        "Risk stratification (likely CRB-65)",
                        "Outpatient vs Inpatient vs Inpatient ICU"
                    ],
                    [
                        "Antibiotics",
                        "Drug"
                    ],
                    [
                        "Disposition",
                        "Home/Admit"
                    ],
                    [
                        "Follow up",
                        "Planned"
                    ]
                ]
            }
        }
    },
    "anaemia": {
        "description": "This document outlines the Anaemia Pathway in India, highlighting the high prevalence of anaemia among women (57.2%) and men (25%) based on NFHS5 data. It details past and current national programs to combat anaemia, acknowledges the persistent challenge despite these efforts, and identifies drivers and barriers to improvement. The pathway further delves into the causes of anaemia, emphasizing iron deficiency, and provides a sequence for diagnosis and management, including criteria for different MCV levels and treatment protocols for IDA, B12/folate deficiency, and specific considerations for thalassemia, sickle cell, and malaria-related anaemia.",
        "lines": {
            "L1": {
                "type": "Tile",
                "content": "Anaemia Pathway"
            },
            "L2": {
                "type": "Heading",
                "content": "Background"
            },
            "L3": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Point prevalence of anaemia is high in India"
            },
            "L4": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='http://rchiips.org/nfhs/NFHS-5_FCTS/India.pdf' target='_blank'>NFHS5 data</a>:"
            },
            "L5": {
                "type": "sub_child",
                "content": "57.2% of women aged 15-49 anaemic (Hb < 12)"
            },
            "L6": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> 54.1% urban, 58.7% rural"
            },
            "L7": {
                "type": "sub_child",
                "content": "25% of men aged 15-49 anaemic (Hb < 13)"
            },
            "L8": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> 20.4% urban, 27.4% rural"
            },
            "L9": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> National Nutritional Anaemia Prevention Programme free iron and folic acid"
            },
            "L10": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span>supplementation for children, expectant/nursing mothers, women who attend family"
            },
            "L11": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> planning services"
            },
            "L12": {
                "type": "sub_child",
                "content": "Has not been successful"
            },
            "L13": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> 2013 National Iron Plus Initiative free iron and folic acid for children/adolescents"
            },
            "L14": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> aged 10-19"
            },
            "L15": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Other programs in the past"
            },
            "L16": {
                "type": "sub_child",
                "content": "Integrated Child Development Services"
            },
            "L17": {
                "type": "sub_child",
                "content": "National Nutrition Policy"
            },
            "L18": {
                "type": "sub_child",
                "content": "National Programme for Nutritional Support to Primary Education (Mid-day Meal"
            },
            "L19": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> Programme)"
            },
            "L20": {
                "type": "sub_child",
                "content": "12 x 12 Initiative"
            },
            "L21": {
                "type": "sub_child",
                "content": "Rajiv Gandhi Scheme for Girls Empowerment of Adolescent, SABLA"
            },
            "L22": {
                "type": "sub_child",
                "content": "National Rural Health Mission"
            },
            "L23": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Currently Anemia Mukt Bharat"
            },
            "L24": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Despite multiple national programs targeting anaemia, overall rates of anaemia have not"
            },
            "L25": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> decreased (per serial NFHS’)<br><br>"
            },
            "L26": {
                "type": "Heading",
                "content": "Drivers of anaemia in India"
            },
            "L27": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Inadequate dietary intake (vegetarian diet)"
            },
            "L28": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Loss of iron during menstrual cycle"
            },
            "L29": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Repeated pregnancy/lactation"
            },
            "L30": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Infections <br><br>"
            },
            "L31": {
                "type": "Heading",
                "content": "Barriers to improving anaemia"
            },
            "L32": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Inadequate supplies/coverage of programs"
            },
            "L33": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Education"
            },
            "L34": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Compliance<br><br>"
            },
            "L35": {
                "type": "Heading",
                "content": "Relevant documents"
            },
            "L36": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='https://www.nhm.gov.in/images/pdf/programmes/child-health/guidelines/Control-of-Iron-Deficiency-Anaemia.pdf' target='_blank'>National Rural Health Mission Guidelines for Control of IDA</a>"
            },
            "L37": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='https://anemiamuktbharat.info/wp-content/uploads/2019/09/Anemia-Mukt-Bharat-Brochure_English.pdf' target='_blank'>Anemia Mukt Bharat Intensified National Iron Plus Initiative</a> <br><br>"
            },
            "L38": {
                "type": "Heading",
                "content": "Causes of anaemia (with an emphasis on LMICs)"
            },
            "L39": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Decreased production"
            },
            "L40": {
                "type": "sub_child",
                "content": "Iron deficiency"
            },
            "L41": {
                "type": "sub_child",
                "content": "Other nutritional deficiencies (folic acid, B12, A)"
            },
            "L42": {
                "type": "sub_child",
                "content": "Depressed bone marrow function"
            },
            "L43": {
                "type": "sub_child",
                "content": "Infectious (HIV, leishmania)"
            },
            "L44": {
                "type": "sub_child",
                "content": "Renal failure"
            },
            "L45": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Loss of RBCs"
            },
            "L46": {
                "type": "sub_child",
                "content": "Acute or chronic haemorrhage"
            },
            "L47": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Increased destruction (haemolysis)"
            },
            "L48": {
                "type": "sub_child",
                "content": "Infections (malaria, HIV)"
            },
            "L49": {
                "type": "sub_child",
                "content": "Haemoglobinopathy (sickle cell, thalassemia)"
            },
            "L50": {
                "type": "sub_child",
                "content": "Drug reaction (e.g. G6PD deficiency) <br><br>"
            },
            "L51": {
                "type": "Heading",
                "content": "Iron-deficiency anaemia (IDA) vs non-iron deficiency anaemia (NIDA)"
            },
            "L52": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> It is likely that the vast majority of anaemia in India is IDA"
            },
            "L53": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> In a <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://journals.sagepub.com/doi/pdf/10.1177/156482650702800309' target='_blank'>2007 study</a> of 100 non-pregnant, non-lactating women in Bangalore, 95% of anaemic"
            },
            "L54": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> women were iron deficient"
            },
            "L55": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> In a <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.cureus.com/articles/111948-non-iron-deficiency-anemia-in-rural-indian-women-a-cross-sectional-study#!/references' target='_blank'>2022 study</a> of 258 mothers (pregnant or post-natal), 65.9% were anaemic. Of women"
            },
            "L56": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> with anaemia, 61.8% had normal ferritin levels"
            },
            "L57": {
                "type": "sub_child",
                "content": "However, risk of confounding here – given the patient population should have"
            },
            "L58": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> been commenced on iron supplementation at time of pregnancy"
            },
            "L59": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> The <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://knowledgecommons.popcouncil.org/' target='_blank'>Comprehensive National Nutrition Survey (CNNS)</a> provides more data, but only"
            },
            "L60": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> sampled patients aged between 0-19"
            },
            "L61": {
                "type": "sub_child",
                "content": "In the survey, 12% of children aged 10-19 were anaemic and iron deficient and"
            },
            "L62": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> 16.9% of the same group were anaemic but NOT iron deficient<br><br>"
            },
            "L63": {
                "type": "Heading",
                "content": "Anaemia Sequence"
            },
            "L64": {
                "type": "Heading",
                "content": "Is the patient stable/actively bleeding"
            },
            "L65": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If there is active bleeding, achieve haemostasis. Refer for blood transfusion and further"
            },
            "L66": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> management <br><br>"
            },
            "L67": {
                "type": "Heading",
                "content": "Consider anaemia patterns based on clinical presentation"
            },
            "L68": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Diet/nutritional deficiency"
            },
            "L69": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Acute blood loss"
            },
            "L70": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Personal or family history of anaemia"
            },
            "L71": {
                "type": "sub_child",
                "content": "Suggests hereditary/genetic syndrome"
            },
            "L72": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Menstrual history"
            },
            "L73": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Alcohol intake"
            },
            "L74": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Renal disease"
            },
            "L75": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Underlying illness"
            },
            "L76": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Malaria"
            },
            "L77": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Helminth infection"
            },
            "L78": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Thalassemia"
            },
            "L79": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Sickle cell disease<br><br>"
            },
            "L80": {
                "type": "Heading",
                "content": "Initial test (first line)"
            },
            "L81": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Hemo-cue (POC Hb)"
            },
            "L82": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Is Hb < 8 (severe anaemia)?"
            },
            "L83": {
                "type": "sub_child",
                "content": "<b>Transfusion based on local protocol</b>"
            },
            "L84": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Is CBC available?"
            },
            "L85": {
                "type": "sub_child",
                "content": "If yes, perform CBC (Hb and MCV inform further assessment)"
            },
            "L86": {
                "type": "sub_child",
                "content": "If no, treat empirically for most likely cause based on age, demographics, local"
            },
            "L87": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> epidemiology, clues from history<br><br>"
            },
            "L88": {
                "type": "Heading",
                "content": "What is the MCV?"
            },
            "L89": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> MCV < 80 fL"
            },
            "L90": {
                "type": "sub_child",
                "content": "Common causes: iron deficiency, thalassemia, anaemia of chronic disease"
            },
            "L91": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> MCV 80-100 fL"
            },
            "L92": {
                "type": "sub_child",
                "content": "Iron deficiency"
            },
            "L93": {
                "type": "sub_child",
                "content": "B12 or folate deficiency"
            },
            "L94": {
                "type": "sub_child",
                "content": "Anaemia of chronic disease"
            },
            "L95": {
                "type": "sub_child",
                "content": "Drug-induced"
            },
            "L96": {
                "type": "sub_child",
                "content": "Infection"
            },
            "L97": {
                "type": "sub_child",
                "content": "Liver disease/alcohol"
            },
            "L98": {
                "type": "sub_child",
                "content": "Haemolysis"
            },
            "L99": {
                "type": "sub_child",
                "content": "Hypothyroid"
            },
            "L100": {
                "type": "sub_child",
                "content": "Other"
            },
            "L101": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> MCV > 100 fL"
            },
            "L102": {
                "type": "sub_child",
                "content": "B12 or folate deficiency"
            },
            "L103": {
                "type": "sub_child",
                "content": "Drug-induced"
            },
            "L104": {
                "type": "sub_child",
                "content": "Liver disease/alcohol use"
            },
            "L105": {
                "type": "sub_child",
                "content": "High reticulocyte count"
            },
            "L106": {
                "type": "sub_child",
                "content": "MDS"
            },
            "L107": {
                "type": "sub_child",
                "content": "Other <br><br>"
            },
            "L108": {
                "type": "Heading",
                "content": "IF MCV < 80"
            },
            "L109": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Is ferritin testing or transferrin saturation available?"
            },
            "L110": {
                "type": "sub_child",
                "content": "If ferritin < 30 ng/mL, <b>treat as iron deficiency</b>"
            },
            "L111": {
                "type": "sub_child",
                "content": "If ferritin > 30 ng/mL, then check transferrin saturation"
            },
            "L112": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> If TSAT < 20%, then treat as IDA"
            },
            "L113": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> If TSAT > 20%, then IDA unlikely"
            },
            "L114": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Consider anaemia of chronic disease or thalassemia"
            },
            "L115": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> If MCV is low out of proportion to Hb, suspect thalassemia"
            },
            "L116": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If ferritin/TSAT not available:"
            },
            "L117": {
                "type": "sub_child",
                "content": "Empirically treat for iron deficiency anaemia"
            },
            "L118": {
                "type": "sub_child",
                "content": "(same treatment as below)"
            },
            "L119": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If IDA:"
            },
            "L120": {
                "type": "sub_child",
                "content": "Commence iron replacement"
            },
            "L121": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> PO iron for mild anaemia, IV iron for moderate-severe anaemia"
            },
            "L122": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Indian government offers combined iron-folic acid pills containing"
            },
            "L123": {
                "type": "None",
                "content": "100mg elemental iron and 500mcg of folic acid"
            },
            "L124": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Consider need for blood transfusion if life-threatening anaemia – this will"
            },
            "L125": {
                "type": "None",
                "content": "require transfer to the closest district hospital"
            },
            "L126": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> PO Albendazole 400mg once on an empty stomach"
            },
            "L127": {
                "type": "sub_child",
                "content": "Re-check Hb in 1 month for response"
            },
            "L128": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> If Hb improved, continue iron replacement"
            },
            "L129": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> 3-6 months of therapy are required for replenish iron stores"
            },
            "L130": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> If not improved after 1 month: re-consider diagnosis (see pathway)"
            },
            "L131": {
                "type": "sub_child",
                "content": "Address underlying cause"
            },
            "L132": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Parasites? (deworming), menstrual bleeding, peptic ulcer, GI malignancy,"
            },
            "L133": {
                "type": "None",
                "content": "etc."
            },
            "L134": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If thalassemia suspected"
            },
            "L135": {
                "type": "sub_child",
                "content": "Suspect if MCV out of proportion to the degree of anaemia"
            },
            "L136": {
                "type": "sub_child",
                "content": "Refer for electrophoresis and further management"
            },
            "L137": {
                "type": "sub_child",
                "content": "If patient has suspected thalassemia and is also iron deficient, iron deficiency"
            },
            "L138": {
                "type": "None",
                "content": "should still be treated (with PO or IV iron)"
            },
            "L139": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If sickle cell suspected"
            },
            "L140": {
                "type": "sub_child",
                "content": "Consider if severe anaemia or family history"
            },
            "L141": {
                "type": "sub_child",
                "content": "POC screening test for sickle cell (HemotypeSC is one POC test)"
            },
            "L142": {
                "type": "sub_child",
                "content": "Confirmatory test – send to lab (HPLC)"
            },
            "L143": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Anaemia of chronic disease <br><br>"
            },
            "L144": {
                "type": "Heading",
                "content": "IF MCV > 100"
            },
            "L145": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Send B12 and folate levels if available"
            },
            "L146": {
                "type": "sub_child",
                "content": "If low, then replace"
            },
            "L147": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> B12:"
            },
            "L148": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Give 1000mcg vitamin B12 IM once"
            },
            "L149": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Then give 1000 mcg vitamin B12 PO daily"
            },
            "L150": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Folate"
            },
            "L151": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Give 1-5g folic acid PO daily"
            },
            "L152": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If B12 and folate normal, consider TSH, alcohol use, serum copper, peripheral blood"
            },
            "L153": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> smear, liver function"
            },
            "L154": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If no testing, treat empirically for B12 and folate deficiency"
            },
            "L155": {
                "type": "sub_child",
                "content": "B12:"
            },
            "L156": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Give 1000mcg vitamin B12 IM once"
            },
            "L157": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Then give 1000 mcg vitamin B12 PO daily"
            },
            "L158": {
                "type": "sub_child",
                "content": "Folate"
            },
            "L159": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Give 1-5g folic acid PO daily"
            },
            "L160": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Re-check Hb and MCV in 1 month for response to treatment"
            },
            "L161": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If no response Perform further assessment. May require additional diagnostic testing or"
            },
            "L162": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> referral <br><br>"
            },
            "L163": {
                "type": "Heading",
                "content": "IF MCV 80-100"
            },
            "L164": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Normocytic anaemia"
            },
            "L165": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Causes:"
            },
            "L166": {
                "type": "sub_child",
                "content": "Nutritional deficiency (iron, B12, folate deficiency)"
            },
            "L167": {
                "type": "sub_child",
                "content": "Anaemia of chronic disease"
            },
            "L168": {
                "type": "sub_child",
                "content": "Chronic kidney disease"
            },
            "L169": {
                "type": "sub_child",
                "content": "Heart failure"
            },
            "L170": {
                "type": "sub_child",
                "content": "Hypothyroidism"
            },
            "L171": {
                "type": "sub_child",
                "content": "Endocrine"
            },
            "L172": {
                "type": "sub_child",
                "content": "Cancer"
            },
            "L173": {
                "type": "sub_child",
                "content": "Stem cell disorder"
            },
            "L174": {
                "type": "sub_child",
                "content": "Early blood loss"
            },
            "L175": {
                "type": "sub_child",
                "content": "Partially treated anaemia"
            },
            "L176": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Is there access to iron studies/further testing?"
            },
            "L177": {
                "type": "sub_child",
                "content": "If no, consider concurrent iron/b12/folate therapy"
            },
            "L178": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Perform iron studies (ferritin and transferrin saturation)"
            },
            "L179": {
                "type": "sub_child",
                "content": "If iron deficiency treat"
            },
            "L180": {
                "type": "sub_child",
                "content": "Re-check after 1 month"
            },
            "L181": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If iron stores normal"
            },
            "L182": {
                "type": "sub_child",
                "content": "Consider nutritional causes"
            },
            "L183": {
                "type": "sub_child",
                "content": "Consider haemolysis"
            },
            "L184": {
                "type": "sub_child",
                "content": "Consider therapy with B12 and folate"
            },
            "L185": {
                "type": "sub_child",
                "content": "Consider underlying illness/anaemia of chronic disease<br><br>"
            },
            "L186": {
                "type": "Heading",
                "content": "How to give IV iron"
            },
            "L187": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Is there local capacity to give IV iron infusion"
            },
            "L188": {
                "type": "sub_child",
                "content": "If no, then refer to district hospital/closest centre with capacity"
            },
            "L189": {
                "type": "sub_child",
                "content": "If yes, then which preparation?"
            },
            "L190": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> IV iron sucrose (most common)"
            },
            "L191": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Give 200mg in 100ml normal saline IV over 30 minutes daily until"
            },
            "L192": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\"></span> desired dose is reached"
            },
            "L193": {
                "type": "None",
                "content": " - <span style=\"font-size: 0.7rem; margin-left: 90px; width: 1.35rem;\">o</span> Use <a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='https://www.mdcalc.com/calc/10139/ganzoni-equation-iron-deficiency-anemia' target='_blank'>Ganzoni equation</a> for iron deficiency anaemia"
            },
            "L194": {
                "type": "None",
                "content": " - <span style=\"font-size: 0.7rem; margin-left: 90px; width: 1.35rem;\">o</span> Total iron deficit, mg = weight, kg x (target hemoglobin,"
            },
            "L195": {
                "type": "None",
                "content": " - <span style=\"font-size: 0.7rem; margin-left: 90px; width: 1.35rem;\"></span>  g/dL – actual hemoglobin, g/dL) x 2.4 + iron stores, mg"
            },
            "L196": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Iron Carboxymaltose (more expensive)"
            },
            "L197": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> 1gm in 100ml normal saline IV over 30 minutes<br><br>"
            },
            "L198": {
                "type": "Heading",
                "content": "If Malaria"
            },
            "L199": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> See CSA malaria pathway (to be developed with the other fever content)"
            },
            "L200": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Leads to anaemia through destruction of RBCs, and decreased RBC production"
            },
            "L201": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Diagnose and treat as per <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://nvbdcp.gov.in/WriteReadData/l892s/20627628441542176662.pdf' target='_blank'>National Malaria Guidelines</a>"
            },
            "L202": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Diagnosis"
            },
            "L203": {
                "type": "sub_child",
                "content": "Microscopy (thick and thin smear) or rapid diagnostic test"
            },
            "L204": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Treatment"
            },
            "L205": {
                "type": "sub_child",
                "content": "P. vivax: chloroquine or primaquine"
            },
            "L206": {
                "type": "sub_child",
                "content": "P. falciparum: Artemisinin combination therapy"
            }
        },
        "Tables": {}
    },
    "heart_failure": {
        "description": "This Heart Failure Pathway addresses HFrEF and HFpEF management in India, focusing on diagnosis, guideline-directed medical therapy, and local adaptations for resource limitations and cost.",
        "lines": {
            "L1": {
                "type": "Tile",
                "content": "Heart Failure Pathway"
            },
            "L2": {
                "type": "Heading",
                "content": "Definition"
            },
            "L3": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Divided into heart failure with reduced ejection fraction (HFrEF) and heart failure with"
            },
            "L4": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> preserved ejection fraction (HFpEF)"
            },
            "L5": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> HFrEF and HFpEF present with similar symptoms<br><br>"
            },
            "L6": {
                "type": "Heading",
                "content": "Background"
            },
            "L7": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> In India, burden of HF is high"
            },
            "L8": {
                "type": "sub_child",
                "content": "<a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='https://pmc.ncbi.nlm.nih.gov/articles/PMC3913650/#:~:text=The%20burden%20of%20HF%20in,of%20491%20600%E2%80%931.8%20million.' target='_blank'>Estimate from 2010, 1.3-4.6 million</a>"
            },
            "L9": {
                "type": "sub_child",
                "content": "Likely higher now"
            },
            "L10": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> 1 year mortality from HF in India is <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.sciencedirect.com/science/article/pii/S2214109X17301961' target='_blank'>23%</a>"
            },
            "L11": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> IHD is the <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.healthdata.org/research-analysis/health-by-location/profiles/india' target='_blank'>leading cause of mortality</a> in India"
            },
            "L12": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Burden not just directly from IHD, but the sequelae of cardiac ischemia, including heart"
            },
            "L13": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> failure<br><br>"
            },
            "L14": {
                "type": "Heading",
                "content": "Links to other pathways"
            },
            "L15": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> This pathway should be considered in conjunction with (mostly to be written)"
            },
            "L16": {
                "type": "sub_child",
                "content": "Risk factor modification pathway"
            },
            "L17": {
                "type": "sub_child",
                "content": "HTN pathway"
            },
            "L18": {
                "type": "sub_child",
                "content": "Diabetes pathway"
            },
            "L19": {
                "type": "sub_child",
                "content": "Chest pain pathway"
            },
            "L20": {
                "type": "sub_child",
                "content": "IHD pathway"
            },
            "L21": {
                "type": "sub_child",
                "content": "Others?<br><br>"
            },
            "L22": {
                "type": "Heading",
                "content": "Questions for contextualisation"
            },
            "L23": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> How do we treat HF at CSA partner sites?"
            },
            "L24": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> What are the barriers to HF management in India?"
            },
            "L25": {
                "type": "sub_child",
                "content": "Financial"
            },
            "L26": {
                "type": "sub_child",
                "content": "Can these be overcome?"
            },
            "L27": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> “The best adapted solution to the problem at hand”<br><br>"
            },
            "L28": {
                "type": "Heading",
                "content": "Outpatient management of HFrEF <br><br>"
            },
            "L29": {
                "type": "Heading",
                "content": "Establish diagnosis"
            },
            "L30": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Clinical signs suggestive of HF"
            },
            "L31": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> ECG may show LV hypertrophy, evidence or previous ischaemia"
            },
            "L32": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Echocardiogram with LVEF < 40% consistent with HFrEF"
            },
            "L33": {
                "type": "sub_child",
                "content": "This will likely require referral to nearest district hospital"
            },
            "L34": {
                "type": "sub_child",
                "content": "<b>Echocardiogram ability of partner locations to be determined</b>"
            },
            "L35": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Pregnant patients require pregnancy specific management – this pathway cannot be used<br><br>"
            },
            "L36": {
                "type": "Heading",
                "content": "Assessment of severity"
            },
            "L37": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> See appendix (NYHA Class)<br><br>"
            },
            "L38": {
                "type": "Heading",
                "content": "Assess and manage comorbid conditions"
            },
            "L39": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Ischaemic heart disease"
            },
            "L40": {
                "type": "sub_child",
                "content": "HF is common sequelae of coronary artery disease"
            },
            "L41": {
                "type": "sub_child",
                "content": "<b>Risk reduction and symptomatic management as per CSA IHD pathway (TBD)</b>"
            },
            "L42": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Hypertension"
            },
            "L43": {
                "type": "sub_child",
                "content": "<b>Manage as per CSA hypertension pathway (TBD)</b>"
            },
            "L44": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Diabetes"
            },
            "L45": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Arrythmias"
            },
            "L46": {
                "type": "sub_child",
                "content": "Particularly AF"
            },
            "L47": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Valvular disease"
            },
            "L48": {
                "type": "sub_child",
                "content": "Refer to specialist"
            },
            "L49": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Cardiomyopathy"
            },
            "L50": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Anaemia"
            },
            "L51": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Smoking <br><br>"
            },
            "L52": {
                "type": "Heading",
                "content": "Symptomatic management"
            },
            "L53": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Diuretic"
            },
            "L54": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> furosemide 20-40mg once or twice a day"
            },
            "L55": {
                "type": "sub_child",
                "content": "Morning and midday dosing to avoid nocturnal diuresis"
            },
            "L56": {
                "type": "sub_child",
                "content": "Monitor renal function once a week"
            },
            "L57": {
                "type": "sub_child",
                "content": "Titrate to minimum dose required to eliminate evidence of fluid retention"
            },
            "L58": {
                "type": "sub_child",
                "content": "Can provide a weigh scale to facilitate this<br><br>"
            },
            "L59": {
                "type": "Heading",
                "content": "IF HFrEF<br><br>"
            },
            "L60": {
                "type": "Heading",
                "content": "Disease modifying management"
            },
            "L61": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063#d53151679e1' target='_blank'>Drug from each of the below classes should be initiated at time of diagnosis</a>"
            },
            "L62": {
                "type": "sub_child",
                "content": "Dosages and sequence of initiation in Appendix I"
            },
            "L63": {
                "type": "sub_child",
                "content": "See below if specific therapies unavailable at CSA partner site"
            },
            "L64": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Angiotensin receptor-neprilysin inhibitor (ARNI), angiotensin converting enzyme (ACE)"
            },
            "L65": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> inhibitor, or angiotensin receptor blocker (ARB)"
            },
            "L66": {
                "type": "sub_child",
                "content": "ARNI: Sacubitril-Valsartan"
            },
            "L67": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Preference for ARNI if possible – however, significant barriers due to cost"
            },
            "L68": {
                "type": "sub_child",
                "content": "ACE inhibitor: Captopril, enalapril, lisinopril, ramipril"
            },
            "L69": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Lisinopril and ramipril and once daily dosing, which may be preferable"
            },
            "L70": {
                "type": "sub_child",
                "content": "ARB"
            },
            "L71": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Candesartan, losartan, valsartan"
            },
            "L72": {
                "type": "sub_child",
                "content": "The use of ARNI/ACE/ARB in patients with eGFR < 30 is not contraindicated,"
            },
            "L73": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> but caution should be exercised"
            },
            "L74": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063#d1e3406' target='_blank'><b>Beta blocker</b></a>"
            },
            "L75": {
                "type": "sub_child",
                "content": "Evidence based beta-blockers: Bisoprolol, carvedilol, metoprolol XR"
            },
            "L76": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063#d1e3406' target='_blank'><b>Mineralocorticoid receptor antagonists (MRA)</b></a>"
            },
            "L77": {
                "type": "sub_child",
                "content": "Spironolactone or eplerenone"
            },
            "L78": {
                "type": "sub_child",
                "content": "Monitor serum potassium, down titrate or discontinue if serum potassium elevated"
            },
            "L79": {
                "type": "sub_child",
                "content": "Contraindications: eGFR < 30 or potassium > 5"
            },
            "L80": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063#d1e3406' target='_blank'><b>SGLT2 inhibitor</b></a>"
            },
            "L81": {
                "type": "sub_child",
                "content": "Dapagliflozin or empagliflozin"
            },
            "L82": {
                "type": "sub_child",
                "content": "Contraindications: T1DM, symptomatic hypotension, frequent UTI, risk factors"
            },
            "L83": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> for foot amputation, eGFR < 30 (dapagliflozin), eGFR < 20 (empagliflozin)"
            },
            "L84": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Monitor blood pressure and electrolytes post initiation"
            },
            "L85": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Ensure SBP > 100 <br><br>"
            },
            "L86": {
                "type": "Heading",
                "content": "Alternative treatment regimens"
            },
            "L87": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> On the basis of current evidence, combination therapy with an ARNI, BB, MRA and"
            },
            "L88": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span>SGLT2 inhibitor has the greatest mortality benefit for patients with HFrEF, and is the"
            },
            "L89": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> CSA preferred regimen"
            },
            "L90": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> However, some of these drugs may not be available at CSA partner sites, due to location"
            },
            "L91": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> or cost"
            },
            "L92": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If the above medications are not available, the below alternative regimens can be"
            },
            "L93": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> considered (Appendix II)"
            },
            "L94": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If ARNI unavailable"
            },
            "L95": {
                "type": "sub_child",
                "content": "Replace ARNI with ACEi (e.g. ramipril) or ARB (e.g. valsartan)"
            },
            "L96": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If SGLT2 unavailable"
            },
            "L97": {
                "type": "sub_child",
                "content": "No comparative alternative<br><br>"
            },
            "L98": {
                "type": "Heading",
                "content": "Drugs to use with caution"
            },
            "L99": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Digoxin is commonly used for the treatment of heart failure in India"
            },
            "L100": {
                "type": "sub_child",
                "content": "Robust evidence to support the use of digoxin in HFrEF is lacking"
            },
            "L101": {
                "type": "sub_child",
                "content": "Digoxin use <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.nejm.org/doi/full/10.1056/NEJM199702203360801' target='_blank'>does not appear to reduce mortality, but may reduce hospitalisations</a>"
            },
            "L102": {
                "type": "sub_child",
                "content": "This should be balanced against the risks of digoxin therapy (i.e. digoxin"
            },
            "L103": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> toxicity), and difficulty with monitoring drug levels in the rural Indian setting"
            },
            "L104": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> In general, we do not recommend the use of digoxin in heart failure, especially if any of"
            },
            "L105": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> the above therapies are available"
            },
            "L106": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If digoxin is to be used (not evidence based), starting dose:"
            },
            "L107": {
                "type": "sub_child",
                "content": "0.125mg daily if eGFR ≥ 30"
            },
            "L108": {
                "type": "sub_child",
                "content": "0.125mg every second day or 0.0625mg daily if eGFR < 30, or elderly, or low"
            },
            "L109": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> body weight"
            },
            "L110": {
                "type": "sub_child",
                "content": "Check electrolytes (particularly potassium) prior to initiation"
            },
            "L111": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Exercise particular caution if digoxin used in conjunction with drugs that suppress heart"
            },
            "L112": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> rate (e.g. beta blockers), or increase digoxin concentration (e.g. furosemide)"
            },
            "L113": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Have a high index of suspicion for digoxin toxicity (e.g. vomiting/nausea, visual"
            },
            "L114": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> disturbances, arrhythmias)<br><br>"
            },
            "L115": {
                "type": "Heading",
                "content": "Other considerations"
            },
            "L116": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Patients with recent myocardial infarction and HFrEF"
            },
            "L117": {
                "type": "sub_child",
                "content": "Major studies of HFrEF have excluded patients with recent myocardial infarction"
            },
            "L118": {
                "type": "sub_child",
                "content": "ACEI/ARB, beta blockers and MRAs have been shown to be beneficial in these"
            },
            "L119": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> patients"
            },
            "L120": {
                "type": "sub_child",
                "content": "<a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.nejm.org/doi/10.1056/NEJMoa2104508' target='_blank'>ARNI is not superior to ACEI in</a> the setting of recent myocardial infarction"
            },
            "L121": {
                "type": "sub_child",
                "content": "The impact of SGLT2 in the post-MI period <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://jamanetwork.com/journals/jamacardiology/article-abstract/2795765?guestAccessKey=da0dbf78-f7e9-4ad1-abdc-a1ebdd2d1ccd&utm_source=twitter&utm_medium=social_jamacard&utm_term=7520032259&utm_campaign=article_alert&linkId=179485921' target='_blank'>still being studied</a>"
            },
            "L122": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Lifestyle modifications (see CSA risk factor/lifestyle modification pathway)"
            },
            "L123": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Cardiac rehab"
            },
            "L124": {
                "type": "sub_child",
                "content": "Refer to physiotherapist/local cardiac rehab program"
            },
            "L125": {
                "type": "sub_child",
                "content": "Can give education materials for home cardiac rehab"
            },
            "L126": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Vaccinations"
            },
            "L127": {
                "type": "sub_child",
                "content": "Pneumococcal, influenza, COVID"
            },
            "L128": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Smoking cessation<br><br>"
            },
            "L129": {
                "type": "Heading",
                "content": "Indications for referral to specialist cardiology services (adapted from <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.jacc.org/doi/10.1016/j.jacc.2020.11.022' target='_blank'>Maddox et al, 2021</a>)"
            },
            "L130": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Heart failure refractory to therapy"
            },
            "L131": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Persistent hypotension"
            },
            "L132": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Renal failure"
            },
            "L133": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Heart failure with atrial fibrillation"
            },
            "L134": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> 2+ issues of decompensation in previous 12 months"
            },
            "L135": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Valvular or structural heart disease"
            },
            "L136": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Inability to tolerate medical therapy for heart failure"
            },
            "L137": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Diagnostic uncertainty"
            },
            "L138": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Patients who are potential candidates for device-based therapies<br><br>"
            },
            "L139": {
                "type": "Heading",
                "content": "Outpatient management of HFpEF"
            },
            "L140": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> The diagnosis of heart failure with preserved ejection fraction requires an"
            },
            "L141": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> echocardiogram"
            },
            "L142": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Unlike HFrEF, there are limited therapeutic options in HFpEF"
            },
            "L143": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.uptodate.com/contents/treatment-and-prognosis-of-heart-failure-with-preserved-ejection-fraction?search=hfpef&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1' target='_blank'>If HFpEF confirmed:</a> "
            },
            "L144": {
                "type": "sub_child",
                "content": "Manage comorbid conditions"
            },
            "L145": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Hypertension, AF, CAD risk management, AD, hyperlipidaemia, obesity,"
            },
            "L146": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\"></span> anaemia, diabetes, CKD, OSA"
            },
            "L147": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If fluid overload, diuretics"
            },
            "L148": {
                "type": "sub_child",
                "content": "Titrate to euvolaemia"
            },
            "L149": {
                "type": "sub_child",
                "content": "furosemide 20-40mg as starting dose"
            },
            "L150": {
                "type": "sub_child",
                "content": "If HFpEF"
            },
            "L151": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Consider SGLT2 inhibitor as first line"
            },
            "L152": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If HFpEF with elevated BNP"
            },
            "L153": {
                "type": "sub_child",
                "content": "Consider SGLT2 inhibitor and MRA"
            },
            "L154": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Avoid the following drugs unless prescribed for other conditions such as hypertension:"
            },
            "L155": {
                "type": "sub_child",
                "content": "ARNI, ACEi, ARB, calcium channel blocker, digoxin"
            },
            "L156": {
                "type": "sub_child",
                "content": "None of the above classes of drugs have been shown to improve clinical outcomes"
            },
            "L157": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> in HFpEF <br><br>"
            },
            "L158": {
                "type": "Heading",
                "content": "Appendices<br><br>"
            },
            "L159": {
                "type": "Heading",
                "content": "Appendix I<br><br>"
            },
            "L160": {
                "type": "None",
                "content": "Sequence of Initiation and Starting and Target doses of Pharmacotherapies for HFrEF (adapted from <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.jacc.org/doi/10.1016/j.jacc.2020.11.022' target='_blank'>Maddox et al, 2021</a>)"
            },
            "L161": {
                "type": "Heading",
                "content": "Sequence of initiation"
            },
            "L162": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> For all patients commencing pharmacotherapy, monitor:"
            },
            "L163": {
                "type": "sub_child",
                "content": "Blood pressure"
            },
            "L164": {
                "type": "sub_child",
                "content": "Electrolytes"
            },
            "L165": {
                "type": "sub_child",
                "content": "Renal function"
            },
            "L166": {
                "type": "sub_child",
                "content": "Potassium"
            },
            "L167": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <b>ARNI or ACEI/ARB AND</b>"
            },
            "L168": {
                "type": "sub_child",
                "content": "If starting ARNI, ensure no history of angioedema"
            },
            "L169": {
                "type": "sub_child",
                "content": "Commence starting dose, then assess tolerability every 2 weeks. If dose is"
            },
            "L170": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> tolerated, then double dose every 2 weeks until target dose"
            },
            "L171": {
                "type": "sub_child",
                "content": "Tolerability defined as SBP > 100, lack of symptomatic hypotension"
            },
            "L172": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <b>Beta Blocker AND</b>"
            },
            "L173": {
                "type": "sub_child",
                "content": "Commence at starting dose, doubling every 2 weeks until target dose"
            },
            "L174": {
                "type": "sub_child",
                "content": "Only bisoprolol, carvedilol and metoprolol have demonstrated mortality benefits"
            },
            "L175": {
                "type": "None",
                "content": "  - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> in HFrEF – avoid other beta blockers"
            },
            "L176": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <b>Diuretics AND</b>"
            },
            "L177": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <b>Aldosterone antagonist AND</b>"
            },
            "L178": {
                "type": "sub_child",
                "content": "Commence starting dose, then assess tolerability. Dose can be doubled every 2"
            },
            "L179": {
                "type": "None",
                "content": "  - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> weeks until target dose"
            },
            "L180": {
                "type": "sub_child",
                "content": "Check electrolytes/potassium and renal function 2-3 days post initiation, then 7"
            },
            "L181": {
                "type": "None",
                "content": "  - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> days after initiation, and then at least every 3 months thereafter"
            },
            "L182": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <b>SGLT2 inhibitor AND</b>"
            },
            "L183": {
                "type": "sub_child",
                "content": "Commence at starting dose, no titration is required"
            },
            "L184": {
                "type": "sub_child",
                "content": "Ensure eGFR ≥ 30ml/min for dapagliflozin"
            },
            "L185": {
                "type": "sub_child",
                "content": "Ensure eGFR ≥ 20ml/min for empagliflozin<br><br>"
            },
            "L186": {
                "type": "Heading",
                "content": "Appendix II"
            },
            "L187": {
                "type": "Heading",
                "content": "Sample treatment regimens for HFrEF"
            },
            "L188": {
                "type": "None",
                "content": "CSA preferred regimen"
            },
            "L189": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Based on recent clinical trials, and in accordance with most updated global guidelines"
            },
            "L190": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Sacubitril/Valsartan AND beta blocker (e.g. bisoprolol) AND MRA (e.g. spironolactone"
            },
            "L191": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> or eplerenone) AND SGLT2 inhibitor (dapagliflozin or empagliflozin)"
            },
            "L192": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <b>Approx annual cost of this regimen: ₹77k</b> <br><br>"
            },
            "L193": {
                "type": "None",
                "content": "If sacubitril/valsartan unavailable"
            },
            "L194": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> E.g. due to cost, then use:"
            },
            "L195": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> ACEI (e.g. ramipril) or ARB (e.g. valsartan) AND beta blocker (e.g. bisoprolol) AND"
            },
            "L196": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> MRA (e.g. spironolactone) AND SGLT2 inhibitor (e.g. dapagliflozin)"
            },
            "L197": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <b>Approx annual cost: ₹10k</b><br><br>"
            },
            "L198": {
                "type": "None",
                "content": "If sacubitril/valsartan AND SGLT2 inhibitors unavailable"
            },
            "L199": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> E.g. due to cost, then use:"
            },
            "L200": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> ACEI (e.g. ramipril) or ARB (e.g. valsartan) AND beta blocker (e.g. bisoprolol) AND"
            },
            "L201": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> MRA (e.g. spironolactone)"
            },
            "L202": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> There are no alternative agents for SGLT2 inhibitors"
            },
            "L203": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <b>Approx annual cost: ₹3k</b>"
            },
            "L204": {
                "type": "None",
                "content": "*Bisoprolol can be replaced with carvedilol or metoprolol XR"
            },
            "L205": {
                "type": "None",
                "content": "**Ramipril can be replaced with alternate ACE inhibitor, valsartan can be replaced with"
            },
            "L206": {
                "type": "None",
                "content": "alternate angiotensin receptor blocker"
            },
            "L207": {
                "type": "Heading",
                "content": "Appendix III<br><br>"
            },
            "L208": {
                "type": "Heading",
                "content": "Key Evidence Summaries"
            },
            "L209": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.nejm.org/doi/full/10.1056/nejmoa1409077' target='_blank'>PARADIGM</a> study (2014)"
            },
            "L210": {
                "type": "sub_child",
                "content": "8442 patients with NYHA Class II-IV HFrEF (EF < 40%) randomized to"
            },
            "L211": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> sacubitril-valsartan vs enalapril, in addition to regular therapy"
            },
            "L212": {
                "type": "sub_child",
                "content": "Sacubitril-valsartan reduced risk of death and hospitalisation compared to"
            },
            "L213": {
                "type": "None",
                "content": "  - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> enalapril"
            },
            "L214": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.nejm.org/doi/full/10.1056/NEJMoa2022190' target='_blank'>EMPEROR-reduced</a> (2020)"
            },
            "L215": {
                "type": "sub_child",
                "content": "3730 patients with NYHA Class II-IV HFrEF (EF < 40%) randomized to"
            },
            "L216": {
                "type": "None",
                "content": "  - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> empagliflozin or placebo, in addition to recommended therapy"
            },
            "L217": {
                "type": "sub_child",
                "content": "Empagliflozin reduced risk of cardiovascular death or hospitalization for heart"
            },
            "L218": {
                "type": "None",
                "content": "  - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> failure compared to placebo, regardless of diabetes status"
            },
            "L219": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.nejm.org/doi/full/10.1056/NEJMoa1911303' target='_blank'>DAPA-HF</a> (2019)"
            },
            "L220": {
                "type": "sub_child",
                "content": "4744 patients with NYHA Class II-IV HFrEF (EF < 40%) randomized to"
            },
            "L221": {
                "type": "None",
                "content": "  - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> dapagliflozin vs placebo, in addition to recommended therapy"
            },
            "L222": {
                "type": "sub_child",
                "content": "Dapagliflozin reduced risk of worsening heart failure or death from"
            },
            "L223": {
                "type": "None",
                "content": "  - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> cardiovascular causes compared to placebo"
            },
            "L224": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.nejm.org/doi/full/10.1056/nejmoa1009492' target='_blank'>EMPHASIS study</a> 2011"
            },
            "L225": {
                "type": "sub_child",
                "content": "2737 patients with NYHA Class II HFrEF (EF < 35%) randomized to eplerenone"
            },
            "L226": {
                "type": "None",
                "content": "  - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> vs placebo, in addition to regular therapy"
            },
            "L227": {
                "type": "sub_child",
                "content": "Eplerenone reduced risk of death and hospitalisation compared to placebo"
            },
            "L228": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Estimated lifetime benefits of comprehensive disease-modifying medical therapies in"
            },
            "L229": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> HFrEF (<a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30748-0/fulltext' target='_blank'>Vaduganathan 2020</a>)"
            },
            "L230": {
                "type": "sub_child",
                "content": "Treatment with ARNI + MRA + SGLT2 inhibitor superior to conventional therapy"
            },
            "L231": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> with ACEI/ARB and BB"
            },
            "L232": {
                "type": "sub_child",
                "content": "Estimate magnitude of benefit for comprehensive disease-modifying therapy:"
            },
            "L233": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> between 2.7 additional years (for an 80-year-old) to 8.3 additional years (for a 55-"
            },
            "L234": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> year-old) before cardiovascular death or first hospital admission for heart failure"
            },
            "L235": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> to 1.4 additional years (for an 80-year-old) to 6.3 additional years (for a 55-year-"
            },
            "L236": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> old) of survival compared to conventional therapy <br><br>"
            },
            "L237": {
                "type": "None",
                "content": "    Estimation of relative treatment effects of comprehensive disease-modifying pharmacological "
            },
            "L238": {
                "type": "None",
                "content": "    therapy on key cardiovascular events (from Vaduganathan 2020) "
            },
            "L239": {
                "type": "Heading",
                "content": "Appendix IV – Assessment of Heart Failure Severity"
            },
            "L240": {
                "type": "Heading",
                "content": "Appendix V"
            },
            "L241": {
                "type": "Heading",
                "content": "Challenges to be addressed (for innovation workstream)"
            },
            "L242": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Cost of medications for HF"
            },
            "L243": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Can HF drugs be added to the government essential drug list?"
            },
            "L244": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <b>How do we integrate POC electrolytes into our treatment pathways?</b>"
            }
        },
        "Tables": {
            "T1": {
                "title": "Starting and Target Doses of Pharmacotherapies for HFrEF",
                "type": "Table",
                "after": "L160",
                "content": [
                    [
                        "Drug",
                        "Starting Dose",
                        "Target Dose"
                    ],
                    [
                        "<b>Beta-Blockers</b>",
                        "",
                        ""
                    ],
                    [
                        "Bisoprolol",
                        "1.25 mg once daily",
                        "10 mg once daily"
                    ],
                    [
                        "Carvedilol",
                        "3.125 mg twice daily",
                        "25 mg twice daily for weight <85 kg and 50 mg twice daily for weight ≥85 kg"
                    ],
                    [
                        "Metoprolol succinate",
                        "12.5–25 mg daily",
                        "200 mg daily"
                    ],
                    [
                        "<b>ARNIs</b>",
                        "",
                        ""
                    ],
                    [
                        "Sacubitril/valsartan",
                        "24/26 mg–49/51 mg twice daily",
                        "97/103 mg twice daily"
                    ],
                    [
                        "<b>ACEIs</b>",
                        "",
                        ""
                    ],
                    [
                        "Captopril",
                        "6.25 mg 3× daily",
                        "50 mg 3× daily"
                    ],
                    [
                        "Enalapril",
                        "2.5 mg twice daily",
                        "10–20 mg twice daily"
                    ],
                    [
                        "Lisinopril",
                        "2.5–5 mg daily",
                        "20–40 mg daily"
                    ],
                    [
                        "Ramipril",
                        "1.25 mg daily",
                        "10 mg daily"
                    ],
                    [
                        "<b>ARBs</b>",
                        "",
                        ""
                    ],
                    [
                        "Candesartan",
                        "4–8 mg daily",
                        "32 mg daily"
                    ],
                    [
                        "Losartan",
                        "25–50 mg daily",
                        "150 mg daily"
                    ],
                    [
                        "Valsartan",
                        "40 mg twice daily",
                        "160 mg twice daily"
                    ],
                    [
                        "<b>Aldosterone antagonists</b>",
                        "",
                        ""
                    ],
                    [
                        "Eplerenone",
                        "25 mg daily",
                        "50 mg daily"
                    ],
                    [
                        "Spironolactone",
                        "12.5–25 mg daily",
                        "25–50 mg daily"
                    ],
                    [
                        "<b>SGLT2 inhibitors</b>",
                        "",
                        ""
                    ],
                    [
                        "Dapagliflozin",
                        "10 mg daily",
                        "10 mg daily"
                    ],
                    [
                        "Empagliflozin",
                        "10 mg daily",
                        "10 mg daily"
                    ]
                ]
            },
            "T2": {
                "title": "Sample Treatment Regimens",
                "type": "Table",
                "after": "L203",
                "content": [
                    [
                        "Regimen",
                        "RAAS",
                        "BB",
                        "MRA",
                        "SGLT2",
                        "Diuretic",
                        "Monitoring"
                    ],
                    [
                        "<b>CSA Preferred</b>",
                        "Sacubitril-Valsartan",
                        "Bisoprolol *",
                        "Eplerenone",
                        "Dapagliflozin",
                        "furosemide",
                        "Electrolytes\nRenal Function"
                    ],
                    [
                        "<b>Alternate #1</b>",
                        "Ramipril or Valsartan **",
                        "Bisoprolol *",
                        "Spironolactone",
                        "Dapagliflozin",
                        "furosemide",
                        "Electrolytes\nRenal Function"
                    ],
                    [
                        "<b>Alternate #2</b>",
                        "Ramipril or Valsartan **",
                        "Bisoprolol *",
                        "Spironolactone",
                        "None",
                        "furosemide",
                        "Electrolytes\nRenal Function"
                    ]
                ]
            },
            "T3": {
                "title": "<a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure' target='_blank'>NYHA Functional Classification</a>",
                "type": "Table",
                "after": "L239",
                "content": [
                    [
                        "Class",
                        "Symptoms"
                    ],
                    [
                        "<b>I</b>",
                        "No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath)."
                    ],
                    [
                        "<b>II</b>",
                        "Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath)."
                    ],
                    [
                        "<b>III</b>",
                        "Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea."
                    ],
                    [
                        "<b>IV</b>",
                        "Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases."
                    ]
                ]
            }
        }
    },
    "chestpain": {
        "description": "This comprehensive pathway adapts Acute Coronary Syndrome (ACS) care for resource-poor Indian settings, focusing on local context for diagnosis, management, referral, training, and medication access to improve outcomes.",
        "lines": {
            "L1": {
                "type": "Tile",
                "content": "Comprehensive Acute Coronary Syndrome Pathway"
            },
            "L2": {
                "type": "Heading",
                "content": "Introduction"
            },
            "L3": {
                "type": "None",
                "content": "This document presents a comprehensive Acute Coronary Syndrome (ACS) pathway tailored for"
            },
            "L4": {
                "type": "None",
                "content": "resource-poor settings in India. It addresses the unique challenges faced in these settings while"
            },
            "L5": {
                "type": "None",
                "content": "leveraging existing infrastructure and government initiatives to improve ACS care outcomes. <br><br>"
            },
            "L6": {
                "type": "Heading",
                "content": "Clinical Pathway<br><br>"
            },
            "L7": {
                "type": "Heading",
                "content": "1. Initial Assessment and Triage (0-5 minutes)"
            },
            "L8": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Standard Approach</p>"
            },
            "L9": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Rapid assessment of consciousness, breathing, and circulation"
            },
            "L10": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Quick pain assessment using OPQRST method<br><br>"
            },
            "L11": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Indian Context Adaptation</p>"
            },
            "L12": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Emphasis on visual assessment due to potential lack of monitoring equipment"
            },
            "L13": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Training for healthcare workers to perform quick manual BP measurements"
            },
            "L14": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Use of locally relevant pain scales (e.g., visual analog scale with culturally appropriate images)</br><br>"
            },
            "L15": {
                "type": "Heading",
                "content": "2. ECG Assessment (within 15 minutes of arrival)<br><br>"
            },
            "L16": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Standard Approach</p>"
            },
            "L17": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> 12-lead ECG performed and interpreted by trained personnel<br><br>"
            },
            "L18": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Indian Context Adaptation</p>"
            },
            "L19": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Alternatives for facilities without ECG machines:"
            },
            "L20": {
                "type": "sub_child",
                "content": "Use of smartphone-based ECG devices (e.g., AliveCor; <a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='https://alivecor.com/in' target='_blank'>https://alivecor.in</a>)"
            },
            "L21": {
                "type": "sub_child",
                "content": "Telemedicine linkages with district hospitals for remote ECG interpretation"
            },
            "L22": {
                "type": "sub_child",
                "content": "Training of local healthcare workers in basic ECG interpretation"
            },
            "L23": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Collaboration with state governments to improve ECG availability in rural areas<br><br>"
            },
            "L24": {
                "type": "Heading",
                "content": "3. Initial Management<br><br>"
            },
            "L25": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Standard Approach</p>"
            },
            "L26": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Oxygen therapy if needed (if patient has hypoxia; no significant benefit in the absence of it-"
            },
            "L27": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> <a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='' target='_blank'>https://www.nejm.org/doi/full/10.1056/NEJMoa1706222#:~:text=Discussion,of%20rehospitaliza</a>"
            },
            "L28": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> <a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='https://www.nejm.org/doi/full/10.1056/NEJMoa1706222#:~:text=Discussion,of%20rehospitalization%20with%20myocardial%20infarction.' target='_blank'>tion%20with%20myocardial%20infarction.</a>; Hofmann and in NEJM have shown the results of a"
            },
            "L29": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> registry-based, randomized clinical trial of the use of supplemental oxygen in 6629 patients in"
            },
            "L30": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> Sweden who had suspected acute myocardial infarction and did not have hypoxemia. Patients"
            },
            "L31": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> were randomly assigned to supplemental oxygen administered through an open face mask (6"
            },
            "L32": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> liters per minute for 6 to 12 hours) or to ambient air. The trial was adequately sized for the"
            },
            "L33": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> assessment of hard clinical end points, with a primary end point of death from any cause at 1"
            },
            "L34": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> year. Supplemental oxygen was not associated with lower all-cause mortality at 1 year than"
            },
            "L35": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> ambient air, and the rate of a key secondary end point — rehospitalization for acute myocardial"
            },
            "L36": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> infarction within 1 year — also did not differ significantly between the study groups. These"
            },
            "L37": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> results clearly support the view that supplemental oxygen offers no benefit in patients with acute"
            },
            "L38": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> myocardial infarction who have normal oxygen saturation."
            },
            "L39": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> oxygen therapy in the absence of hypoxemia may even be harmful"
            },
            "L40": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Pain management<br><br>"
            },
            "L41": {
                "type": "Heading",
                "content": "Initial Management"
            },
            "L42": {
                "type": "None",
                "content": "For all suspected ACS:"
            },
            "L43": {
                "type": "None",
                "content": "Give Aspirin 300 mg (chewed)"
            },
            "L44": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>Costs about ₹0.50, available as Jan Aushadhi Aspirin"
            },
            "L45": {
                "type": "None",
                "content": "If BP allows, give sublingual nitroglycerine"
            },
            "L46": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>Costs ₹55-70 for 30 tablets, not in Jan Aushadhi"
            },
            "L47": {
                "type": "None",
                "content": "Oxygen if needed, start IV if you can<br><br>"
            },
            "L48": {
                "type": "Heading",
                "content": "If it's a STEMI:"
            },
            "L49": {
                "type": "None",
                "content": "Add Clopidogrel 300 mg"
            },
            "L50": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>Costs ₹15-20, available as Jan Aushadhi Clopidogrel"
            },
            "L51": {
                "type": "None",
                "content": "Arrange transfer to a PCI center if it’s less than 2 hours away"
            },
            "L52": {
                "type": "None",
                "content": "If transfer will take longer, consider thrombolysis with Streptokinase"
            },
            "L53": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>Costs ₹1500-2000, might be free in government hospitals<br><br>"
            },
            "L54": {
                "type": "Heading",
                "content": "For suspected NSTEMI or Unstable Angina:<br><br>"
            },
            "L55": {
                "type": "None",
                "content": "Add anticoagulation to aspirin and Plavix; transfer to a PCI center asap<br><br>"
            },
            "L56": {
                "type": "None",
                "content": "Unfractionated Heparin<br><br>"
            },
            "L57": {
                "type": "None",
                "content": "Dose: 60 units/kg IV bolus (max 4000 units) followed by 12 units/kg/hour infusion"
            },
            "L58": {
                "type": "None",
                "content": "Jan Aushadhi availability: No"
            },
            "L59": {
                "type": "None",
                "content": "Typical market price: ₹150-200 per 5000 IU vial"
            },
            "L60": {
                "type": "None",
                "content": "Note: Preferred in resource-poor settings due to lower cost and no need for refrigeration<br><br>"
            },
            "L61": {
                "type": "None",
                "content": "Enoxaparin (if Unfractionated Heparin is unavailable)<br><br>"
            },
            "L62": {
                "type": "None",
                "content": "Dose: 1 mg/kg subcutaneously every 12 hours"
            },
            "L63": {
                "type": "None",
                "content": "Jan Aushadhi availability: No"
            },
            "L64": {
                "type": "None",
                "content": "Typical market price: ₹250-350 per 40mg prefilled syringe"
            },
            "L65": {
                "type": "None",
                "content": "Note: Consider this option only if cold chain can be maintained<br><br>"
            },
            "L66": {
                "type": "Heading",
                "content": "Discharge management"
            },
            "L67": {
                "type": "None",
                "content": "Give medications as available:"
            },
            "L68": {
                "type": "None",
                "content": "Beta-blocker (e.g., Metoprolol 25-50 mg)"
            },
            "L69": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>Costs ₹2-3 per tablet, available as Jan Aushadhi Metoprolol"
            },
            "L70": {
                "type": "None",
                "content": "ACE inhibitor (e.g., Enalapril 2.5 mg)"
            },
            "L71": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>Costs ₹2-3 per tablet, available as Jan Aushadhi Enalapril"
            },
            "L72": {
                "type": "None",
                "content": "Statin (e.g., Atorvastatin 40-80 mg)"
            },
            "L73": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>Costs ₹5-7 per tablet, available as Jan Aushadhi Atorvastati<br><br>"
            },
            "L74": {
                "type": "Heading",
                "content": "4. Referral Network<br><br>"
            },
            "L75": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Standard Approach</p>"
            },
            "L76": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Clear criteria for transfer to PCI-capable centers"
            },
            "L77": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Ambulance transfer with trained paramedics<br><br>"
            },
            "L78": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Indian Context Adaptation<p style='text-decoration:underline; font-style: italic;'>"
            },
            "L79": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Tiered referral system aligned with Indian healthcare structure:"
            },
            "L80": {
                "type": "sub_child",
                "content": "Primary Health Centers → Community Health Centers → District Hospitals → Tertiary Care"
            },
            "L81": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> Centers"
            },
            "L82": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Alternative transport solutions:"
            },
            "L83": {
                "type": "sub_child",
                "content": "Collaboration with local taxi services or community vehicles"
            },
            "L84": {
                "type": "sub_child",
                "content": "Use of 108 Emergency Response Service where available"
            },
            "L85": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>WhatsApp groups for real-time communication within referral network<br><br>"
            },
            "L86": {
                "type": "Heading",
                "content": "5. Training and Education<br><br>"
            },
            "L87": {
                "type": "Heading",
                "content": "Healthcare Provider Training<br><br>"
            },
            "L88": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Standard Approach</p>"
            },
            "L89": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Regular CME programs for healthcare providers<br><br>"
            },
            "L90": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Indian Context Adaptation</p>"
            },
            "L91": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Tiered training program:"
            },
            "L92": {
                "type": "sub_child",
                "content": "Basic ACS recognition for ASHAs and ANMs"
            },
            "L93": {
                "type": "sub_child",
                "content": "Comprehensive pathway training for rural physicians"
            },
            "L94": {
                "type": "sub_child",
                "content": "Advanced management techniques for referral center staff"
            },
            "L95": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Use of mobile learning apps for continuous education"
            },
            "L96": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Collaboration with local medical colleges for training support<br><br>"
            },
            "L97": {
                "type": "Heading",
                "content": "6. Community Engagement and Education<br><br>"
            },
            "L98": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Standard Approach<p style='text-decoration:underline; font-style: italic;'>"
            },
            "L99": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Public awareness campaigns about heart attack symptoms<br><br>"
            },
            "L100": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Indian Context Adaptation</p>"
            },
            "L101": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Leverage existing community structures:"
            },
            "L102": {
                "type": "sub_child",
                "content": "Training for panchayat health committees"
            },
            "L103": {
                "type": "sub_child",
                "content": "Incorporation of ACS awareness in village health and nutrition days"
            },
            "L104": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>Use of local folk media (street plays, puppet shows) for health education"
            },
            "L105": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Multilingual education materials in regional languages<br><br>"
            },
            "L106": {
                "type": "Heading",
                "content": "7. Resource Utilization<br><br>"
            },
            "L107": {
                "type": "Heading",
                "content": "Medication Access and Affordability<br><br>"
            },
            "L108": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Standard Approach</p>"
            },
            "L109": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Prescription of guideline-directed medical therapy<br><br>"
            },
            "L110": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Indian Context Adaptation<p style='text-decoration:underline; font-style: italic;'>"
            },
            "L111": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Integration with Jan Aushadhi scheme:"
            },
            "L112": {
                "type": "sub_child",
                "content": "List of ACS medications available under Jan Aushadhi with costs"
            },
            "L113": {
                "type": "sub_child",
                "content": "Guidance on using Jan Aushadhi store locator"
            },
            "L114": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span>(<a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='https://janaushadhi.gov.in/DistributorDetails.aspx' target='_blank'>https://janaushadhi.gov.in/DistributorDetails.aspx</a>)"
            },
            "L115": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Ayushman Bharat scheme integration for hospitalization costs"
            },
            "L116": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Bulk purchasing strategies for rural health centers<br><br>"
            },
            "L117": {
                "type": "Heading",
                "content": "Diagnostic Resources<br><br>"
            },
            "L118": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Standard Approach</p>"
            },
            "L119": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Access to standard diagnostic tools (ECG, troponin testing, etc.)<br><br>"
            },
            "L120": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Indian Context Adaptation</p>"
            },
            "L121": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Exploration of point-of-care testing options suitable for rural settings"
            },
            "L122": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Collaboration with state governments and NGOs to improve diagnostic capabilities in resource-"
            },
            "L123": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> poor areas<br><br>"
            },
            "L124": {
                "type": "Heading",
                "content": "8. Monitoring and Evaluation<br><br>"
            },
            "L125": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Standard Approach</p>"
            },
            "L126": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Regular audit of ACS care metrics<br><br>"
            },
            "L127": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Indian Context Adaptation</p>"
            },
            "L128": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Simplified data collection tools for resource-limited settings"
            },
            "L129": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Collaboration with ICMR and national institutions for rural ACS research"
            },
            "L130": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Innovation challenges for low-cost ACS care solutions<br><br>"
            },
            "L131": {
                "type": "Heading",
                "content": "9.ACS Management Guidelines<br><br>"
            },
            "L132": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Standard Approach</p>"
            },
            "L133": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Based on international best practices for ACS care<br><br>"
            },
            "L134": {
                "type": "None",
                "content": "<p style='text-decoration:underline; font-style: italic;'>Indian Context Adaptation</p>"
            },
            "L135": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Adapted to align with Indian Council of Medical Research (ICMR) and Cardiological Society"
            },
            "L136": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> of India guidelines"
            },
            "L137": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Based on extensive lit review published from India and the global south, GRADE system and"
            },
            "L138": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> consensus opinions from practitioners on the ground"
            },
            "L139": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Considerations for resource constraints in rural settings<br><br>"
            },
            "L140": {
                "type": "Heading",
                "content": "Conclusion"
            },
            "L141": {
                "type": "None",
                "content": "This comprehensive ACS pathway for resource-poor settings in India demonstrates a deep"
            },
            "L142": {
                "type": "None",
                "content": "understanding of the unique challenges and opportunities within the Indian healthcare system."
            },
            "L143": {
                "type": "None",
                "content": "By adapting international best practices to the local context, leveraging existing government"
            },
            "L144": {
                "type": "None",
                "content": "initiatives, and addressing specific resource constraints, this pathway aims to improve ACS care"
            },
            "L145": {
                "type": "None",
                "content": "outcomes across diverse settings in India."
            }
        },
        "Tables": {}
    },
    "copd": {
        "description": "This pathway addresses COPD in India, focusing on diagnosis challenges (spirometry, unique etiologies), cost/cultural barriers, and management including non-pharmacological, maintenance therapies, exacerbations, and interventions to avoid.",
        "lines": {
            "L1": {
                "type": "Tile",
                "content": "Chronic Obstructive Pulmonary Disease Pathway"
            },
            "L2": {
                "type": "Heading",
                "content": "Background"
            },
            "L3": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> COPD is the <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.healthdata.org/research-analysis/health-by-location/profiles/india' target='_blank'>number 2</a> cause of mortality in India"
            },
            "L4": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Obstructive lung diseases are <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.thelancet.com/action/showPdf?pii=S2214-109X%2815%2900152-7' target='_blank'>the 2nd most common reason</a> for presentation to primary"
            },
            "L5": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> care practitioners in India"
            },
            "L6": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Up to <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.atsjournals.org/doi/10.1164/rccm.201804-0621CI?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed' target='_blank'>70% of COPD worldwide</a> may be un-diagnosed"
            },
            "L7": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Smoking and environmental exposures (e.g. indoor fuel burning) are major risk factors"
            },
            "L8": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> for COPD<br><br>"
            },
            "L9": {
                "type": "Heading",
                "content": "India specific challenges to overcome"
            },
            "L10": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Diagnostic challenges"
            },
            "L11": {
                "type": "sub_child",
                "content": "Spirometry access + training of providers"
            },
            "L12": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Adequate technique required to generate meaningful flow curves for"
            },
            "L13": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\"></span> diagnosis"
            },
            "L14": {
                "type": "sub_child",
                "content": "Diagnostic entities unique to India"
            },
            "L15": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Non-smoker COPD (e.g. biomass fuels)"
            },
            "L16": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pmc.ncbi.nlm.nih.gov/articles/PMC5592751/' target='_blank'>TB</a>-associated <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://onlinelibrary.wiley.com/doi/10.1111/crj.12621' target='_blank'>COPD/ Post TB</a>"
            },
            "L17": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='' target='_blank'>Occupation associated</a>"
            },
            "L18": {
                "type": "sub_child",
                "content": "In the absence of spirometry, how do we diagnose?"
            },
            "L19": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Current standard practice in India  dx based on symptom complex"
            },
            "L20": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Cost barriers"
            },
            "L21": {
                "type": "sub_child",
                "content": "Inhalers are costly"
            },
            "L22": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Cultural barriers"
            },
            "L23": {
                "type": "sub_child",
                "content": "Stigma associated with inhaler use"
            },
            "L24": {
                "type": "sub_child",
                "content": "Compliance issues with increasing number of inhalers (not necessarily India-"
            },
            "L25": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> specific)"
            },
            "L26": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Existing practice"
            },
            "L27": {
                "type": "sub_child",
                "content": "Broad use of theophylline<br><br>"
            },
            "L28": {
                "type": "Heading",
                "content": "Diagnosis"
            },
            "L29": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Consider COPD if history of shortness of breath/dyspnoea or chronic cough, and risk"
            },
            "L30": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> factors for COPD – consider duration of symptoms"
            },
            "L31": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Consider and rule out differentials, including:"
            },
            "L32": {
                "type": "sub_child",
                "content": "Respiratory: Asthma, bronchiectasis, TB, obliterative bronchiolitis, diffuse"
            },
            "L33": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> bronchiolitis (sputum and CXR)"
            },
            "L34": {
                "type": "sub_child",
                "content": "Cardiac: heart failure (see CSA HF pathway)"
            },
            "L35": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <b>Spirometry</b> is required for diagnosis: post-bronchodilation FEV1/FVC < 0.70"
            },
            "L36": {
                "type": "sub_child",
                "content": "See spirometry instructions in Appendix"
            },
            "L37": {
                "type": "sub_child",
                "content": "Training staff in adequate spirometry technique will be a challenge"
            },
            "L38": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> CXR: not diagnostic but can rule out other causes. COPD may present with lung"
            },
            "L39": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> hyperinflation"
            },
            "L40": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> IF spirometry unavailable (all CSA sites to be given spiro)"
            },
            "L41": {
                "type": "sub_child",
                "content": "In the absence of spirometry, diagnosis of COPD in India is often made based on"
            },
            "L42": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> symptom complex"
            },
            "L43": {
                "type": "sub_child",
                "content": "Symptoms suggestive of COPD include:"
            },
            "L44": {
                "type": "sub_child",
                "content": "There is significant overlap between COPD symptoms and other lung pathologies,"
            },
            "L45": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> including asthma, bronchiectasis, interstitial lung disease, etc."
            },
            "L46": {
                "type": "sub_child",
                "content": "If COPD is diagnosed based on symptoms alone, trial therapy with careful follow"
            },
            "L47": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> up. If no clinical improvement, diagnosis <b style='margin-left:5px; margin-right:5px;'>must</b> be revisited<br><br>"
            },
            "L48": {
                "type": "Heading",
                "content": "Severity Assessment"
            },
            "L49": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> COPD severity can be categorised based on symptoms (mMRC scale; see appendix)"
            },
            "L50": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Frequency of exacerbations/hospitalisations for COPD<br><br>"
            },
            "L51": {
                "type": "Heading",
                "content": "Management of comorbidities"
            },
            "L52": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> COPD specific: sarcopenia/fragility, weight loss – Promote nutrition"
            },
            "L53": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Others: cardiovascular diseases, metabolic syndrome, osteoporosis, lung cancer, mental"
            },
            "L54": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> health"
            },
            "L55": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> See CSA pathways for appropriate management<br><br>"
            },
            "L56": {
                "type": "Heading",
                "content": "Non-pharmacological management"
            },
            "L57": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <b>Smoking cessation</b>"
            },
            "L58": {
                "type": "sub_child",
                "content": "Do we need a CSA pathway for this?"
            },
            "L59": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Reduce exposure to indoor smoke/<a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://erj.ersjournals.com/content/40/1/239' target='_blank'>biomass fuels</a>"
            },
            "L60": {
                "type": "sub_child",
                "content": "Use of biomass fuels may be more prevalent in rural settings (i.e. places where"
            },
            "L61": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> CSA partner sites are)"
            },
            "L62": {
                "type": "sub_child",
                "content": "How do we make this practical for people? This is a big structural issue"
            },
            "L63": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Pulmonary rehab"
            },
            "L64": {
                "type": "sub_child",
                "content": "Rehab/physiotherapy pathway TBD"
            },
            "L65": {
                "type": "sub_child",
                "content": "Offer alternate occupation"
            },
            "L66": {
                "type": "sub_child",
                "content": "Treat comorbidity<br><br>"
            },
            "L67": {
                "type": "Heading",
                "content": "Maintenance medical therapy"
            },
            "L68": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.who.int/publications/i/item/who-package-of-essential-noncommunicable-(pen)-disease-interventions-for-primary-health-care' target='_blank'>WHO basic minimum package:</a>"
            },
            "L69": {
                "type": "sub_child",
                "content": "Maintenance: Salbutamol PRN +/- PO theophylline, +/- theophylline if available"
            },
            "L70": {
                "type": "sub_child",
                "content": "Exacerbation: abx, pred, salbumtamol, O2"
            },
            "L71": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Need costings for all the below:"
            },
            "L72": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> SABA"
            },
            "L73": {
                "type": "sub_child",
                "content": "Salbutamol"
            },
            "L74": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> LABA"
            },
            "L75": {
                "type": "sub_child",
                "content": "Salmeterol or Formeterol"
            },
            "L76": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> SAMA"
            },
            "L77": {
                "type": "sub_child",
                "content": "Ipratropium"
            },
            "L78": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> LAMA"
            },
            "L79": {
                "type": "sub_child",
                "content": "Tiotropium"
            },
            "L80": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> ICS<br><br>"
            },
            "L81": {
                "type": "Heading",
                "content": "Assess disease severity and initiate maintenance therapy"
            },
            "L82": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> mMRC system (appendix)"
            },
            "L83": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> A – less symptomatic and low risk of exacerbation"
            },
            "L84": {
                "type": "sub_child",
                "content": "PRN bronchodilator – SABA or SAMA (see formulary for options) <b>OR</b>"
            },
            "L85": {
                "type": "sub_child",
                "content": "Combination SABA/SAMA"
            },
            "L86": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> B – more symptomatic and low risk of exacerbation"
            },
            "L87": {
                "type": "sub_child",
                "content": "Regular long-acting bronchodilator (LABA or LAMA) <b>AND</b>"
            },
            "L88": {
                "type": "sub_child",
                "content": "PRN SABA"
            },
            "L89": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> E – high risk of exacerbation (>2 moderate exacerbations or >= 1 leading to"
            },
            "L90": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> hospitalization)"
            },
            "L91": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> ICS: Can consider if 2 or more exacerbations annually and if blood eosinophils greater"
            },
            "L92": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> ICS: than 300<br><br>"
            },
            "L93": {
                "type": "Heading",
                "content": "Ongoing management"
            },
            "L94": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> COPD is a chronic disease and requires follow-up and medication titration"
            },
            "L95": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> A constant COPD cycle of care is required"
            },
            "L96": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If patient is not improving or remains symptomatic despite initiation of medical therapy,"
            },
            "L97": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> consider and address:"
            },
            "L98": {
                "type": "sub_child",
                "content": "Inhaler technique/non-compliance"
            },
            "L99": {
                "type": "sub_child",
                "content": "COPD diagnosis – is there are more compelling differential diagnosis?"
            },
            "L100": {
                "type": "sub_child",
                "content": "Exacerbation of COPD"
            },
            "L101": {
                "type": "sub_child",
                "content": "Concomitant pathology"
            },
            "L102": {
                "type": "sub_child",
                "content": "Need for additional inhaler"
            },
            "L103": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If inappropriate response to treatment AND if inhaler technique adequate AND if"
            },
            "L104": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> diagnosis is still COPD, can consider additional agent:"
            },
            "L105": {
                "type": "sub_child",
                "content": "If on LABA or LAMA  LAMA + LAMA"
            },
            "L106": {
                "type": "sub_child",
                "content": "If on LABA + LAMA and if eosinophils > 300  LABA + LAMA + ICS"
            },
            "L107": {
                "type": "sub_child",
                "content": "If on LABA + LAMA and if eosinophils > 100 and if 2+ exacerbations a year "
            },
            "L108": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> LABA + LAMA + ICS"
            },
            "L109": {
                "type": "sub_child",
                "content": "If on ICS and inadequate response to treatment, consider de-escalation of ICS"
            },
            "L110": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> How do we want to address roflumilast? Any role for azithro?<br><br>"
            },
            "L111": {
                "type": "Heading",
                "content": "Preventative care"
            },
            "L112": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Preventative vaccination"
            },
            "L113": {
                "type": "sub_child",
                "content": "COVID (all), flu (all), pneumococcal (65+ and high risk), pertussis<br><br>"
            },
            "L114": {
                "type": "Heading",
                "content": "Interventions to avoid"
            },
            "L115": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Do not use methylxanthines (theophylline) routinely for the management of COPD"
            },
            "L116": {
                "type": "sub_child",
                "content": "Inhalers are first line therapy – they are safer and more effective"
            },
            "L117": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Do not use inhaled steroids as monotherapy in COPD"
            },
            "L118": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Mucolytic agents are not effective for the treatment of COPD"
            },
            "L119": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Do not use long term oral steroids for the treatment of COPD<br><br>"
            },
            "L120": {
                "type": "Heading",
                "content": "Management of advanced COPD (referral to specialist)"
            },
            "L121": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Supplemental O2"
            },
            "L122": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Procedural interventions"
            },
            "L123": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Palliative care<br><br>"
            },
            "L124": {
                "type": "Heading",
                "content": "Indications for home oxygen therapy (given now possible after COVID)"
            },
            "L125": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> From <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.uptodate.com/contents/long-term-supplemental-oxygen-therapy?search=copd%20oxygen&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1' target='_blank'>UpToDate</a>"
            },
            "L126": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> PaO2 ≤55 mmHg (7.32 kPa) or SaO2 ≤88 percent"
            },
            "L127": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If cor pulmonale <b>AND</b>"
            },
            "L128": {
                "type": "sub_child",
                "content": "PaO2 ≤59 mmHg (7.85 kPa) or SaO2 ≤89 percent"
            },
            "L129": {
                "type": "sub_child",
                "content": "EKG evidence of P pulmonale"
            },
            "L130": {
                "type": "sub_child",
                "content": "Hematocrit >55 percent"
            },
            "L131": {
                "type": "sub_child",
                "content": "Clinical evidence of right heart failure<br><br>"
            },
            "L132": {
                "type": "Heading",
                "content": "Management of exacerbations"
            },
            "L133": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Assess stability"
            },
            "L134": {
                "type": "sub_child",
                "content": "Transfer patient if unstable, or if signs of airway compromise"
            },
            "L135": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Cardinal symptoms of COPD exacerbation"
            },
            "L136": {
                "type": "sub_child",
                "content": "Increased frequency/severity of cough"
            },
            "L137": {
                "type": "sub_child",
                "content": "Increase/change in sputum"
            },
            "L138": {
                "type": "sub_child",
                "content": "Increased dyspnoea"
            },
            "L139": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Consider differentials (see relevant CSA pathways for management)"
            },
            "L140": {
                "type": "sub_child",
                "content": "Respiratory: CAP, COVID, pulmonary embolism, pneumothorax, ptld"
            },
            "L141": {
                "type": "sub_child",
                "content": "Cardiac: HF, ACS"
            },
            "L142": {
                "type": "sub_child",
                "content": "Other: sepsis"
            },
            "L143": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Airway management"
            },
            "L144": {
                "type": "sub_child",
                "content": "All patients: Supplemental O2 if hypoxic, titrate to SpO2 88-92%"
            },
            "L145": {
                "type": "sub_child",
                "content": "NIV or intubation according to patient status and operator availability"
            },
            "L146": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Relevant investigations (not required if outpatient management)"
            },
            "L147": {
                "type": "sub_child",
                "content": "ABG – not often available or understood for management"
            },
            "L148": {
                "type": "sub_child",
                "content": "CXR"
            },
            "L149": {
                "type": "sub_child",
                "content": "ECG"
            },
            "L150": {
                "type": "sub_child",
                "content": "Electrolytes"
            },
            "L151": {
                "type": "sub_child",
                "content": "Covid swab (CXR and CBC – infection)"
            },
            "L152": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Determining outpatient vs inpatient management"
            },
            "L153": {
                "type": "sub_child",
                "content": "Potential indications for inpatient management"
            },
            "L154": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Initial therapy"
            },
            "L155": {
                "type": "sub_child",
                "content": "Regular SABA +/- SAMA via spacer"
            },
            "L156": {
                "type": "sub_child",
                "content": "Prednisone 40mg for 5 days"
            },
            "L157": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Threshold for antibiotic administration"
            },
            "L158": {
                "type": "sub_child",
                "content": "<a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://goldcopd.org/2023-gold-report-2/' target='_blank'>2 or more of:</a>"
            },
            "L159": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Increased dyspnoea"
            },
            "L160": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Increased sputum volume"
            },
            "L161": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Increase sputum purulence"
            },
            "L162": {
                "type": "sub_child",
                "content": "Abx option"
            },
            "L163": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Azithromycin"
            },
            "L164": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> 2nd or 3rd generation cephalosporin"
            },
            "L165": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Amox/Clav"
            },
            "L166": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Potentially cipro for pseudomonal cover (though use in India given TB) –"
            },
            "L167": {
                "type": "None",
                "content": "- <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\"></span> Duration (avoid Levi in view of its anti-tubercular action)"
            },
            "L168": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> only Amox (BHS)"
            },
            "L169": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\"></span> (Elderly + diabetics)"
            }
        },
        "Tables": {
            "T1": {
                "title": "mMRC system",
                "type": "Table",
                "after": "L169",
                "content": [
                    [
                        "mMRC Grade",
                        "Description"
                    ],
                    [
                        "Grade 0",
                        "I only get breathless with strenuous exercise"
                    ],
                    [
                        "Grade 1",
                        "I get short of breath when hurrying on the level or walking up a slight hill"
                    ],
                    [
                        "Grade 2",
                        "I walk slower than people of the same age on the level because of breathlessness, or I have to stop for breath when walking on my own pace on the level"
                    ],
                    [
                        "Grade 3",
                        "I stop for breath after walking about 100 metres or a few minutes on the level"
                    ],
                    [
                        "Grade 4",
                        "I am too breathless to leave the house or I am too breathless when dressing or undressing"
                    ]
                ]
            },
            "T2": {
                "title": "List of available drugs along with cost information",
                "type": "Table",
                "after": "L169",
                "content": [
                    [
                        "Drug Class",
                        "Drug name",
                        "Type",
                        "Brand",
                        "Pricing"
                    ],
                    [
                        "<b>SABA</b>",
                        "Salbutamol",
                        "Rotacaps",
                        "Cipla - Asthalin",
                        "200 mcg - 60 capsules in 1 bottle - Rs 98/pack"
                    ],
                    [
                        "",
                        "",
                        "Metered dose inhaler",
                        "Cipla - Asthalin",
                        "Rs 110/ box"
                    ],
                    [
                        "",
                        "",
                        "Respules",
                        "Cipla - Asthalin",
                        "2.5mg/2.5 ml pack of 5 - Rs 28"
                    ],
                    [
                        "",
                        "Levisalbutamol",
                        "Rotacaps",
                        "Cipla-Levolin",
                        "100 mcg - 30 capsules in 1 bottle - Rs 30/pack"
                    ],
                    [
                        "",
                        "",
                        "Metered dose inhaler",
                        "Cipla-Levolin",
                        "50 mcg inhaler / Rs 200 per pack"
                    ],
                    [
                        "",
                        "",
                        "Respules",
                        "Cipla - Levolin ,\nLupin-Salbair",
                        "0.63 Mg/ 1 respule - Rs 5 per respule,\n0.63mg/2.5 mL respule - Rs 7 per respule"
                    ],
                    [
                        "<b>Combination - SABA and SAMA</b>",
                        "Ipravent and Levosalbutamol",
                        "Rotacaps",
                        "Cipla - Duolin",
                        "60 capsules - 100 + 40 mcg/ Rs 144 per bottle"
                    ],
                    [
                        "",
                        "",
                        "Metered dose inhaler",
                        "Cipla - Duolin Forte",
                        "200 mdi inhaler - Rs 393"
                    ],
                    [
                        "",
                        "",
                        "Respules",
                        "Cipla - Duolin",
                        "3 ml respules - pack of 5 - Rs 104"
                    ],
                    [
                        "<b>ICS</b>",
                        "Fluticasone",
                        "Rotacaps",
                        "",
                        ""
                    ],
                    [
                        "",
                        "",
                        "Metered dose inhaler",
                        "Cipla - Flohale",
                        "125 mcg/dose, Rs 267/ inhaler"
                    ],
                    [
                        "",
                        "",
                        "Respules",
                        "Cipla-Flohale",
                        "0.5 mg respules - Rs 240"
                    ],
                    [
                        "",
                        "Budesonide",
                        "Rotacaps",
                        "Cipla - Budecort\nCipla-Budesonide",
                        "200 mcg, 30 capsules in 1 bottle - Rs 92"
                    ],
                    [
                        "",
                        "",
                        "Metered dose inhaler",
                        "",
                        "100, 200 mg - Rs 400"
                    ],
                    [
                        "",
                        "",
                        "Respules",
                        "Cipla - Budecort respules",
                        "0.5 mg respules, Rs 115 - pack of 5"
                    ],
                    [
                        "",
                        "Ciclesonide",
                        "Rotacaps",
                        "Cipla - Ciclohale",
                        "400 mcg - 30 capsules, Rs 195"
                    ],
                    [
                        "",
                        "",
                        "Metered dose inhaler",
                        "Cipla-Ciclohale,\nRanbaxy - Osonide",
                        "Ciclohale- 160 mcg - Rs 350,\nOsonide- 160 mcg - Rs 300"
                    ],
                    [
                        "",
                        "",
                        "Respules",
                        "NA",
                        ""
                    ],
                    [
                        "<b>Triple therapy, combination drug ICS+LABA+LAMA</b>",
                        "beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/G)",
                        "pressurized metered-dose inhaler",
                        "TRIMBOW®, Chiesi Farmaceutici SpA",
                        "Single dosage - 87/5/9 µg (two inhalations twice daily)"
                    ],
                    [
                        "",
                        "Fluticasone Furoate/Umeclidinium/Vilanterol FF/UMEC/VI",
                        "Multidose dry-powder inhaler (MDDPI) formulation to be delivered through the ELLIPTA inhaler device (SingleInhaler Triple Therapy (SITT))",
                        "TRELEGY ELLIPTA®, GlaxoSmithKline",
                        "Single dosage - 92/22/55 µg (one inhalation per day) - Maintenance treatment of both asthma and COPD"
                    ],
                    [
                        "",
                        "GlaxoSmithKline FF/UMEC/VI",
                        "Dry powder inhaler",
                        "Trelegy Ellipta",
                        "Once daily - Maintenance treatment of COPD; ₹2822/box"
                    ],
                    [
                        "",
                        "AstraZeneca BDP/FOR/GP Beclomethasone/Formoterol/Glycopyrronium",
                        "pressurized metered-dose inhaler",
                        "BREZTRI",
                        "Twice daily (CJ: can't find this drug online; probably not sold in India yet)"
                    ],
                    [
                        "",
                        "Novartis IND/GLY/MF Indacaterol/Glycopyrronium/ Mometasone furoate",
                        "Dry powder inhaler",
                        "Enerzair Breezhaler",
                        "Once daily (CJ: can't find this drug online; probably not sold in India yet)"
                    ],
                    [
                        "",
                        "Glenmark GLY/FOR/FP Glycopyrronium/Formoterol/Fluticasone propionate",
                        "Dry powder inhaler",
                        "Airz-FF",
                        "Twice daily ; ₹535/box of 30 capsules"
                    ],
                    [
                        "",
                        "Cipla GLY/FOR/BUD Glycopyrronium/Formoterol/Budesonide",
                        "Dry powder inhaler",
                        "Glycohale-FB",
                        "Twice daily; ₹184.7/box of 10 rotacaps"
                    ],
                    [
                        "",
                        "Tiotropium/Formoterol/Ciclesonide (TFC)",
                        "Dry powder inhaler (DPI)/\nPressured metered dose inhaler (pMDI)",
                        "Triohale®, Cipla",
                        "18 mcg/12 mcg/400 mcg - once-daily; ₹1132/ inhaler with 200 metered doses"
                    ],
                    [
                        "ICS and LABA-combination",
                        "Fluticasone and Salmeterol",
                        "Rotacaps",
                        "Macleods Pharma-Flutrol,\nZydus Cadila-Forair R cap,\nSeroflo- 500 rotacaps",
                        "Flutrol rota capsule- 50/100 mcg- Rs 155,\nForair R cap- 100/50 mcg- Rs 361- for 30 capsules,\nSeroflo500 rotacaps -500/50 mcg- Rs 472"
                    ],
                    [
                        "",
                        "",
                        "Respules",
                        "Lupin Labs-Esiflo,",
                        "Esiflo- 100/50 mcg- 30 capsules Rs 108"
                    ],
                    [
                        "",
                        "",
                        "Metered dose inhaler",
                        "Glenmark - Airtec SF,\nSun pharma-Combitide",
                        "Airtec SF- 50 mcg/100 mcg- Rs 330, Combitide - 25/125 mcg - Rs 292"
                    ],
                    [
                        "(rapid onset)",
                        "Budesonide and Formoterol",
                        "Rotacaps, Respules",
                        "Zydus cadila - Formonide Resicaps,",
                        "Formonide resicaps- 200/6 mcg- Rs 147- for a bottle of 30"
                    ],
                    [
                        "",
                        "",
                        "Metered dose inhaler",
                        "Kopran Pharma-VentFB inhaler",
                        "Vent FB inhaler - 100/6 mcg- Rs 134"
                    ],
                    [
                        "",
                        "Fluticasone and Vilanterol",
                        "Rotacaps",
                        "",
                        ""
                    ],
                    [
                        "ICS and SABA combo",
                        "Budesonide(0.5 Mg) + Salbutamol/Albuterol(1.25 Mg)",
                        "",
                        "",
                        "Budesal 0.5mg 2ml Packet Of 5 Respules for ~ Rs 240\nDerisal 0.5mg 2ml Packet Of 7 Respules for ~ RS 340"
                    ],
                    [
                        "",
                        "Levosalbutamol (50mcg) + Beclometasone (50mcg)",
                        null,
                        "Cipla",
                        "Aerocort Inhaler for ~Rs 270 / 1 Packet 200 MDI Inhaler"
                    ],
                    [
                        "",
                        "",
                        "Respules",
                        "",
                        ""
                    ],
                    [
                        "",
                        "",
                        "Metered dose inhaler",
                        "",
                        ""
                    ],
                    [
                        "LABA+LAMA",
                        "Formoterol Fum.",
                        "single inhaler device disposable",
                        "Tioform",
                        "Dosage- 6 or 12 µg (18/12 mcg; 9/6 mcg); ₹677"
                    ],
                    [
                        "Prednisolone",
                        "",
                        "(40-50mg)",
                        "various brands\nDepomax S 40mg Injection,\nMpss 40mg Injection",
                        "40mg oral - avg Rs 25/ strip of 10 tablets\nRs 100-150"
                    ]
                ]
            }
        }
    },
    "stroke": {
        "description": "This pathway addresses stroke care in India, detailing initial workup, CT scan dependence, thrombolysis considerations, and management for ischemic, hemorrhagic, and TIA cases, with emphasis on resource limitations.",
        "lines": {
            "L1": {
                "type": "Tile",
                "content": "Stroke Pathway"
            },
            "L2": {
                "type": "Heading",
                "content": "Background"
            },
            "L3": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> 3rd leading cause of <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.healthdata.org/research-analysis/health-by-location/profiles/india' target='_blank'>mortality in India</a>"
            },
            "L4": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Age adjusted prevalence: 84-262/100,000 in rural, 224-424/100,000 in urban areas"
            },
            "L5": {
                "type": "sub_child",
                "content": "Lower rate in rural – is this due to higher mortality? Or inadequate ascertainment?"
            },
            "L6": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Higher mortality rate in rural compared to urban settings (<a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.ahajournals.org/doi/10.1161/strokeaha.108.531293' target='_blank'>28-day mortality 37.1% rural</a>"
            },
            "L7": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.ahajournals.org/doi/10.1161/strokeaha.108.531293' target='_blank'>vs 24.5% urban in one study</a>)"
            },
            "L8": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Timely CT scan/stroke response capacity does not exist <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.ahajournals.org/doi/10.1161/STROKEAHA.119.026733' target='_blank'>in rural settings</a>"
            },
            "L9": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Very low rate of thrombolysis"
            },
            "L10": {
                "type": "sub_child",
                "content": "<a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.ahajournals.org/doi/10.1161/STROKEAHA.119.026733' target='_blank'>Approx 100 centers</a> country-wide equipped for thrombolysis"
            },
            "L11": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Indian National Stroke Guidelines contain reasonable recommendations, but the"
            },
            "L12": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> resources required to implement these are lacking<br><br>"
            },
            "L13": {
                "type": "Heading",
                "content": "Global standard of care for stroke (high income settings)"
            },
            "L14": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Time sensitive and resource dependent (that are difficult to implement in resource limited"
            },
            "L15": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> settings)"
            },
            "L16": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Initial/hyperacute management is guided by CT imaging (to differentiate between"
            },
            "L17": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> ischaemic and haemorrhagic causes of stroke)  determines ongoing management<br><br>"
            },
            "L18": {
                "type": "Heading",
                "content": "Considerations for stroke care in India"
            },
            "L19": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Healthcare system capacity"
            },
            "L20": {
                "type": "sub_child",
                "content": "Infrastructure required for"
            },
            "L21": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Hyperacute stroke management"
            },
            "L22": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Post-stroke inpatient care"
            },
            "L23": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Ongoing stroke rehabilitation"
            },
            "L24": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>Initial presentation may be delayed"
            },
            "L25": {
                "type": "sub_child",
                "content": "In a <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='http://journalsarchive.com/FILES/IJMSPH/01.AWARENESS%20OF%20STROKE%20AMONG%20STROKE%20%20%20PATIENTS.pdf' target='_blank'>case series of 524 stroke patients from Jaipur</a>, Rajasthan, the mean"
            },
            "L26": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> presentation time was 26 hours post-symptom onset, and the mean distance"
            },
            "L27": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> between place of residence and hospital was 66km"
            },
            "L28": {
                "type": "sub_child",
                "content": "Only 10.5% of patients presented within 4 hours<br><br>"
            },
            "L29": {
                "type": "Heading",
                "content": "Management of stroke of uncertain type (SOUT)"
            },
            "L30": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='http://ahajournals.org/doi/10.1161/STROKEAHA.121.037297' target='_blank'>Treatment paradigm for stroke depends on aetiology</a>"
            },
            "L31": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> It is difficult to treat stroke without establishing cause"
            },
            "L32": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Initiation of aspirin in first 48 hours after ischaemic acute stroke decreased risk of"
            },
            "L33": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> recurrent ischaemic stroke and in-hospital death compared to placebo"
            },
            "L34": {
                "type": "sub_child",
                "content": "<a style='color: #2463eb; text-decoration: underline; margin-left: 0px; margin-right:5px' href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933138/' target='_blank'>Subgroup analysis of the IST and CAST</a> studies showed no outcome difference in"
            },
            "L35": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> patients with haemorrhagic stroke who (inadvertently) received aspirin – but"
            },
            "L36": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> study not designed to assess this"
            },
            "L37": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Implications: <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pmc.ncbi.nlm.nih.gov/articles/PMC4933138/' target='_blank'>it may be safe to give aspirin to SOUT, but this is unclear</a>"
            },
            "L38": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Given the benefit seen in IST/CAST was when aspirin was initiated in first 24 hours, and"
            },
            "L39": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> highest risk of ICH expansion is in first 24 hours, <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pmc.ncbi.nlm.nih.gov/articles/PMC4933138/' target='_blank'>giving aspirin between 25 and 48 hours</a>"
            },
            "L40": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> <a style='color: #2463eb; text-decoration: underline; margin-left: 0px; margin-right:5px' href='https://pmc.ncbi.nlm.nih.gov/articles/PMC4933138/' target='_blank'>may be an option</a>"
            },
            "L41": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> However, these recommendations are made by physicians in high income countries"
            },
            "L42": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> What is the magnitude of benefit?<br><br>"
            },
            "L43": {
                "type": "Heading",
                "content": "Initial Workup (Hyperacute Stage)"
            },
            "L44": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Is there a CT scanner at your facility"
            },
            "L45": {
                "type": "sub_child",
                "content": "If yes, continue pathway"
            },
            "L46": {
                "type": "sub_child",
                "content": "If no, transfer to nearest centre with CT scanner"
            },
            "L47": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Primary survey"
            },
            "L48": {
                "type": "sub_child",
                "content": "Airway, breathing, circulation"
            },
            "L49": {
                "type": "sub_child",
                "content": "Measure glucose (rule out hypoglycaemia)"
            },
            "L50": {
                "type": "sub_child",
                "content": "Oxygen saturation"
            },
            "L51": {
                "type": "sub_child",
                "content": "ECG (rule out arrhythmia)"
            },
            "L52": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Lab tests"
            },
            "L53": {
                "type": "sub_child",
                "content": "If available: CBC, troponin, coagulation studies"
            },
            "L54": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Establish time course"
            },
            "L55": {
                "type": "sub_child",
                "content": "If <4.5 hours, patient may be a candidate for <b>thrombolysis</b>"
            },
            "L56": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> INFO Box"
            },
            "L57": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Establishing stroke onset is extremely important"
            },
            "L58": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> If stroke symptoms have been present since awakening (i.e. “wake up"
            },
            "L59": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\"></span> stroke”) then assume onset of symptoms was when the patient was last"
            },
            "L60": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\"></span> seen well"
            },
            "L61": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Thrombolysis may be carefully considered in patients with severe stroke"
            },
            "L62": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\"></span> symptoms and if there is capability to deliver tissue plasminogen activator"
            },
            "L63": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\"></span> <b>AND</b> manage complications of thrombolysis"
            },
            "L64": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> N.B. there is limited thrombolysis capability in India, and the vast"
            },
            "L65": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\"></span> majority of patients arrive outside of the thrombolysis window"
            },
            "L66": {
                "type": "sub_child",
                "content": "If >4.5 hours, patient is not a candidate for thrombolysis"
            },
            "L67": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Have symptoms resolved?"
            },
            "L68": {
                "type": "sub_child",
                "content": "If yes, then treat as transient ischaemic attack (TIA) vs differential diagnosis"
            },
            "L69": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Assess stroke severity"
            },
            "L70": {
                "type": "sub_child",
                "content": "<a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.mdcalc.com/calc/715/nih-stroke-scale-score-nihss' target='_blank'>NIH Stroke Scale</a>"
            },
            "L71": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> It is <b style='margin-left:5px; margin-right:5px;'>not</b> possible to differentiate between an ischaemic and haemorrhagic stroke without a"
            },
            "L72": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> CT scan"
            },
            "L73": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Is there clinical evidence of raised ICP? If yes, suspect haemorrhagic stroke"
            },
            "L74": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Is CT available?"
            },
            "L75": {
                "type": "sub_child",
                "content": "If yes: urgent CT brain to differentiate between ischaemic and haemorrhagic"
            },
            "L76": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> stroke"
            },
            "L77": {
                "type": "sub_child",
                "content": "If haemorrhagic stroke:"
            },
            "L78": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Reverse anticoagulation (if required)"
            },
            "L79": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> <a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='https://www.ahajournals.org/doi/10.1161/STR.0000000000000407' target='_blank'>Blood pressure control:</a>"
            },
            "L80": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> If SBP > 220, then immediate treatment to reduce systolic BP"
            },
            "L81": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\"></span> below 220mmHg. Subsequent treatment over 1-2 hours to reduce"
            },
            "L82": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\"></span> systolic BP to 140-160 mmHg"
            },
            "L83": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> If SBP between 150 and 220 mmHg, reduce SBP to 140 mmHg"
            },
            "L84": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\"></span> within 1 hour"
            },
            "L85": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Transfer patient to higher centre for management"
            },
            "L86": {
                "type": "sub_child",
                "content": "If ischaemic stroke, start aspirin (300mg), atorvastatin (80mg daily)"
            },
            "L87": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Consider thrombolysis if available and within window"
            },
            "L88": {
                "type": "sub_child",
                "content": "Is thrombolysis available?"
            },
            "L89": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.ahajournals.org/doi/10.1161/STR.0000000000000211' target='_blank'>Indications for thrombolysis</a>"
            },
            "L90": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Clinical diagnosis of ischaemic stroke causing measurable"
            },
            "L91": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\"></span> neurologic deficit"
            },
            "L92": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Onset of symptoms within 4.5 hours"
            },
            "L93": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Age ≥ 18 years"
            },
            "L94": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.ahajournals.org/doi/10.1161/STR.0000000000000211' target='_blank'>Contraindications to thrombolysis</a>"
            },
            "L95": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Mild, non-disabling stroke symptoms (NIHSS score 0-5 without"
            },
            "L96": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\"></span> disabling deficit)"
            },
            "L97": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Haemorrhagic stroke"
            },
            "L98": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Ischaemic stroke in the last 3 months"
            },
            "L99": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Severe head trauma within the last 3 months"
            },
            "L100": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Acute head trauma"
            },
            "L101": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Intracranial/intraspinal surgery in last 3 months"
            },
            "L102": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> History of intracranial haemorrhage"
            },
            "L103": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Subarachnoid haemorrhage"
            },
            "L104": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> GI malignancy or GI bleed within 21 days"
            },
            "L105": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Coagulopathy or recent therapeutic anticoagulation"
            },
            "L106": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Concomitant Abciximab"
            },
            "L107": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Concomitant IV aspirin"
            },
            "L108": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Infective endocarditis"
            },
            "L109": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Aortic arch dissection"
            },
            "L110": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Intra-axial intracranial neoplasm"
            },
            "L111": {
                "type": "None",
                "content": "- <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Alteplase dose: Infuse 0.9 mg/kg (maximum dose 90 mg) over 60 min,"
            },
            "L112": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\"></span> with 10% of the dose given as a bolus over 1 min."
            },
            "L113": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span>Ensure BP is < 185/110 prior to alteplase"
            },
            "L114": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span><b>Do not use streptokinase – Alteplase/tPA must be used</b>"
            },
            "L115": {
                "type": "sub_child",
                "content": "If haemorrhagic stroke, stop anticoagulation, consider transfer"
            },
            "L116": {
                "type": "sub_child",
                "content": "If patient is not being thrombolysed, <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.ahajournals.org/doi/epub/10.1161/STR.0000000000000211' target='_blank'>hypertension does not require acute</a>"
            },
            "L117": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span>  <a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='https://www.ahajournals.org/doi/epub/10.1161/STR.0000000000000211' target='_blank'>management unless SBP > 220</a>"
            },
            "L118": {
                "type": "sub_child",
                "content": "Consider need for transfer to higher centre/stroke unit (if available)"
            },
            "L119": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If CT is not available:"
            },
            "L120": {
                "type": "sub_child",
                "content": "Urgent transfer to nearest centre with stroke capability"
            },
            "L121": {
                "type": "sub_child",
                "content": "The judicious use of aspirin in patients with stroke WITHOUT CT SCAN can be"
            },
            "L122": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> considered, based on subgroup analysis from major trials that suggests this may"
            },
            "L123": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span>be safe"
            },
            "L124": {
                "type": "sub_child",
                "content": "Blood pressure targets: If patient is not being thrombolysed, <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.uptodate.com/contents/initial-assessment-and-management-of-acute-stroke' target='_blank'>hypertension does</a>"
            },
            "L125": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> <a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='https://www.uptodate.com/contents/initial-assessment-and-management-of-acute-stroke' target='_blank'>not require acute management unless SBP > 220</a>"
            },
            "L126": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Definitive investigations for stroke (likely requires transfer to higher centre)"
            },
            "L127": {
                "type": "sub_child",
                "content": "CT brain + US carotids"
            },
            "L128": {
                "type": "sub_child",
                "content": "If available, MRI/MR angio"
            },
            "L129": {
                "type": "sub_child",
                "content": "Cardiac monitoring (exclude cardiac cause) and echocardiogram"
            },
            "L130": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> At least 24 hours of cardiac monitoring"
            },
            "L131": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> If embolic phenomenon is suspected, prolonged external telemetry (Zio"
            },
            "L132": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\"></span> patch/ILR). To be contextualised"
            },
            "L133": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If symptoms have resolved"
            },
            "L134": {
                "type": "sub_child",
                "content": "TIA is defined as a transient episode of neurologic dysfunction caused by focal"
            },
            "L135": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> brain, spinal cord, or retinal ischemia, <b>without</b> acute infarction"
            },
            "L136": {
                "type": "sub_child",
                "content": "Start aspirin <b>300mg</b> immediately (reversibility of symptoms suggested ischaemic"
            },
            "L137": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> cause, as haemorrhagic progress would not expect to be reversible)"
            },
            "L138": {
                "type": "sub_child",
                "content": "Consider differential diagnosis:"
            },
            "L139": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Seizure, migraine with aura, syncope"
            },
            "L140": {
                "type": "sub_child",
                "content": "Use ABCD2 score to estimate subsequent stroke risk"
            },
            "L141": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> If ABCD2 < 4, start <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/9174558/' target='_blank'>aspirin monotherapy</a>"
            },
            "L142": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> If ABCD2 >=4, consider <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/30563866/' target='_blank'>dual antiplatelet therapy with clopidogrel for 21</a>"
            },
            "L143": {
                "type": "None",
                "content": "- <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\"></span> <a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/30563866/' target='_blank'>days. If unavailable, aspirin monotherapy is acceptable</a>"
            },
            "L144": {
                "type": "sub_child",
                "content": "Transfer to higher centre for ongoing workup<br><br>"
            },
            "L145": {
                "type": "Heading",
                "content": "Inpatient Care"
            },
            "L146": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> To be completed at the district hospital"
            },
            "L147": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='' target='_blank'>Stroke unit guidelines for India are available</a> <br><br>"
            },
            "L148": {
                "type": "Heading",
                "content": "Prevention of recurrence/risk factor modification"
            },
            "L149": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Smoking cessation"
            },
            "L150": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Exercise/diet/alcohol"
            },
            "L151": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Management of co-morbidities that increase risk of stroke"
            },
            "L152": {
                "type": "sub_child",
                "content": "HTN"
            },
            "L153": {
                "type": "sub_child",
                "content": "Diabetes"
            },
            "L154": {
                "type": "sub_child",
                "content": "Atrial fibrillation (AF)"
            },
            "L155": {
                "type": "sub_child",
                "content": "Hypercholesterolaemia"
            },
            "L156": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If ischaemic stroke, commence antiplatelets and statin"
            },
            "L157": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If stroke due to AF, commence anticoagulation (warfarin or DOAC)"
            },
            "L158": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Measure H1bA1c<br><br>"
            },
            "L159": {
                "type": "Heading",
                "content": "Stroke Rehabilitation and Ongoing Recovery"
            },
            "L160": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Inpatient rehab"
            },
            "L161": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Functional assessment"
            },
            "L162": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Spasticity/contractures"
            },
            "L163": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Falls risk"
            },
            "L164": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Telehealth integration<br><br>"
            },
            "L165": {
                "type": "Heading",
                "content": "Points for contextualisation"
            },
            "L166": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> In high income settings, the majority of strokes are ischaemic in nature (<a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.ahajournals.org/doi/10.1161/STR.0000000000000375' target='_blank'>see AHA figure</a>"
            },
            "L167": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> <a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='https://www.ahajournals.org/doi/10.1161/STR.0000000000000375' target='_blank'>below</a>)"
            },
            "L168": {
                "type": "sub_child",
                "content": "Approx 88% of ischaemic stroke, 10% intracerebral haemorrhage, 2%"
            },
            "L169": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> subarachnoid haemorrhage"
            },
            "L170": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Of these ischaemic strokes, 77% are non-lacunar and 23% are lacunar "
            },
            "L171": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Is the epidemiology similar in India? Does this require further investigation? "
            }
        },
        "Tables": {}
    },
    "Diarrhoea": {
        "description": "This pathway addresses adult diarrhea in India, defining it and highlighting its high mortality burden. It discusses local challenges like antibiotic misuse and delves into causes, severity assessment, rehydration, and antimicrobial treatment, emphasizing appropriate testing and tailored regimens.",
        "lines": {
            "L1": {
                "type": "Tile",
                "content": "Adult Diarrhoea Pathway"
            },
            "L2": {
                "type": "Heading",
                "content": "Definition"
            },
            "L3": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Passage of loose/watery stools 3+ times in 24 hours<br><br>"
            },
            "L4": {
                "type": "Heading",
                "content": "Background"
            },
            "L5": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://www.healthdata.org/research-analysis/health-by-location/profiles/india' target='_blank'>Diarrhoeal diseases</a> 4th leading cause of deaths in India overall, number 1 infectious cause"
            },
            "L6": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> of mortality (IHME)"
            },
            "L7": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> 632,000 diarrhea deaths (all ages) in 2019"
            },
            "L8": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Greatest burden of diarrhoea deaths in the 70+ age group (385,000)<br><br>"
            },
            "L9": {
                "type": "Heading",
                "content": "Local context"
            },
            "L10": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/22265057/' target='_blank'>Antibiotics</a> are <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/19001680/' target='_blank'>widely used</a> for acute diarrhoea in India amongst both adults and children"
            },
            "L11": {
                "type": "sub_child",
                "content": "However, the majority of acute diarrhoeal syndromes <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://iris.who.int/bitstream/handle/10665/43209/9241593180.pdf?sequence=1&isAllowed=y' target='_blank'>do not require treatment</a>"
            },
            "L12": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> with antibiotics"
            },
            "L13": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Diarrhoea in adults is not as well studied as in children<br><br>"
            },
            "L14": {
                "type": "Heading",
                "content": "What causes acute diarrhoea?"
            },
            "L15": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Diarrhoea can be caused by viruses, bacteria, and protozoa"
            },
            "L16": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Diarrhoea caused by viruses cannot be treated with antibiotics, and bacterial and"
            },
            "L17": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span>  protozoal diarrhoea often resolves without antibiotic therapy"
            },
            "L18": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> CSA performed a systematic review to provide further guidance in this area"
            },
            "L19": {
                "type": "sub_child",
                "content": "Search conducted to identify all Indian studies published in the last 5 years"
            },
            "L20": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> reporting microbiological information on the aetiology of infectious diarrhoea."
            },
            "L21": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> Studies had to recruit from the general population, and test for multiple"
            },
            "L22": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> pathogens, to reduce risk of bias"
            },
            "L23": {
                "type": "sub_child",
                "content": "10 studies were identified from 9 states of India"
            },
            "L24": {
                "type": "sub_child",
                "content": "4 studies included adults, 6 studies were limited to children only"
            },
            "L25": {
                "type": "sub_child",
                "content": "The yield of pathogen detection in included studies ranged from 16.3 (examining"
            },
            "L26": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> parasites only) to 65.2%"
            },
            "L27": {
                "type": "sub_child",
                "content": "When studies investigating parasites only excluded, yield of microbiological"
            },
            "L28": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> testing ranged from 25.6% to 65.2%"
            },
            "L29": {
                "type": "sub_child",
                "content": "Common pathogens included viruses (rotavirus, norovirus) and bacteria (E coli,"
            },
            "L30": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> shigella, cholera)<br><br>"
            },
            "L31": {
                "type": "Heading",
                "content": "Other challenges"
            },
            "L32": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Patients in many parts of India do not need to see a doctor to obtain antibiotics for"
            },
            "L33": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> diarrhoea  lack of stewardship"
            },
            "L34": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Patients may not present to CSA partner sites with mild-moderate diarrhoea (can present"
            },
            "L35": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> directly to pharmacy for antibiotics)<br><br>"
            },
            "L36": {
                "type": "Heading",
                "content": "Key questions to answer"
            },
            "L37": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> How to test/when to test"
            },
            "L38": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> How to treat/when to treat<br><br>"
            },
            "L39": {
                "type": "Heading",
                "content": "Methods"
            },
            "L40": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> UpToDate"
            },
            "L41": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> American College of Gastroenterology Clinical Guidelines (2016)"
            },
            "L42": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Infectious Diseases Society of America Guidelines (2017)"
            },
            "L43": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Indian Council of Medical Research (2019)"
            },
            "L44": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> WHO (2005)"
            },
            "L45": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> MSF (2021)<br><br>"
            },
            "L46": {
                "type": "Heading",
                "content": "Proposed Pathway"
            },
            "L47": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Stable or unstable"
            },
            "L48": {
                "type": "sub_child",
                "content": "If unstable, resuscitate"
            },
            "L49": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Establish time course/chronicity"
            },
            "L50": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Consider differential diagnoses"
            },
            "L51": {
                "type": "sub_child",
                "content": "Sepsis"
            },
            "L52": {
                "type": "sub_child",
                "content": "Acute abdomen"
            },
            "L53": {
                "type": "sub_child",
                "content": "Malaria"
            },
            "L54": {
                "type": "sub_child",
                "content": "Chronic diarrhoea/inflammatory causes"
            },
            "L55": {
                "type": "sub_child",
                "content": "Treat and investigate primary diagnosis as per appropriate pathway<br><br>"
            },
            "L56": {
                "type": "Heading",
                "content": "Severity Assessment and Rehydration"
            },
            "L57": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Volume depletion is a major cause of morbidity and mortality from diarrhoea"
            },
            "L58": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> For all adult diarrhoea:"
            },
            "L59": {
                "type": "sub_child",
                "content": "Assess degree of dehydration (Appendix)"
            },
            "L60": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Mild/moderate/severe"
            },
            "L61": {
                "type": "sub_child",
                "content": "If no signs/mild signs of hypovolaemia/dehydration, give ORS after each stool"
            },
            "L62": {
                "type": "sub_child",
                "content": "If signs of moderate hypovolaemia/dehydration, give 2.2 – 4 litres of ORS over 4"
            },
            "L63": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> hours"
            },
            "L64": {
                "type": "sub_child",
                "content": "If severe hypovolaemia/dehydration, will require IV fluid replacement"
            },
            "L65": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> 30ml/kg over 30 minutes"
            },
            "L66": {
                "type": "None",
                "content": "    - <span style=\"font-size: 1.5rem; margin-left: 58px; width: 1.5rem;\">•</span> Repeat bolus if severe dehydration persists/pulses remain weak"
            },
            "L67": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Then 70ml/kg over 2.5 hours"
            },
            "L68": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> Diarrhoea with severe hypovolaemia will require inpatient management"
            },
            "L69": {
                "type": "None",
                "content": " - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\"></span> until patient can tolerate oral replacement"
            },
            "L70": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1.5rem; margin-left: 35px; width: 1.5rem;\">▪</span> ORS should be given until IV access is possible"
            },
            "L71": {
                "type": "sub_child",
                "content": "In cases of severe diarrhoea, assess ability to manage at CSA partner site – may"
            },
            "L72": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> require transfer"
            },
            "L73": {
                "type": "sub_child",
                "content": "In all, aim to replace ongoing losses as maintenance<br><br>"
            },
            "L74": {
                "type": "Heading",
                "content": "Anti-microbial treatment of diarrhoea"
            },
            "L75": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Most acute diarrhoea has an uncomplicated disease course and is self-resolving"
            },
            "L76": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> The decision to investigate (i.e. stool microbiology) and treat acute diarrhoea in difficult"
            },
            "L77": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> even in resource-rich settings"
            },
            "L78": {
                "type": "sub_child",
                "content": "Microbiology is time consuming, can have variable yield, and not all pathogens"
            },
            "L79": {
                "type": "None",
                "content": " - <span style=\"font-size: 2rem; margin-top: -3px; margin-left: 13px; width: 1.5rem;\"></span> identified on microbiological testing require treatment"
            },
            "L80": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Indications for microbiological testing +/- antibiotic therapy"
            },
            "L81": {
                "type": "sub_child",
                "content": "Signs of sepsis (see also: sepsis pathway TBD)"
            },
            "L82": {
                "type": "sub_child",
                "content": "Grossly bloody stool"
            },
            "L83": {
                "type": "sub_child",
                "content": "Stool with pus or mucus"
            },
            "L84": {
                "type": "sub_child",
                "content": "Severe dehydration"
            },
            "L85": {
                "type": "sub_child",
                "content": "Extended disease course (how many days – ICMR suggest 3 days)"
            },
            "L86": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> In most other cases, microbiological testing and antibiotic therapy is NOT required<br><br>"
            },
            "L87": {
                "type": "Heading",
                "content": "Suggested Treatment Regimens for Acute Diarrhoea"
            },
            "L88": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If required, treatment should be targeted towards suspected causative organism (see table)"
            },
            "L89": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If cholera suspected:"
            },
            "L90": {
                "type": "sub_child",
                "content": "300mg Doxycycline PO once <b>OR</b>"
            },
            "L91": {
                "type": "sub_child",
                "content": "Azithromycin 1g once"
            },
            "L92": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If Shigella suspected/bloody diarrhoea"
            },
            "L93": {
                "type": "sub_child",
                "content": "Ciprofloxacin 500mg BD for 3 days <b>OR</b>"
            },
            "L94": {
                "type": "sub_child",
                "content": "Azithromycin 500mg daily for 3 days<br><br>"
            },
            "L95": {
                "type": "Heading",
                "content": "Follow up activities"
            },
            "L96": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> If tolerating oral intake, discharge home with oral rehydration and instructions"
            },
            "L97": {
                "type": "sub_child",
                "content": "Water to be boiled"
            },
            "L98": {
                "type": "sub_child",
                "content": "Hand hygiene"
            },
            "L99": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Isolation of patient from other household contacts if possible"
            },
            "L100": {
                "type": "None",
                "content": "- <span style=\"font-size: 2rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\">•</span> Return to CSA partner site if"
            },
            "L101": {
                "type": "sub_child",
                "content": "Worsening symptoms"
            },
            "L102": {
                "type": "sub_child",
                "content": "Unable to tolerate oral fluid intake"
            },
            "L103": {
                "type": "sub_child",
                "content": "Development of gross blood/mucus/pus in stool"
            }
        },
        "Tables": {}
    },
    "diabetic_foot_ulcer": {
        "description": "This pathway addresses Diabetic Foot Ulcers, covering their global burden, screening methods, physical examination findings (WIfI classification), and management principles including debridement, off-loading, wound dressings, and treatment for infection and peripheral arterial disease.",
        "lines": {
            "L1": {
                "type": "Tile",
                "content": "Diabetic Foot Ulcer (DFU) Pathway"
            },
            "L2": {
                "type": "None",
                "content": "Approximately 18.6 million people worldwide are affected by a diabetic foot ulcer each year."
            },
            "L3": {
                "type": "None",
                "content": "These ulcers precede 80% of lower extremity amputations among people diagnosed with"
            },
            "L4": {
                "type": "None",
                "content": "diabetes and are associated with an increased risk of death. Approximately <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/35063288/' target='_blank'>50% of ulcers</a> become"
            },
            "L5": {
                "type": "None",
                "content": "infected, with up to 20% of these requiring hospitalization; between 15% and 20% of moderate"
            },
            "L6": {
                "type": "None",
                "content": "to severe infections eventually lead to a lower-extremity amputation. People with a diabetic foot"
            },
            "L7": {
                "type": "None",
                "content": "ulcer have a <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/26248037/' target='_blank'>5-year mortality rate of 30%</a>, with a mortality rate greater than 70% for people with"
            },
            "L8": {
                "type": "None",
                "content": "an above-foot amputation.<br><br>"
            },
            "L9": {
                "type": "None",
                "content": "According to the International Diabetes Federation, India had an estimated 77 million adults"
            },
            "L10": {
                "type": "None",
                "content": "living with diabetes in 2019, and this number is expected to rise to 101 million by 2030. Up to"
            },
            "L11": {
                "type": "None",
                "content": "approximately <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/28614678/' target='_blank'>34% of people with type 1 or 2 diabetes develop a foot ulcer during their lifetime.</a>"
            },
            "L12": {
                "type": "None",
                "content": "This incidence is similar when reviewing the limited published data from India.<br><br>"
            },
            "L13": {
                "type": "Heading",
                "content": "Why do ulcers develop?"
            },
            "L14": {
                "type": "Heading",
                "content": "Screening for DFU"
            },
            "L15": {
                "type": "None",
                "content": "Individuals with diabetes are assessed for loss of protective sensation as a sign of large fiber"
            },
            "L16": {
                "type": "None",
                "content": "neuropathy."
            },
            "L17": {
                "type": "None",
                "content": "- <span style=\"font-size: 1rem; margin-left: -5px; width: 1.5rem;\">1.</span>   The Semmes-Weinstein 5.07 <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/37243927/' target='_blank'>monofilament test</a> to assess for absence of pressure"
            },
            "L18": {
                "type": "None",
                "content": "  - <span style=\"font-size: 1rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> sensation at a minimum of 3 sites per foot (likelihood ratio for ulceration range, 11-16)"
            },
            "L19": {
                "type": "None",
                "content": " - <span style=\"font-size: 1rem; margin-top: -3px; margin-left: -5px; width: 1.5rem;\"></span> OR"
            },
            "L20": {
                "type": "None",
                "content": "- <span style=\"font-size: 1rem; margin-left: -5px; width: 1.5rem;\">2.</span> the 128-Hz tuning fork to assess for absence of <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/37243927/' target='_blank'>vibratory perception</a> (using an on-off"
            },
            "L21": {
                "type": "None",
                "content": " - <span style=\"font-size: 1rem; margin-left: -5px; width: 1.5rem;\"></span> technique or timed methods; likelihood ratio range, 16-35) are important components of"
            },
            "L22": {
                "type": "None",
                "content": " - <span style=\"font-size: 1rem; margin-left: -5px; width: 1.5rem;\"></span> this assessment."
            },
            "L23": {
                "type": "None",
                "content": "- <span style=\"font-size: 1rem; margin-left: -5px; width: 1.5rem;\">3.</span> In the absence of this equipment, the <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/37243927/' target='_blank'>Ipswich Touch Test</a> is an acceptable alternative that"
            },
            "L24": {
                "type": "None",
                "content": " - <span style=\"font-size: 1rem; margin-left: -5px; width: 1.5rem;\"></span> can be used to evaluate whether a <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://diabeticfootonline.com/2012/04/01/the-ipswich-touch-test-iptt-your-diagnostic-tool-is-at-hand/' target='_blank'>patient can perceive light touch</a> from an examiner’s"
            },
            "L25": {
                "type": "None",
                "content": " - <span style=\"font-size: 1rem; margin-left: -5px; width: 1.5rem;\"></span>  index finger applied to 6 or 8 prespecified sites on the feet (likelihood ratio range, 10-15)<br><br>"
            },
            "L26": {
                "type": "Heading",
                "content": "Physical exam in patients with DFU"
            },
            "L27": {
                "type": "None",
                "content": "*General*"
            },
            "L28": {
                "type": "None",
                "content": "<a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='https://diabeticfootonline.com/2009/08/04/comprehensive-diabetic-foot-examination-cdfe-video-and-text/' target='_blank'>Physical examination</a> should include evaluation for calluses, interdigital maceration, and"
            },
            "L29": {
                "type": "None",
                "content": "thickened nails, which may indicate a fungal infection and may be associated with increased"
            },
            "L30": {
                "type": "None",
                "content": "pressure on the nail bed.<br><br>"
            },
            "L31": {
                "type": "None",
                "content": "Digital deformities such as hammer toes or claw toes appear as increased prominence of the"
            },
            "L32": {
                "type": "None",
                "content": "interphalangeal joints dorsally and the metatarsal heads on the plantar surface and are common"
            },
            "L33": {
                "type": "None",
                "content": "sites of ulceration. The tip of a toe exposed to increased pressure in contact with the ground or"
            },
            "L34": {
                "type": "None",
                "content": "shoe is also a common site of ulceration. Assessment of dorsiflexion and plantarflexion ankle"
            },
            "L35": {
                "type": "None",
                "content": "range of motion can identify equinus deformity (ie, less than 0 degrees of dorsiflexion at the"
            },
            "L36": {
                "type": "None",
                "content": "ankle joint), which increases forefoot plantar pressure. <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/12381796/' target='_blank'>In a prospective study</a> of 1666 people"
            },
            "L37": {
                "type": "None",
                "content": "with diabetes, equinus deformity was present in 10.3% . <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/37218537/' target='_blank'>Charcot arthropathy</a>, defined as a foot"
            },
            "L38": {
                "type": "None",
                "content": "fracture with possible joint dislocation in people with peripheral neuropathy, affects"
            },
            "L39": {
                "type": "None",
                "content": "approximately 0.3% of people with diabetes, can lead to significant deformity, and increases the"
            },
            "L40": {
                "type": "None",
                "content": "risk of a diabetic foot ulcer, particularly in the midfoot and ankle/hindfoot. Although"
            },
            "L41": {
                "type": "None",
                "content": "approximately 40% of people with Charcot arthropathy have concomitant tissue loss, a unilateral"
            },
            "L42": {
                "type": "None",
                "content": "red, hot, swollen foot without a wound or diagnosis of deep vein thrombosis may indicate"
            },
            "L43": {
                "type": "None",
                "content": "Charcot arthropathy.<br><br>"
            },
            "L44": {
                "type": "None",
                "content": "Pulse palpation at the ankle and on the foot is a central part of the vascular examination, but"
            },
            "L45": {
                "type": "None",
                "content": "palpable pulses have <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/26947795/' target='_blank'>low sensitivity (71.7%) and specificity (72.3%)</a> for detecting peripheral"
            },
            "L46": {
                "type": "None",
                "content": "artery disease. Because peripheral artery disease affects approximately half of people with"
            },
            "L47": {
                "type": "None",
                "content": "diabetic foot ulcers, clinicians should consider noninvasive testing with the ankle-brachial index.<br><br>"
            },
            "L48": {
                "type": "None",
                "content": "*Ulcer assessment*"
            },
            "L49": {
                "type": "None",
                "content": "The Wound, Ischemia, Foot Infection (WIfI) classification system was developed and validated"
            },
            "L50": {
                "type": "None",
                "content": "as a method to combine all 3 variables (wound, ischemia, and foot infection) and to accurately"
            },
            "L51": {
                "type": "None",
                "content": "assess the risk of limb loss for patients with diabetic foot ulcers."
            },
            "L52": {
                "type": "None",
                "content": "<b>Wound:</b> Degree of tissue loss, class 1- small/shallow; class 2 exposed bone/joint/tendon; class 3"
            },
            "L53": {
                "type": "None",
                "content": "extensive deep wound may/may not involve the calcaneum<br><br>"
            },
            "L54": {
                "type": "None",
                "content": "<b>Infection:</b> The diagnosis of diabetic foot infection is primarily based on clinical assessment and"
            },
            "L55": {
                "type": "None",
                "content": "is suggested by presence of more than 2 signs of inflammation, such as erythema, swelling and"
            },
            "L56": {
                "type": "None",
                "content": "possibly purulence, fluctuance, or lymphangitis."
            },
            "L57": {
                "type": "None",
                "content": "DO NOT OBTAIN WOUND CULTURES: Randomized clinical trial data are not available to"
            },
            "L58": {
                "type": "None",
                "content": "support obtaining wound cultures from all patients with diabetic foot ulcers"
            },
            "L59": {
                "type": "None",
                "content": "An <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/18285592/' target='_blank'>erythrocyte sedimentation rate greater than 70 mm/h can be helpful in improving diagnostic</a>"
            },
            "L60": {
                "type": "None",
                "content": "<a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/18285592/' target='_blank'>accuracy for osteomyelitis (likelihood ratio, 11)</a>"
            },
            "L61": {
                "type": "None",
                "content": "Particularly among hospitalized patients, for whom the pretest probability of osteomyelitis is"
            },
            "L62": {
                "type": "None",
                "content": "high, the combination of a positive probe-to-bone test and plain film radiography can be"
            },
            "L63": {
                "type": "None",
                "content": "sufficient to diagnose osteomyelitis (likelihood ratio, 14) <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/32729421/' target='_blank'>without the need for other, more</a>"
            },
            "L64": {
                "type": "None",
                "content": "<a style='color: #2463eb; text-decoration: underline; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/32729421/' target='_blank'>expensive radiological studies</a><br><br>"
            },
            "L65": {
                "type": "None",
                "content": "<b>Ischemia:</b> 1. <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/26342129/' target='_blank'>Palpation of anterior tibial and posterior tibial pulses (35% sensitive, 100% specific-</a>"
            },
            "L66": {
                "type": "None",
                "content": "<a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/26342129/' target='_blank'>for wound healing)</a><br><br>"
            },
            "L67": {
                "type": "None",
                "content": "2. Lower extremity peripheral artery disease can be assessed noninvasively with the ankle-"
            },
            "L68": {
                "type": "None",
                "content": "brachial index. An ankle-brachial index (ABI) less than 0.90 is approximately 98% specific and"
            },
            "L69": {
                "type": "None",
                "content": "approximately 85% sensitive for peripheral artery disease. Limitations of ABI- people with"
            },
            "L70": {
                "type": "None",
                "content": "diabetes often have medial calcinosis of lower extremity peripheral vessels, resulting in falsely"
            },
            "L71": {
                "type": "None",
                "content": "elevated peripheral pressures and a high ankle-brachial index that is insensitive to presence of"
            },
            "L72": {
                "type": "None",
                "content": "peripheral artery disease. (RESOURCE LIMITATIONS) In these individuals, the toe-brachial"
            },
            "L73": {
                "type": "None",
                "content": "index can be measured, since the digital arteries are less commonly affected by medial"
            },
            "L74": {
                "type": "None",
                "content": "calcinosis.35 A toe-brachial index less than 0.70 is consistent with peripheral artery disease.33"
            },
            "L75": {
                "type": "None",
                "content": "Toe pressure of 30 mm Hg or greater, transcutaneous oxygen pressure of 25 mm Hg or greater,"
            },
            "L76": {
                "type": "None",
                "content": "and skin perfusion pressure of 40 mm Hg or greater have been associated with higher rates of"
            },
            "L77": {
                "type": "None",
                "content": "ulcer healing. <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/26804365/' target='_blank'>The sensitivity and specificity of transcutaneous oxygen pressure for ulcer healing</a>"
            },
            "L78": {
                "type": "None",
                "content": "<a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/26804365/' target='_blank'>were 0.72 (95% CI, 0.61-0.81) and 0.86 (95% CI, 0.68-0.95), respectively, with a diagnostic OR</a>"
            },
            "L79": {
                "type": "None",
                "content": "<a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/26804365/' target='_blank'>of 15.81 (95% CI, 3.36-74.45). This is compared with a relatively low progno</a>accuracy for ulcer"
            },
            "L80": {
                "type": "None",
                "content": "healing using the ankle-brachial index (with cutoffs of <0.9 and ≥1.3), with a sensitivity of 0.48"
            },
            "L81": {
                "type": "None",
                "content": "(95% CI, 0.36-0.61), a specificity of 0.52 (95% CI, 0.42-0.63), and a diagnostic OR of 1.02 (95%"
            },
            "L82": {
                "type": "None",
                "content": "CI, 0.40-2.64).<br><br>"
            },
            "L83": {
                "type": "None",
                "content": "A <a style='color: #2463eb; text-decoration: underline; margin-left: 5px; margin-right:5px' href='https://pubmed.ncbi.nlm.nih.gov/31230866/' target='_blank'>higher score on the WIfI scale</a> is associated with lower extremity amputation and morbidity"
            },
            "L84": {
                "type": "None",
                "content": "and can be used to determine the need for revascularization. WIfI scores of 1, 2, 3, and 4 were"
            },
            "L85": {
                "type": "None",
                "content": "associated with 1-year amputation rates of 0%, 8%, 11%, and 38%, respectively<br><br>"
            },
            "L86": {
                "type": "Heading",
                "content": "Management"
            },
            "L87": {
                "type": "None",
                "content": "3 pillars"
            },
            "L88": {
                "type": "None",
                "content": "- <span style=\"font-size: 1rem; margin-left: -5px; width: 1.5rem;\">1.</span> Debridement"
            },
            "L89": {
                "type": "None",
                "content": "- <span style=\"font-size: 1rem; margin-left: -5px; width: 1.5rem;\">2.</span> Off loading"
            },
            "L90": {
                "type": "None",
                "content": "- <span style=\"font-size: 1rem; margin-left: -5px; width: 1.5rem;\">3.</span> Wound dressings<br><br>"
            },
            "L91": {
                "type": "None",
                "content": "<b>Debridement:</b> Debridement is a standardized approach used to facilitate healing.52 Healing is"
            },
            "L92": {
                "type": "None",
                "content": "achieved by eliminating nonviable wound bed and wound edge tissue, including excess callus on"
            },
            "L93": {
                "type": "None",
                "content": "the periphery and nonviable dermal tissue, as well as foreign materials and bacterial components."
            },
            "L94": {
                "type": "None",
                "content": "Although guidelines recommend regular debridement, defined as weekly or every other week,"
            },
            "L95": {
                "type": "None",
                "content": "randomized clinical trials are lacking<br><br>"
            },
            "L96": {
                "type": "None",
                "content": "<b>Off loading:</b> The most effective treatment for off-loading a plantar foot ulcer is a knee-high"
            },
            "L97": {
                "type": "None",
                "content": "nonremovable off-loading device, either a total contact cast or a knee-high walker rendered"
            },
            "L98": {
                "type": "None",
                "content": "nonremovable. Two national surveys of clinicians in the United States and Australia show that"
            },
            "L99": {
                "type": "None",
                "content": "the total contact cast was used in only 2% and 15% of patients, respectively, as a primary means"
            },
            "L100": {
                "type": "None",
                "content": "of off-loading. Clinicians frequently cited patient preference as a reason for lack of total contact "
            },
            "L101": {
                "type": "None",
                "content": "cast use "
            },
            "L102": {
                "type": "None",
                "content": "Dressings: Few data are available regarding the optimal wound dressing for diabetic foot"
            },
            "L103": {
                "type": "None",
                "content": "ulcers.The selection of a wound dressing for a diabetic foot ulcer should be based on wound"
            },
            "L104": {
                "type": "None",
                "content": "characteristics, ie, location, presence and/or degree of inflammation, and amount of exudate The"
            },
            "L105": {
                "type": "None",
                "content": "dressing should promote a moist environment conducive to tissue growth and epithelial"
            },
            "L106": {
                "type": "None",
                "content": "migration without causing excess maceration. It is important to select dressings that remove"
            },
            "L107": {
                "type": "None",
                "content": "excess fluid to prevent further tissue inflammation and damage from prolonged contact with the"
            },
            "L108": {
                "type": "None",
                "content": "wound or its periphery. In general, hydrogels are preferred for wounds that produce little"
            },
            "L109": {
                "type": "None",
                "content": "exudative drainage, while alginates or hydrofibers are recommended for heavily draining wounds"
            },
            "L110": {
                "type": "Heading",
                "content": "Treatment of Infected ulcers"
            },
            "L111": {
                "type": "None",
                "content": "Osteomyelitis present- links to AvoMD abx pathways"
            },
            "L112": {
                "type": "None",
                "content": "Osteomyelitis absent- links to AvoMD abx pathways<br><br>"
            },
            "L113": {
                "type": "None",
                "content": "Although many diabetic foot ulcer infections are superficial, some may require surgical"
            },
            "L114": {
                "type": "None",
                "content": "intervention to remove infection in deep soft tissue. <b>In the absence of an acute soft tissue</b>"
            },
            "L115": {
                "type": "None",
                "content": "<b>infection in forefoot osteomyelitis, antibiotics may be as effective as surgery.</b><br><br>"
            },
            "L116": {
                "type": "Heading",
                "content": "Treatment of Peripheral arterial disease<br><br>"
            },
            "L117": {
                "type": "None",
                "content": "DO NOT’S- Pentoxifylline, vasodilator drugs<br><br>"
            },
            "L118": {
                "type": "None",
                "content": "In patients with chronic limb-threatening ischemia who require revascularization for tissue"
            },
            "L119": {
                "type": "None",
                "content": "healing, delayed revascularization is associated with slower healing. A prospective study of 478"
            },
            "L120": {
                "type": "None",
                "content": "patients identified an improved rate of wound healing among patients undergoing"
            },
            "L121": {
                "type": "None",
                "content": "revascularization with shorter time to healing among those who received a referral for"
            },
            "L122": {
                "type": "None",
                "content": "revascularization within 56 days compared with those who had a longer time to revascularization"
            },
            "L123": {
                "type": "None",
                "content": "(hazard ratio [HR], 1.96; 95% CI, 1.52-2.52; P < .001 [absolute rates not provided]).<br><br>"
            },
            "L124": {
                "type": "None",
                "content": "Revascularization should be offered to most patients with chronic limb-threatening ischemia;"
            },
            "L125": {
                "type": "None",
                "content": "however, cost, older age, presence and severity of medical comorbidities, impaired functional"
            },
            "L126": {
                "type": "None",
                "content": "status, and shorter life expectancy are important preoperative factors to consider when"
            },
            "L127": {
                "type": "None",
                "content": "determining whether revascularization is likely to improve outcomes."
            }
        },
        "Tables": {
            "T1": {
                "title": "Off-loading methods",
                "type": "Table",
                "after": "L101",
                "content": [
                    [
                        "Off-loading methods",
                        "Description",
                        "Outcome/benefit"
                    ],
                    [
                        "Knee-high nonremovable off-loading device[51]",
                        "Total contact cast or knee-high walker rendered nonremovable",
                        "Reduces pressure at the ulcer by 80%-90% compared with a standard shoe[55]; promotes better healing compared with removable devices (relative risk, 1.24; 95% CI, 1.09–1.41 [absolute rates not provided]). First-choice off-loading treatment in international guidelines.[51]"
                    ],
                    [
                        "Removable knee-high and ankle-high walkers[51]",
                        "Off-loading devices that can be removed by the patient",
                        "Reduces pressure effectively but does not promote healing as well as nonremovable walkers or total contact cast. Second-choice off-loading treatment in international guidelines.[51] A study of 20 patients wearing waist-mounted activity monitor and device-mounted monitor reported patients engaged in only 28% of their total daily activity while wearing the protective boot compared with when it was not worn (345 [SD, 219] min vs 874 [SD, 828] min; *P* = .01).[59]"
                    ]
                ]
            },
            "T2": {
                "title": "Dressing type",
                "type": "Table",
                "after": "L109",
                "content": [
                    [
                        "Dressing type",
                        "Characteristics and use"
                    ],
                    [
                        "Alginates",
                        "These dressings form a damp gel on absorption, necessitating a secondary dressing. They are conformable, filling dead spaces and managing moderate to heavy exudate effectively. Suitable for wounds with light to moderate serous drainage."
                    ],
                    [
                        "Antimicrobial dressings",
                        "These dressings contain substances such as silver or iodine that inhibit bacterial growth in the wound, making them suitable for infected wounds or those at high risk of infection. However, it is important to note that, as with each of these categories, there is a lack of strong evidence recommending their use."
                    ],
                    [
                        "Collagens",
                        "Derived from bovine, equine, porcine, or ovine (sheep) sources, these products help stimulate wound healing. Available in various forms such as gel, pad, paste, powder, and sheets. Some dissolve entirely while others need removal per the manufacturer’s guidelines. Ideal for wounds showing granulation tissue."
                    ],
                    [
                        "Film dressings",
                        "Thin, transparent dressings that foster a moist environment, promoting healing and enabling wound assessment without removal. Ideal for superficial wounds with minimal exudate."
                    ],
                    [
                        "Foams",
                        "These dressings are capable of absorbing moderate quantities of exudate and can be used under compression."
                    ],
                    [
                        "Gauze",
                        "Highly permeable dressing material, suitable for wound cleaning, as a cover dressing, and for securing dressings. Gauze is not generally recommended as a primary wound dressing because it can remove healthy granulation tissue during dressing changes."
                    ],
                    [
                        "Hydrocolloids",
                        "These bacteria-proof dressings facilitate autolytic debridement. They are not appropriate for infected wounds as they may damage fragile skin. Ideal for wounds with insignificant serous drainage."
                    ],
                    [
                        "Hydrogels",
                        "These are glycerin and water-based products available as amorphous gels, sheets, or impregnated dressings. They can be antimicrobial, donate moisture to wounds, assist in autolytic debridement, and possibly reduce pain. They require a secondary dressing and are suitable for low-exudate wounds needing moisture."
                    ]
                ]
            }
        }
    }
}